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                                                             ABSTRACT 
 
Multiple sclerosis (MS) is a neurodegenerative disease associated with immune attack of the 
central nervous system (CNS) leading to neuronal and axonal loss. This affects neurotransmission 
accumulating residual disability and the development of neurological signs such as spasticity. 
Numerous studies have reported a beneficial role of cannabinoids in alleviating symptoms 
associated with neurological damage. The endocannabinoid system has been shown to control 
experimental spasticity in experimental autoimmune encephalomyelitis (EAE) an animal model of 
multiple sclerosis (MS). The orphan G-protein coupled receptor 55 (GPR55) has been identified as 
a functionally –related cannabinoid receptor known to be stimulated by lysophosphatidylinositol.  
In the current study a novel GPR55 gene knockoutmouse and GPR55-transfected cell line was 
obtained and characterised andthe function and distribution of GPR55 was analyzed. Due to the 
lack of GPR55 specific antibodies, we attempted to generate GPR55-specific monoclonal 
antibodies in GPR55 knockout mice, however none of these reacted only specifically to the native 
protein. As alternatives to antibodies, GPR55 mRNA levels were quantified using quantitative 
polymerase chain reaction (qPCR) and in situ hybridization. 
The GPR55 knockout mice on the C57BL/6 mouse background failed to generate an autoimmune 
response during EAE in an initial experiment suggesting that GPR55 controls immune function. 
Disease was variable in the C57BL/6 mice and EAE was induced in the GPR55 knockout mice on the 
ABH background and animals developed spasticity. VSN16R is a drug that has shown to inhibit 
experimental spasticity and binds specifically to GPR55, without the typical side effects associated 
with cannabis.  This compound was found to be an allosteric modulator of GPR55. Animals were 
treated with VSN16R however the anti-spastic effect remained in the GPR55 knockout mice. 















1.1 Cannabinoids and Cannabinoid receptors 
 
The Asian hemp plant Cannabis sativa belongs to the family Cannabaceae and contains at least 60 
active compounds (Gaoni & Mechoulam., 1964). Despite the fact the plant was discovered many 
thousands of years ago the major active ingredient of cannabis, ∆9tetrahydrocannabinol (THC), 
was only isolated in 1964 (Brown et al., 2009; Gaoni et al., 1964). After the discovery of the 
structure of THC there was a debate on whether the drug acted on specific receptors (Brown et al., 
2009). However, by using high affinity synthetic chemical autoradiography with radioactively 
labeled compounds distinct tissue distributions suggestive of an activity of a receptor was 
identified (Howlett et al., 2002; Howlett et al., 2010). This debate ended in 1990 when the 
cannabinoid receptor 1 (CB1) was cloned from a cDNA library of rat cortex (Matsuda et al., 1990). 
The CB1 gene is located at chomosome 6q14-q15 and encodes a 472 amino acid residue (Figure 
1.1) in humans. The CB1 receptor is the most abundant G protein coupled receptor (GPCR) in the 
CNS and has been found to be expressed at high levels in the hippocampus, basal ganglia, cerebral 
cortex, amygdala, and cerebellum (Glass et al., 1997a; Herkenham et al., 1990; Tsou et al., 1998). 
The distribution of the CB1 receptor correlates with the documented effects of cannabinoids 
including cognitive impairment, memory, motor coordination and induced sign of analgesia 
(Howlett et al., 2002). The CB1 receptor is also expressed in other peripheral organs including 
spleen and tonsils (Galiegue et al., 1995; Glass et al., 1997a; Herkenham et al., 1990). CB1 
receptors are located notably presynaptic where they mediate inhibition of ongoing release of a 
number of different excitatory and inhibitory neurotransmitters (Howlett et al., 2002; Howlett et 
al., 2010; Wilson et al., 2002). Shortly after the discovery of the CB1 receptor a second cannabinoid 
receptor 2 (CB2) was cloned from human promyelocytic leukaemia cells (Munro et al., 1993). 
Human CB2 gene is located at chomosome 1p36.11 and encodes a 360 amino acid residue (Figure 
1.1).The CB2 receptor only shares an amino acid sequence homology of 44% to the CB1 receptor 
thoughout the total protein (Munro et al., 1993). Most studies indicate a restricted expression 
profile of CB2 receptors to the periphery and in lymphoid organs (Munro et al., 1993). Although 
some studies have suggested neuronal expression of CB2 receptor this has been inconsistent 
(Howlett et al., 2002; Nunez et al., 2004). For example, it has been reported that CB2 receptors can 




receptors can modulate immune cell migration and cytokine release both outside and within the 
brain upon activation (Pertwee, 2005a).  
Both receptors belong to a family of G protein-coupled receptors. The receptors are predicted to 
be composed by seven membrane domain helices, an extracellular N-terminus and an intracellular 
C-terminus. The heterotrimeric G proteins that predominantly interact with GPCR consist of ,  
and  subunits (Fredriksson et al., 2003). The GPCR main function is to transduce extracellular 
stimuli into intracellular signals. The receptors are activated by many extracellular ligands 
including neurotransmitters, lipids, proteins, hormones and chemokines (Kroeze et al., 2003). A 
conformational change of the receptor occurs upon ligand binding to the GPCRs. Upon G protein 
complex interaction with an active receptor the GDP (guanine diphosphate) bound to the  
subunit is exchanged for GTP (guanine triphophate) and dissociated from the /  subunit. This in 
turn can lead to the activation of an associated G-protein and depending on the type of G-protein 
the receptor is coupled to a range of downstream signalling pathways can be activated (Kroeze et 
al., 2003). CB1 and CB2 receptors signalling though Gi/o is recurrently exploited in the in vitro assays 
for cannabinoid receptor agonism, 35S GTPyS binding assay and the cyclic adenosine 
monophosphate (cAMP) assay, used to detect cannabinoid activity (Howlett et al., 2002). CB1 and 
CB2 receptors inhibit adenylyl cyclase and activate mitogen-activated protein kinase (MAPK) 
activity though their binding to Gi/o proteins (Felder et al., 1995; Howlett et al., 1984; Kobayashi et 
al., 2001) and are Bordetella pertussis toxin (PTX) –sensitive (Howlett et al., 2002). In addition CB1 
receptors can signal though Gs proteins (Glass et al., 1997b). Furthermore CB1 receptors are 
coupled to calcium channels, inwardly rectifying potassium channels and other ion channels 
(Howlett et al., 2002; Howlett et al., 2010; Mackie et al., 1995). CB1 receptors also have one or 
more allosteric sites that can be targeted by ligands in a manner that augments or inhibits the 
activation of this receptor by direct agonists (Howlett et al., 2002; Price et al., 2005).  
1.1.1 Cannabinoid CB1 and CB2 receptor ligands 
Although cannabinoids were originally defined to describe the dibenzopyran compounds within 
the cannabis plant, this definition has been extended to any compounds that bind to the 
cannabinoid receptors (Figure 1.2) (Howlett et al., 2002). Cannabinoid agonists are currently 
classified in four major groups according to their chemical structures:  classical, nonclassical, 
aminoalkylindole and eicosanoid (Howlett et al., 2002). The classical group consists of 
dibenzopyran derivates and includes ∆9-THC the major psychoactive substance in the plant 
cannabis and compounds such as HU-210 a synthetic analogue of THC (Pertwee, 2005b). The non-




includes the synthetic compound CP55,940 (Pertwee, 2005b). Aminoalkylindole structures differ 
distinctly from the classical and non classical cannabinoid agonists one example is WIN 55,212-2, 
which is a commonly used synthetic research tool (Pertwee, 2005b). The two most studied 
eicosanoids are the endocannabinoids anandamide (N-arachidonylethanolamine) and 2-
arachidonylglycerol (2-AG).  
 
 



















The cannabinoid recptors CB1 (472 amino acid) and CB2 (360 amino acid) belong to a family of seven transmembrane 
receptors with an extracellular N-terminus and an intracellular C-terminus. Each dot represents an amino acid residue 
(adapted from http://www.hampapartiet.se/cb1cb2.htm). 
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Figure 1.2 Structures of cannabinoid agonists 
       Classical cannabinoids 
 
 













1.1.2 Endocannabinoid system 
Endogenous cannabinoid receptor agonists from mammalian tissues were discovered after the 
cloning of the CB1 receptor.The two most studied endocannabinoids are anandamide and 2-AG. 
Anandamide is a natural fatty acid originally isolated from porcine brain (Devane et al., 1992; 
Melck et al., 1999) and has the ability to bind to and activate CB1 and CB2 with a similar potency 
(Lauckner et al., 2008). The endocannabinoid system regulates signalling between neurons and 
endocannabinoid ligands and act in a retrograde manner (Howlett et al., 2002; Howlett et al., 
2010; (Wilson et al., 2001). Endocannabinoids are derivates of archidonic acid that are generated 
by post-synaptic neurons “on demand” in response to elevations of intracellular calcium resulting 
from depolarization induced opening of voltage controlled Ca2+ channels (Di Marzo et al., 2005; 
Howlett et al., 2004; Piomelli, 2003). Upon release from the post-synaptic membrane the 
endocannabinoids diffuse retrogradely across the synapse and this in turn activates the pre-
synaptic CB1 receptors to decrease release of either excitatory or inhibitory transmitters (Howlett 
et al., 2002; Howlett et al., 2010; Katona et al., 2012). Endocannabinoids appear to be released ‘on 
demand’ from membrane precursors via multi-step enzymatic pathways upon augmented 
intracellular calcium after neuronal activation or via stimulation of metabotropic receptors 
coupled to Gq/11 proteins (Kammermeier et al., 2003). Metabotropic glutamate receptors 
(mGluRs) have shown to modulate neuronal excitability and transmitter release (Katona et al., 
2012). Anandamide can be synthesized though a number of pathways (Battista et al., 2012). N-
acyl-phosphatidylethanolamine selective phospholipase D (NAPE-PLD) is considered the major 
enzyme responsible for the synthesis of anandamide (Okamoto et al., 2009). However, another 
group have demonstrated that NAPE-PLD deficient mice did not show altered anandamide 
expression levels compared to wildtype littermates, suggesting that anandamide can also be 
synthesized though other pathways (Leung et al., 2006). Synthesis of 2-AG is generated via 
phospholipase C (PLC) mediated hydrolysis of NAPE (Di Marzo, 2008) followed by the activity of 
the sn-1-diacylglycerol lipases (DAGL and DAGL) (Bisogno et al., 2003; Di Marzo, 2008; Wang et 
al., 2009; Yoshida et al., 2006). Regulation of 2-AG production was recently reported in a study 
where DAGLα and DAGLβ knockout mice were generated (Gao et al., 2010; Tanimura et al., 2010). 
The main route of synthesis for 2-AG was found to be mediated by DAGLα and retrograde 
endocannabinoid induced signalling was lost in DAGLα knockout mice. Additionally, adult 
neurogenesis in both DAGLα and β knockout mice was reduced, compared to wildtype littermates 
(Gao et al., 2010). 2-AG can also be produced via phospholipase A1 (PLA1) hydrolysis of 
phosphoinositol precursors (Di Marzo, 2008). Endocannabinoids are enzymatically degraded once 




hydrolase (FAAH) (Cravatt et al., 2001). FAAH is the major degradative enzyme of anandamide in 
vivo whereas 2-AG is degraded by monoglycerol lipase (MAG lipase) and two novel serine 
hydrolases alpha-beta-hydrolase domain 6 and 12 (ABHD6 and ABHD12)(Blankman et al., 2007; 
Dinh et al., 2002; Dinh et al., 2004). Intracellular fatty acid binding proteins (FABPs) have been 
reported to act as carriers for anandamide thereby facilitating its degradation by FAAH (Kaczocha 
et al., 2009). 
Endocannabinoids have been implicated in a number of physiological functions. One of the 
important roles of the endocannabinoid system is to maintain homeostasis. Altered levels of 
endocannabinoids have been associated with a number of disorders including pain and 
inflammation, immunological and neurological conditions and obesity (Andre et al., 2010; Eckel et 
al., 2005).In obesity, caused by high–fat food intake, upregulated levels of endocannabinoids has 
shown to be associated with an increased risk for cardiovascular and associated metabolic 
diseases.  A pharmacological blockade of the system could therefore be used for treatment of 
obesity (Di Marzo, 2008; Eckel et al., 2005). Indeed, the CB1 receptor antagonist SR141617A 
(ribonamant) was licenced for the control of dietary intake in obesity, before its withdrawal due to 
adverse neurobehavioural effects, anxiety, depression and suicidal tendency (Eckel et al., 2005; 
Pertwee, 2005a). 
1.2 Non-CB1/non-CB2 receptors possibly related to the cannabinoid 
system 
1.2.1 GPR119 
GPR119 is an intronless GPCR that belongs to the MECA (melancortin, endothelial differentiation 
gene, cannabinoid, adenosine) group of receptors (Fredriksson et al., 2003). The GPR119 gene is 
located to chomosome Xq26.1 and encodes a 335 amino acid GPCR in humans (Fredriksson et al., 
2003). The receptor is phylogenetically related to cannabinoid receptors and fatty acid amides 
such as N-oleoyl dopamine, oleoyl ethanolamide, palmitoyl ethanolamide and anandamide bind to 
GPR119 (Overton et al., 2006). The receptor is expressed in the pancreas, where it is thought to be 
involved in the control of glucose-dependent insulin release, and in gastrointestinal organs 
(Lauffer et al., 2008). 
1.2.2 GPR18 
The GPR18 gene is located to chomosome 13q32.3 and encodes a 331 amino acid GPCR (Gantz et 
al., 1997; Pertwee et al., 2010). The receptor has been found to be expressed in the lymphoid 




2006). N-arachidonoyl glycine (NAGly) is an endogenous lipid that is structurally similar to 
anandamide. However, NAGly does not activate cannabinoid receptors. NAGly has been shown to 
induce intracellular calcium mobilization in GPR18-transfected cells (Kohno et al., 2006).GPR18 
cells have been found to be PTX–sensitive in the same study suggesting Gi coupling. Anandamide 
has vasoactive effects on the vasculature independent of CB1 and CB2 (Howlett et al., 2002).GPR18 
is expressed on the vasculature and immune cells and has been reported to be a vasculature 
target (Parmar, 2009). GPR18 has also been suggested to be a receptor for abnormal cannabidiol 
(Abn-Cbd). However, there is currently no data showing the activation of the receptor by CB1 or 
CB2 receptor ligands(Kohno et al., 2006). 
1.2.3 GPR35 
The GPR35 gene is located to chromosome 2q37.3 and encodes a protein of 309 amino acids 
(O'Dowd et al., 1998). GPR35 expression has been detected in the rat intestine and mainly in 
mouse spleen, lymph nodes, small intestine, lung, colon, pancreas, stomach, trachea, adipose and 
brain. High levels of human GPR35 were also detected in small intestine, colon, spleen, peripheral 
leucocytes and low levels in stomach, adipose and thymus (O'Dowd et al., 1998; Wang et al., 
2006). The metabolite kynurenicacid has been reported as an endogenous ligand for GPR35. 
GPR35 transfected cells have been shown to be activated by kynurenic acid, no response was seen 
in vector transfected cells (Wang et al., 2006). Kynurenic acid has been shown to elicit calcium 
mobilization and inositol phosphate production in a GPR35-dependent manner (Wang et al., 
2006). Kynurenic acid has also been shown to stimulate [35S] GTPS binding in a GPR35-dependent 
manner and induce internalization of GPR35, this effect was abolished by pre-treatment with PTX 
suggesting that GPR35 activation by kynurenic acid couples to a PTX-sensitive Gi/o pathway (Wang 
et al., 2006). Kynurenic acid did not activate around 40 other GPCRs including GPR55 (Wang et al., 
2006). As GPR35 shares sequence similarity with GPR55 the effect of several cannabinoid ligands 
has been examined. THC has shown to induce calcium levels in a GPR35 transfected cell line and 
not in the vector-transfected cells (Oka et al., 2010). In contrast, the ligands CP55940, WIN55212-2 




1.3 G-protein coupled receptor 55(GPR55) 
1.3.1 GPR55 
The biological activity of certain cannabinoids and atypical cannabinoids, cannabinoids that do not 
mediate their effects though CB1 or CB2receptors, as shown in CB1 or CB2 deficient mice has 
prompted some people to hypothesize the existence of a third cannabinoid receptor (CB3). 
However, the human genome has been sequenced and there are no highly structurally-related 
receptors present. This suggests that if present the putative CB3 is more likely to be functionally 
related than structurally-related. The orphan receptor G-coupled receptor 55 (GPR55) was 
identified as a novel cannabinoid receptor in 2006 based on data in the patent literature relating 
to ligand binding (Baker et al., 2006b). Human GPR55 was cloned in 1999 through an expressed 
sequence database by conducting homology searches of the amino acid sequences of known G-
protein coupled receptors. The orphan receptor belongs to group  of rhodopsin-like class A 
receptors (Fredriksson et al., 2003). The gene was mapped to chromosome 2q37 and encodes a 
319 amino acid protein in humans (Sawzdargo et al., 1999). Mouse and Rat GPR55 mRNA have 
been described to be 75-78% identical to human GPR55 (Ryberg et al., 2007). GPR55 however only 
shares a sequence homology of 13.5% with CB1 and 14.4% with CB2 (Baker et al., 2006b). The 
association of GPR55 with cannabinoids was first described in a patent from GlaxoSmithKline 
where the interaction was demonstrated in a yeast expression system (Baker et al., 2006). In this 
system yeast cells expressing human GPR55 were shown to be activated by the CB1 antagonists 
AM251 and SR141716A at micro molar concentrations (Brown et al., 2001). A subsequent patent 
from AstraZeneca (Drmota et al., 2004) described the binding of GPR55 transfected human 
embryonic kidney (HEK) cell membranes of the cannabinoid ligands CP55940 and SR141716A and 
anandamide whereas WIN55212-2 did however not show binding to GPR55 in the same assay 
(Ryberg et al., 2007). Human GPR55 mRNA has been detected in different parts of the brain, 
mainly in the caudate nucleus and putamen as shown by Northern blot analysis and in situ 
hybridization  (Sawzdargo et al., 1999) and  in lymphoid organs such as spleen and thymus (Oka et 
al., 2009). GPR55 mRNA has been detected in rat hippocampus, thalamic nuclei and in the 
midbrain (Sawzdargo et al., 1999). Mouse GPR55 mRNA is expressed in the adrenal glands, large 
dorsal root ganglions (DRG), frontal cortex, striatum, jejunum, ileum, colon and testis (Ryberg et 
al., 2007). GPR55 and CB1 receptors have been shown to form heterodimers and can alter each 
others signalling capacities in HEK293 cells. Co-expression of the receptors has been shown to 
inhibit GPR55-mediated transcription factor activation,such as nuclear factor of activated T-cells 




Whereas GPR55-mediated signalling was inhibited in the presence of the CB1 receptor; this effect 
was not seen when the CB1 receptor was inactive. However, the signalling properties of the CB1 
were enhanced in the presence of GPR55 (Kargl et al., 2012). Recently the ligand binding 
properties of GPR55 were analyzed by applying homology modelling.  An amino acid residue Lys80 
was found to be crucial in GPR55 ligand recognition though a critical hydrogen bonding interaction 
with the docked ligands (Elbegdorj et al., 2012). 
1.3.2 Distribution of GPR55 
The distribution of GPR55 has been confirmed from in situ hybridization or quantitative 
polymerase reaction (qPCR). There has been few studies reported using antibody staining. Here it 
has been reported that GPR55 is expressed on dorsal root ganglion, spinal cord and peripheral 
nerve (Sanudo-Pena et al., 1999). Whilst this did appear to be selective for the target, it has been a 
common problem in cannabinoid biology that polyclonal antibodies are non-specific or need to be 
diluted exceptionally to obtain an apparent signal or there is significant batch variability. This has 
been the common with CB1 specific antibodies (Egertova et al., 2000; Grimsey et al., 2008) and 
notably with CB2- specific antibodies, which have contributed to the confusion of the expression of 
CB2 in the nervous system. (Howlett et al., 2002; Nunez et al., 2004). The influence of dilution and 
specificity should be avoided if using monoclonal antibodies. However, because there is 
evolutionary conservation amongst species animals may be immunologically tolerant to targets. 
However gene knockout animals have not seen their targets and thus could prove a source to 
make monoclonal antibodies. 
1.4 Putative GPR55 ligands, endocannabinoids and cannabinoids 
 
The identification of GPR55 as a putative cannabinoid receptor (Baker et al., 2006) prompted 
investigation of this receptor. GPR55 has also been found to be stimulated by endogenous, plant-
derived and synthetic cannabinoid ligands (Drmota 2004; Ryberg et al., 2007). However it is now 
clear that the ligand binding profile of chemicals to GPR55 is complex and inconsistent (Ross, 
2009). In order to resolve the inconsistencies in classification of various agonists, a β-arrestin 
reporter assay has been used as the readout. The readout of the assay corresponds to early events 
of receptor activation compared to other employed assays where the downstream signalling 
pathways have been observed (Kapur et al., 2009). β-arrestins are intracellular proteins that bind 
and desensitize activated GPCR thereby forming stable receptor/arrestin signalling complexes 
(Oka et al., 2009). Upon ligand/agonist binding the β-arrestins are relocated to the activated 




arrestin2 (βarr2) distribution and GPR55 receptor internalization following activation by 
lysophosphatidylinositol (LPI), the most potent GPR55 agonist, were assessed and the authors 
demonstrated that anandamide modulated agonist-mediated recruitment of βarr2 (Kapur et al., 
2009). No evidence of anandamide-dependent GPR55 receptor internalization on its own induced 
βarr2 trafficking in GPR55 U2OS cells (Kapur et al., 2009). 
1.4.1 Anandamide 
Anandamide has demonstrated a higher potency for GPR55 than for CB1 or CB2 in a [
35S] GTPS 
binding assay (Ryberg et al., 2007). Several other groups have used calcium mobilization assays 
and demonstrated similar or lower potency for anandamide at GPR55 compared to CB1 or CB2 
(Lauckner et al., 2008; Waldeck-Weiermair et al., 2008). In contrast to the CB1 and CB2 receptors, 
stimulation by the agonist anandamide did not increase GPR55 mediated ERK1/2 
phosphorylationin GPR55 transfected HEK293 cells (Kapur et al., 2009; Lauckner et al., 2008; 
Waldeck-Weiermair et al., 2008). Previous studies have reported that anandamide exerts anti-
proliferative effects on cholangiocarcinoma independent of any known cannabinoid receptors 
(DeMorrow et al., 2007). However, since the identification of GPR55 the role of the receptor has 
now been evaluated(Huang et al., 2011). Treatment with anandamide has shown to reduce 
cholangiocarcinoma cell proliferation in vitro and in vivo and this effect was not seen when the 
receptor was knockout down (Huang et al., 2011). Recent studies have shown that anandamide 
can act as a partial agonist; enhancing the agonist effect at low concentrations and inhibiting it at 
high concentrations (Sharir et al., 2012).   
1.4.2 2-Arachidonoyl Glycerol 
2-AG has been reported to be a GPR55 agonist in [35S] GTPS binding assay using GPR55 
transfected HEK293 cells at a concentration of 3nM (Ryberg et al., 2007). In contrast, other studies 
have demonstrated the lack of effect by 2-AG on calcium mobilization in GPR55 transfected 
HEK293 cells (Lauckner et al., 2008). An alteration in ERK1/2 phosphorylation was not observed in 
the GPR55 transfected cell lines HEK293 and U2OS nor did the endocannabinoid affect GPR55 
receptor internalization or β-arrestin recruitment (Kapur et al., 2009; Yin et al., 2009). GPR55 
expression has been shown to increase in human blood neutrophils upon activation by 2-AG 
(Balenga et al., 2011a). 
1.4.3 Tetrahydrocannabinol 
THC has shown to act as a GPR55 agonist in the [35S] GTPS binding assay using GPR55 transfected 




arrestin recruitment was however again absent (Kapur et al., 2009; Yin et al., 2009). Increased 
intracellular calcium levels have been observed in GPR55 transfected HEK cells and dorsal root 
ganglion neurons upon treatment with THC (Lauckner et al., 2008). 
1.4.4 Rimonabant 
The CB1 receptor antagonist SR14617A (rimonabant) was developed as an anti-obesity drug. 
Inconsistent data has been reported regarding the activity of rimonabant at GPR55. GPR55 
antagonism has been reported in GPR55-transfected HEK293 cells at micromolar levels (Lauckner 
et al., 2008). An agonist activity has been reported for rimonabant in which the compound has 
shown to mediatecalcium mobilization in GPR55-transfected HEK293 cells (Henstridge et al., 
2009). GPR55 activation by rimonabant has also shown to downregulate the receptor via GPCR-
associated sorting protein-1 (Kargl et al., 2011). 
1.4.5 CP55, 940 
CP55,940 exerts high affinity for CB1 and CB2 receptors and a similar potency has been shown for 
the ligand at GPR55 when using the [35S]-GTPS binding assay (Ryberg et al., 2007). In ERK1/2 
activation or calcium mobilization GPR55 assays no agonistic activity was demonstrated by 
CP55,940 (Lauckner et al., 2008; Oka et al., 2007). CP55,940 has also shown to act as an 
antagonist/partial agonist at low micro molar concentrations by inducing the blocking of GPR55 
internalization, the formation of β-arrestin GPR55 complexes and the phosphorylation of ERK1/2 
(Kapur et al., 2009). CP55940 has been shown to modulates cytokine rat mRNA expression in 
cerebellar granule cells however, this has shown to be a GPR55 receptor-independent mechanism 
(Chiba et al., 2011). 
1.4.6 WIN 55,212-2 
WIN 55,212-2, a structural analogue of the aminoalkylindole JWH015, has demonstrated a CB1 
independent inhibition of glutamatergic neurotransmission suggesting a novel cannabinoid 
sensitive receptor in mouse hippocampus (Hajos et al., 2001). The ability of the cannabinoid 
receptor radioligand [3H]-WIN55, 212-2 to bind to membranes prepared from the HEK293 cells 
GPR55 transfected cells has been examined. However, no detectable binding was observed when 
using 50 nM of [3H]-WIN55, 212-2 (Kapur et al., 2009; Ryberg et al., 2007). The lack of activity of 





Cannabidiol is the major non psychoactive compound of cannabis (Mechoulam et al., 2007). The 
stimulation of [35S]-GTPS by anandamide in GPR55 transfected HEK293 cells has been 
demonstrated to be antagonized by CBD (Ryberg et al., 2007).  The phytocannbinoid has however 
demonstrated low affinity for CB1 and CB2 receptors (Drmota 2004; Ryberg et al., 2007). It has also 
been reported to act as a GPR55 antagonist in human osteoclasts using an ERK1/2 
phosphorylation assay (Whyte et al., 2009). CBD has recently been shown to have an anti-
inflammatory role in acute pancreatitis (AP) that might be GPR55 related (Li et al., 2013). 
1.4.8 Abnormal cannabidiol 
The GPR55 receptor has also been postulated to be an endothelial receptor possibly responsible 
for mediating the vasodilatory effects induced by atypical cannabinoids such as Abn-Cbd (Ryberg 
et al., 2007). Although Abn-Cbd lacks significant affinityfor CB1 and CB2 receptors (Drmota 2004; 
Ryberg et al., 2007) it has shown to stimulate [35S]-GTPS binding in GPR55 transfected cells (Johns 
et al., 2007; Ryberg et al., 2007). The atypical cannabinoid however failed to induce GPR55-
modulated βarr2 redistribution (Kapur et al., 2009) nor did the ligand induce GPR55 mediated 
ERK1/2 activation (Oka et al., 2007). The ligand did not affect calcium mobilization in GPR55 
transfected HEK293 cells (Lauckner et al., 2008).  
1.4.9 O-1602 
O-1602, an analogue of Abn-Cbd was synthesized in order to study structural requirements for the 
vasodilator activity of Abn-Cbd. The analogue has shown to be active in vasorelaxation (Ho et al., 
2004; Jarai et al., 1999) and has shown to stimulate [35S]-GTPS binding in GPR55 transfected cells 
(Johns et al., 2007; Ryberg et al., 2007). O-1602 causes vasodilatation and hypotension but does 
not bind to either CB1 or CB2 receptors.  Although GPR55 is activated by O-1602 it does not appear 
to mediate the vasodilator effects of this agent (Johns et al., 2007). The analogue has 
demonstrated to promote GPR55 mediated ERK1/2 phosphorylation in human osteoclasts (Whyte 
et al., 2009). In contrast, O-1602 failed to induce GPR55-modulated βarr2 redistribution (Kapur et 
al., 2009). O-1602 has recently been demonstrated to be involved in reducing nociception in a rat 




1.4.10 O-1918  
The Abn-Cbd analogue 1,3-Dimethoxy-5-methyl-2-[(1R,6R)-3 -methyl-6-(1-methylethenyl)-2-
cyclohexen-1-yl]benzene (O-1918),which is a stereoisomer of O-1602, has shown to inhibit 
vasorelaxation induced by anandamide (Offertaler et al., 2003). The analogue can also antagonize 
vasorelaxation induced by the GPR55 agonists virodhamine (Ho and Hiley, 2004) and oleamide 
(Hoi et al., 2006). O-1918 has also been shown to abolish an anti-nociceptive effect induced by a 
GPR55 agonist in an arthitis rat model (Schuelert et al., 2011). Also, in the same study O-1918 
was reported to be a GPR18 and BK (Big potassium) calcium channel antagonist (Schuelert et al., 
2011).  
1.4.11 Lysophosphatidylinositol..................................................................................................  
GPR55 was recently reported as a lysophosphatidylinositol (LPI) receptor as it has consistently 
been shown to be stimulated by the agonist (Anavi-Goffer et al., 2012; Henstridge et al., 2009; 
Kotsikorou et al., 2011; Lauckner et al., 2008; Oka et al., 2007). LPI is an acidic lysophosholipid and 
is thought to be a result of degradation of phosphatidylinositol by phospholipase A (PLA)(Oka et 
al., 2009; Pineiro et al., 2012). LPI has shown to stimulate [35S] GTPS binding to GPR55 expressing 
cell membranes (Oka et al., 2007). It has also been reported that LPI can activate ERK1/2 
phosphorylation in GPR55 transfected HEK293 cells and U2OS cell lines (Kapur et al., 2009; Oka et 
al., 2007). In addition, LPI has been shown to be an agonist when using GPR55 receptor 
internalization or β-arrestin recruitment assays (Henstridge et al., 2009; Kapur et al., 2009; Yin et 
al., 2009). The endogenous compound  2- arachidonoyl lysophosphatidylinositol has recently been 
demonstrated to activate GPR55 in HEK293 cells more potently than LPI suggesting that this ligand 
might be the be the most potent GPR55 agonist (Oka et al., 2007). 
1.4.12 Other ligands 
The GPR55 receptor has also been shown to be stimulated by the cannabinoid receptor agonists, 
noladin ether and virodhamine and non CB1/CB2 receptor ligands such as the anti-inflammatory 
compound palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) in the [35S]-GTPS binding 
assay (Drmota 2004; Ryberg et al., 2007). Although some CB1 and CB2 cannabinoid ligands that 
bind to GPR55 there are other distinct chemical classes which like LPI do not recognize CB1 and CB2 
receptors however these have shown to bind to GPR55 (Zhao et al., 2012). 
Using the β-arrestin recruitment assay a library screen of 290,000 compounds was performed in 
the NIH Molecular Libraries program (by the Sanford-Burnham Center for Chemical Genomics) 




identified: piperazine, ML184 (2440433) with 263 nM potency, tricyclic triazoloquinoline, ML185 
(CID1374043) with 658 nM potency and morpholinosulfonylphenylamide, ML186 (CID15945391) 
with 305 nM potency (Table 1.1) (Heynen-Genel et al., 2010a). All agonists had between 48-120 
fold selectivity against GPR35, CB1 and CB2 (Heynen-Genel et al., 2010a). Thee antagonists for 
GPR55 have also been identified: piperadinyloxadiazolone, ML191 (23612552) with 160 nM 
potency, thienopyrimidine, ML192 (CID1434953) with 1080 nM potency; and quinoline aryl 
sulfonamide, ML193 (CID1261822) with a 221 nM potency (Table 1.1)(Heynen-Genel et al., 
2010b). All antagonists had between 27- 145 fold selectivity against GPR35, CB1 and CB2 (Heynen-
Genel et al., 2010b). All agonists and antagonists were involved in activating downstream 
responses of ERK phosphorylation and PKC β II translocation (Heynen-Genel et al., 2010a; Heynen-
Genel et al., 2010b). 
 




POTENCY1 GPR55 ANTAGONISTS 
 
POTENCY2 
piperazine, ML184 (2440433) 263 nM piperadinyloxadiazolone, 
ML191 (23612552) 
160 nM 
tricyclic triazoloquinoline, ML185 
(CID1374043) 














. The potency (EC50) of the compounds have been reported previously (Heynen-
Genel et al., 2010a; Heynen-Genel et al., 2010b). 
 
GSK494581A belongs to a series of benzoylpiperazines initially reported to act as inhibitors of the 
glycine transporter subtype 1 (Brown et al., 2011). One of the benzoylpiperazines GSK575594A has 
been identified as a GPR55 ligand with 60-fold selectivity for the receptor. This ligand is similar to 
ML184 (CID2440433) (Zhao et al., 2012). The benzoylpiperazine agonists has shown to activate 
human not rodent GPR55 (Brown et al., 2011). 
 
Recently a molecular model of GPR55 was derived in which interaction of the recently identified 
GPR55 agonists CID1792197, CID2440433 (ML184) and CID1172084 (ML185) ligands was 
examined. An important residue for agonist activation of GPR55 was identified and the three 
ligands resembled LPI and not cannabinoid ligands (Kotsikorou et al., 2011). To date, no low 




to characterize binding at this receptor making it a hurdle to identify ligand binding properties 
(Zhao et al., 2012). Unfortunately, these recently identified GPR55 specific ligands were 
synthesized after initiation of our experiments and were unavailable for this study. 
1.5 GPR55 signalling and intracellular mechanisms 
 
GPR55 signalling promote receptor coupling to multiple signalling pathways and is linked to 
heterotrimeric G proteins (Ryberg et al., 2007). GPR55 has been shown to use Gq, G12, G13 for 
signal transduction that mediates activation of members of the Rho family of GTPases including 
rhoA, cdc42 and rac1 (Henstridge et al., 2009; Lauckner et al., 2008). RhoA has been reported to 
be involved in regulation of the actin cytoskeleton (Lauckner et al., 2008; Waldeck-Weiermair et 
al., 2008).LPI has shown to induce a rapid phosphorylation of ERK (extracellular signal-regulated 
kinase) in the MAPK/ERK (mitogen-activated protein kinase) signal transduction pathway in GPR55 
transfected HEK293 cells (Oka et al., 2007). In another study LPI induced the rapid phosphorylation 
of p38 MAPK in GPR55 expressing cells, this effect was absent in the vector transfected cells. 
MAPK p38 is involved in responses for cellular stresses such as activation of proinflammatory 
cytokines, heat shock, osmotic stress and regulation of cellular activities such as gene expression, 
differentiation and apoptosis (Pearson et al., 2001).  
1.6 Biological function of GPR55 
 
At the time of initiation of this project the biological role of GPR55 was unclear. The role of GPR55 
in hyperalgesia associated with inflammatory and neuropathic pain has been suggested from 
studies in GPR55 knockout mice. GPR55 knockout mice showed no mechanical hyperalgesia 
following partial nerve ligation when compare to wildtype mice (Staton et al., 2008). An increase in 
the anti-inflammatory cytokines interleukin (IL) four and IL-10 was seen in the genetically modified 
mice after administration of Freund’s adjuvant compared to wild type littermates  suggesting a 
protective role in inflammation induced pain (Staton et al., 2008). 
GPR55 has been suggested to play a role in bone metabolism as it has been demonstrated that 
mice lacking CB1 and CB2 receptors have abnormal bone phenotypes (Idris et al., 2008; Ofek et al., 
2006). Recently, GPR55 mRNA were detected in human and mouse osteoblasts and osteoclasts 
generated from macrophage colony-stimulating factor-dependent monocytes. The synthetic 
agonist O-1602 was used to investigate the role of GPR55 in osteoclast formation. It was found 
that O-1602 did not affect the formation of human osteoclast in vitro. In contrast the GPR55 




that GPR55 plays an inhibitory role in osteoclastogenesis. Mouse osteoclast formation in vitro was 
however inhibited by O-1602 and LPI whereas the inhibitory effect was antagonized by CBD. The 
inhibitory effect was absent in GPR55 knockout mice (Whyte et al., 2009).   
Increased LPI levels have been found in obese patients (Moreno-Navarrete et al., 2012). The same 
study also demonstrated higher GPR55 levels in diabetic patients compared with control group 
(Moreno-Navarrete et al., 2012). Other studies have shown that activation of GPR55 by O-1602 
promotes the increase of glucose stimulated insulin secretion in isolated rat pancreatic islets 
(Romero-Zerbo et al., 2011). In vivo activation of GPR55by O-1602 increases insulin levels in rats 
suggesting a role for GPR55 in endocrine pancreatic function (Lipina et al., 2012; Moreno-
Navarrete et al., 2012; Romero-Zerbo et al., 2011). 
 
Numerous studies have reported that endocannabinoids and phytocannabinoids exert effects on 
intestinal contractility by inhibiting acetylcholine release from enteric neurons (Heinemann et al., 
1999; Roth, 1978). The atypical cannabinoid O-1602 has shown to inhibit neurogenic contractions 
in the gut mediated by GPR55 independent of CB1 and CB2 receptors (Ross et al., 2012). 
 
GPR55 has been suggested to be the cannabinoid- binding receptor responsible for vasodilatation 
to atypical ligands such as Abn-cbd and O-1602 however the vasodilatory effect to both ligands 
were comparable in GPR55 knockout and wildtype mice(Johns et al., 2007). O-1918 also showed 
similar inhibitory effects of the vasodilatation induced by Abn-cbd in both mouse strains (Johns et 
al., 2007). 
1.7 GPR55 and cancer 
 
There is limited information available about the role of LPI ligand in humans but increased levels 
have however been shown in ascites fluid and blood plasma in people with ovarian cancer 
(Sutphen et al., 2004; Xiao et al., 2001). This has been linked to tumourogenesis and a role for 
GPR55 and LPI in modulation, orientation, polarisation of breast cancer cells was recently 
presented (Pineiro et al., 2010). A highly metastatic breast cancer cell line MDA-MB-231 was found 
to express 30-fold higher levels of GPR55 compared to a lower metastatic breast cancer cell line 
hence suggesting a role for GPR55 in control of metastasis (Ford et al., 2010). LPI stimulated [35S]-
GTPS binding to membranes from the highly metastatic cell line and enhanced migration of the 
MDA-MB-231 cells. It was not possible to knockout the receptor in the MDA-MB-231 cell line 
therefore it remains to confirm the role of GPR55 as the receptor responsible for the effects of LPI 




and proliferation in vitro, and tumor growth in a xenograft-based model of glioblastoma (Andradas 
et al., 2011; Ford et al., 2010; Pineiro et al., 2011). 
GPR55 has been demonstrated to drive chemically-induced mouse skin tumour development. 
Wild-type mice were shown to have an increased papilloma and carcinoma formation, enhanced 
skin cancer cell anchorage-independent growth, invasiveness and tumorigenicity in vivo, compared 
to GPR55 knockout mice (Perez-Gomez et al., 2012). While all the carcinomas in the GPR55 
knockout mice were well differentiated, 22% of the carcinomas were found to be poorly 
differentiated in the wildtype mice (Perez-Gomez et al., 2012). Higher GPR55 mRNA levels were 
also detected in the carcinomas compared to control mouse skin (Perez-Gomez et al., 2012). TPA 
(phorbol ester 12-O-tetradecanoylphorbol-13-acetate),  a proliferation inducing agent has been 
described to induce local inflammation when applied on mouse skin and causes and increased 
dermal cell population(Perez-Gomez et al., 2012). An increase of inflammatory CD45 positive cells 
and cytokines including ILb1 and TNF has been observed in the dermis of wildtype and not in 
the GPR55 deficient mice (Perez-Gomez et al., 2012). The lack of highly selective and high affinity 
reagents have hampered with the elucidation of the true biology of GPR55. 
1.8 Multiple sclerosis (MS) 
 
Multiple sclerosis (MS) is an immune-mediated demyelinating and neurodegenerative disease of 
the central nervous system (CNS). The disease is associated with repeated immune attack of the 
CNS leading to demyelination, axonal and neuronal loss thereby affecting normal 
neurotransmission (Compston & Coles., 2002; Compston & Coles., 2008). The symptoms vary 
depending on where demyelination and nerve loss occurs and leads to the development of 
neurological signs and symptoms including spasms, tremor, ataxia, weakness or paralysis, 
cognitive impairment and incontinence (Compston & Coles., 2002). 
MS has an incidence of about 7 per 100,000 every year in the UK,  however the incidence may be 
higher in certain areas of the UK and affect up to 1 in 170 in the Orkney islands (Visser et al., 2012) 
and affects around 2.5 million individuals worldwide (Kurtzke, 1993).  A total of 80% of non-benign 
MS patients present relapsing-remitting MS (RRMS) characterized by episodes of neurological 
deficits that develops into chonic secondary progressive MS (SPMS) (Figure 1.3) (Compston & 
Coles., 2002). Progressive disease from the onset is termed primary progressive and is presented 
in 10-15% of the patients and primarily affects the spinal cord and in some cases the optic nerve, 
cerebrum and cerebellum (Compston & Coles., 2002; Kurtzke, 1993). Depending on where the 




anatomy. Magnetic resonance imaging (MRI) is a technique used to assess affected sites in MS. 
The cerebrum and the spinal cord are most frequently affected when assessed with MRI. A 
minimum of two attacks affecting more than one anatomical site separated in time is a diagnostic 
criteria required for clinically delineated MS. However, a combination of clinical presentation and 
MRI can be used as a diagnostic criteria (Compston et al., 2008; Polman et al., 2011). Other clinical 
features associated with the disease are findings of oligoclonal bands in 90% of cases (Compston 
et al., 2002b). The aetiology of the disease remains unknown although epidemiological data 
indicate the involvement of environmental factors and genetic susceptibility (Dyment et al., 2004). 
Globally, the risk of MS increases with distance north or southofthe equator (Kurtzke, 1975). 
Immigrants that migrate from high-risk to low-risk areas in childhood are associated with a 
reduced risk of developing MS and vice versa (Hammond et al., 2000). The disease is more 
common in northern Europeans and twice as common in women as in men (Compston et al., 
2002b). The incidence is also higher for relatives;  (Compston et al., 2002b). Although diagnosis of 
the disease is usually around 20-40 years old (McQualter et al., 2007), 7% of patients are under 16 
years old (Compston & Coles., 2002). Life expectancy for MS patients from disease onset is around 
25 years although death may occur quickly within months or after many years. Average life 
expectancy is only reduced by about 7 years but the quality of life is significantly affected. A 
number of environmental factors have been investigated including infection, dietary factors, 
pollution and chemical agents. Viruses are among the most studied infectious agents related to 
MS pathogenesis. Suggested candidates have included Epstein Barr virus (EBV), Herpes simplex 
1&2, Varicella zoster virus, Human Herpesvirus type 6  and reactivation of human endogenous  
retroviruses (Hauser et al., 2006). There is strong evidence for a role of EBV where a late EBV 
infection and higher titres of a latent EBV antigen are associated with increased risk of developing 
MS.Individuals that have never been infected by EBV are associated with a low risk of developing 














An initial period of repeated inflammatory episodes results in blood: brain barrier dysfunction and in 
some occasions relapsing neurological deficit induced by persistent demyelination. This creates a chonic 
neurodegenerative microenvironment, seen by brain atrophy, which reaches a theshold beyond which 
clinical disease progresses unabated (adapted from Compston & Coles 2002). 
Population studies have suggested an association between multiple sclerosis and alleles of 
themajor histocompatibility complex (MHC) (Compston &Coles 2008). HLA type HLA-DR2 and in 
particular the allele HLA-DRB1*1501 has been linked to MS susceptibility (Barcellos et al., 2003; 
Oksenberg et al., 2004). To date over so non-MHC have been linked to susceptibility of MS 
(Wandstrat et al., 2001). These are essentially all immune related. Other minor susceptibility loci 
include interleukin 2 and 7 receptors, the c-type lectin domain family 16 member A and the 
adhesion molecule CD58 (De Jager et al., 2009). Vitamin D levels and sunlight exposure may 
provide a possible explanations for the association of latitude and MS risk (Pierrot-Deseilligny, 
2009). Vitamin D affects the differentiation and function of cells in the immune system (Liblau et 
al., 1995) and has shown to regulateHLA gene expression by a direct interaction with a functional 
vitamin D response element in the promoter region of HLA-DRB1 (Ramagopalan et al., 2009). 
These results provide a mechanism linking genetic and environmental factors of MS susceptibility. 
Although vitamin D could influence disease course this could be in utero where vitamin D levels of 
the pregnant mother may influence immune development (Ebers, 2008; Dobson et al., 2012). Over 
so other genetic variants have been linked to disease susceptibility which are largely linked to 





1.8.1 Pathogenesis of MS 
The pathology of MS is complex and the sequence of events leading to initiation of disease 
remains to be confirmed. One of the major missions in MS research has been to establish the 
sequence of events that lead to the development of inflammatory plaque (lesions) (Raine, 1994). 
MS appears to be an immune-mediated disease initiated by the activation of autoreactive T cells, 
which leads to inflammatory events and myelin destruction, axonal loss, neurological deficit 
(Weiner, 2004) and activation of lymphocytes by exogenous pathogens or by nonspecific 
activation of T and B cells due structural homology between self-protein and a protein in the 
pathogen, a process called molecular mimicry (Steinman et al., 2002). 
 
MS is initiated by an unknown mechanism, which appears to initiate an inflammatory response 
where auto-reactive T cells are activated in the periphery and adhere to receptors on endothelial 
cells and migrate across the disrupted blood-brain barrier(BBB) (Compston et al., 2008; Hauser et 
al., 2006). The disruption of the BBB in MS has been shown using histology (Broman, 1964) and 
clinically using gadolinium enhanced MRI (Alnemri et al., 1996) which detects active lesions in MS 
patients (Grossman et al., 1986). CD11a/CD18 and CD49d/CD29 are integrins predominantly 
involved in leucocyte trafficking. CD11a/CD18 and CD49d/CD29 are expressed on lymphocytes and 
have been detected on leucocyte infiltration in MS lesions (Bo et al., 1996). CD49d/CD29 binds the 
vascular cell adhesion molecule CD106 during an inflammatory response (Hauser et al., 
2006).After crossing the endothelial cell layer activated T cells must past though the sub-
endothelial basement membrane composed of type IV collagen, which is only found in basement 
membranes (Steinman et al., 2002). Activated T cells then use enzymes like matrix 
metalloproteinases (MMP) that lyse the sub-endothelial basal lamina and allow the transmigration 
via a Rho-dependent pathway (Steinman et al., 2002; Walters et al., 2002). Type IV collagen  has 
been shown to be particularly targeted by MMP 2 and 9, which are both detected in the CSF in MS 
(Steinman et al., 2002). T cells that have crossed the blood brain barrier (BBB) are then reactivated 
by fragments of myelin antigens. Originally myelin proteins were considered the main candidates 
for initiation of MS, however other factors have also been implicated (Hauser et al., 2006). The 
small heat shock-protein  crystallin has been found to function as immunodominant myelin 
antigen when expressed at high levels in MS lesions (van Noort et al., 1995). Antibodies against 
neurofascin, a cell adhesion molecule, have been suggested to mediate axonal injury in MS 
(Mathey et al., 2007). Following the initial activation of myelin specific T cells and activation of the 
vasculature to upregulate adhesion molecules and chemokines a secondary wave of cells enter the 




macrophages the immune response is enhanced by proinflammatoty cytokines stimulation of 
naïve microglia (Compston & Coles., 2002). Th17 (T cells that produce IL-17) cells may cause 
damage to axons (Wu et al., 2011) and there may be CD8 mediated killing of oligodendrocytes and 
neurons (Pierson et al., 2012). A contact is then created between activated microglia and 
components of the oligodendrocyte-myelin unit allowing the delivery of toxic signals such as 
though tumour necrosis factor  (TNF-) (Zajicek et al., 1992). In acute demyelinating lesions 
axonal injury with transection has been observed; which correlates with T cell and microglial 
activation (Trapp et al., 1998). This is known at the outside-in hypothesis of autoimmunity, 
however analysis of early MS lesions suggest that disease is an inside-out disease where early 
lesions occur before significant infiltration of T cells (Barnett et al., 2004; Geurts et al., 2010; 
Tsunoda et al., 2002). At later secondary progressive stages areas of demyelination have been 
observed together with significant axonal and neuronal degeneration and it is now believed that 
progress in disability is due to neurodegeneration (Anderson et al., 2008; Dutta et al., 2011; Trapp, 
1999). Remyelination is seen as shadow plaques and is mostly active during the acute 
inflammatory process and also involves phagocytic removal of myelin debris (Compston et al., 
2008). Remyelination of plaques has been observed in 20% of MS patients and is ongoing in grey 
matter lesions (Chang et al., 2012; Patrikios et al., 2006; Trapp, 2012). These ‘pre-active’ lesions 
contains clusters of microglia around the oligodendrocytes and occur in the grey and white matter, 
thus it is possible that the inflammatory response is recruited to clear the myelin debris. However 
it is clear that immunosuppression inhibits relapsing MS (Compston et al., 2002a; Compston et al., 
2008). This implicates the immune system in this process. However, triggering events inside the 
CNS such as HERV activation in oligodendrocytes could trigger production of stress response that is 
recognized by peripherally recruited α crystallin responsive cells (van Noort et al., 2012) 
1.8.2 MS therapies 
Immunosuppressive therapies were primarily used to treat MS based on the assumption that MS 
is an autoimmune disease (Whitaker, 1994). Corticosteroids are currently used to treat relapses 
and modulate the duration of relapse in MS patients by suppressing important components of the 
immune system and vascular permeability (Tischner et al., 2007). However, many of these 
treatments produce numerous side effects and are only partially effective in reducing disease 
severity (Thrower, 2009; Tischner et al., 2007). 
Anti-inflammatory and immunosuppressive therapies can provide beneficial effects on relapse 
rate and accumulation of disability early disease, however these do not appear to impact on 




first line and second line disease modifying therapy (DMT) for relapsing-remitting MS and 
symptomatic therapy (Dobson, 2013). The existing DMT therapies are aimed at modulating the 
immune response.  
Beta interferons (IFN-) were the initial drugs shown to be efficient in reducing the relapse rate 
(Hemmer et al., 2005). These are now first line treatments in the UK based on costs and side effect 
potential. The immunomodulatory drugs interferon-β-1a and the non-glycosylated interferon-β-1b 
reduce the relapse rate in MS by about 30% and decrease disability accumulation (Capobianco et 
al., 2008). Initially the interferons were mainly used for their anti-viral properties as viral infections 
are suggested to generate relapses (Hong et al., 2002). Interferons have shown to act as 
antagonists of proinflammatory cytokines and have been suggested to down regulate MHC class II 
antigen expression, however the precise mechanism of action is unclear (Hall et al., 1997). 
Approximately 3–30% of patients of IFNβ-treated patients develop neutralising antibodies (NAbs) 
during treatment which impact negatively on the effect of the drug (Capobianco et al., 2008). 
Glatiramer acetate (Copaxone) is another first line drug for treatment of relapsing remitting 
MS(Capobianco et al., 2008). The drug is a polymer molecular mimic of a region of myelin basic 
protein and has demonstrated to suppress the relapse rate by about 30% (Flechter et al., 2002). In 
addition the drug effects cytokine production and prevents presentation of autoantigens by 
monocytes and dendritic cells and may provoke active T cell suppression against MBP (Farina et 
al., 2005; Neuhaus et al., 2001). These are first line based on the lower costs and side-effect 
profile, which are restricted mainly to injection- site, reactions and flu-like symptoms in the case of 
beta interferons. Second-line drugs for MS treatment include monoclonal antibodies and small 
molecules, which are more potent but have more side-effects and considerably higher costs. The 
humanized monoclonal antibody (mAb) Natalizumab (Tysabri®) binds to the α4-integrin (CD49d) 
component of adhesion molecules found on lymphocytes, monocytes, and eosinophils and 
prevents entry of immune cells into the CNS (Selewski et al., 2010; Tsunoda et al., 2007). 
Natalizumab can reduce the relapse rate by approximately 70% (Hutchinson et al., 2009). 
Natalizumab however can be associated with hypersensitivity because it is an immunogenic 
protein and importantly about 2.77:1000 currently develop progressive multifocal 
leukoencephalopathy a disabling or fatal infectious demyelinating disease of the brain (Bloomgren 
et al., 2012; Rice et al., 2001; Yousry et al., 2006). In fact this increases to 1 in 94 people on 
Natalizumab for more than 24 months who have previously been treated with 
immunosuppressants and are infected with the JC virus (Bloomgren et al., 2012). Mitoxantrone is a 
cytotoxic agent with immunosuppressant properties and has shown to reduce the number of B 




2005). The drug is associated with a more toxic effect than the interferons and is mainly used by 
patients with high relapse frequency and aggressive relapse disease; this causes cardiotoxicity and 
the development of cancer (Edan et al., 1997; Mulroy et al., 2012; Paul et al., 2009). Natalizumab 
and mitoxantrone are drugs used as second- or third- line treatments (Brinkmann et al., 2010). 
Fingolimod (Gilenya®, FTY720) is an oral drug that mediates modulation of sphingosine-1-
phosphate receptors (Brinkmann et al., 2010). Current research suggests that the action of FTY720 
is mainly mediated by modulation of the sphingosine-1-phosphate receptors on the lymphocytes 
preventing exit of central effector cells from lymphoid tissue thereby reducing the infiltration of 
autoaggressive lymphocytes into the CNS (Brinkmann, 2009; Chun et al., 2010). The drug has also 
been demonstrated to reduce astrogliosis in EAE (Choi et al., 2010). Other recently developed 
drugs include Lemtrada®, (Alemtuzumab, Campath-1H) which targets CD52 to deplete T and B 
cells and is undergoing regulatory approval(Buttmann, 2010; Goldenberg, 2012). Daclizumab is a 
humanized monoclonal antibody which targets CD25, a molecule which is involved in T cells 
activation and inhibits Natural killer cell function (Bielekova, 2012; Kaur et al., 2012; Perry et al., 
2012). Ocrelizumab is a humanized anti-CD20 monoclonal antibody which depletes CD20 
expressing B-cells (Lulu et al., 2012). Although Cladribine, an oral drug that is a purine synthesis 
inhibitor which depletes peripheral  lymphocyte levels, demonstrated significant  efficacy  and a 
relative safe profile in phase II and phase III studies compared to placebo, this drug was not 
granted regulatory approval in the EU or in the USA (Lulu et al., 2012; Muir et al., 2011). The 
company was requested to conduct a second phase III trial for cladribine and decided to stop 
manufacturing the drug due to costs and other factors. Other oral drugs that are licensed for use 
in MS include BG12 (Tecfidera®), Teriflunomide (Aubagio®) and Laquinimod (Limmroth, 2012; 
Papadopoulou et al., 2012; Toubi et al., 2012). BG12, a fumaric acid ester, decreases leucocyte 
infiltration through the BBB, it also activates antioxidant pathways such as nuclear factor 
(erythoid-derived 2)-like 2 (Nrf2-2) pathway thereby protecting against neuronal death and myelin 
injury (Limmroth, 2012; Nguyen et al., 2009). Teriflunomide is a pyrimidine synthesis inhibitor that 
decreases T-cell proliferation by reducing activity of mitochondrial enzyme dihydro-orotate 
dehydrogenase which is required for DNA synthesis (Papadopoulou et al., 2012). Laquinimod has 
demonstrated to have an immunomodulatory effect and inhibits T-cell and macrophage entry into 
the CNS; it also stimulates pro-inflammatory cells into shifting to anti-inflammatory cells (Toubi et 
al., 2012). However, Laquinimod had low efficiency compared to the beta interferons but it have 
an effect on atrophy. There are no licensed drugs that inhibit either non-relapsing, gadolinium 




1999a; Coles et al., 1999b), Cladribine (Rice et al., 2000) and bone marrow transplantation (Inglese 
et al., 2004) that inhibit relapse but do not halt progression. This supports the concept of MS 
containing a neurodegenerative nature and component.  
1.8.3 Cannabis and MS 
Cannabis has been used for medical purposes for over thousands of years (Pertwee, 2009). The 
increased self-medication of this illegal drug has been reported in anecdotal reports especially by 
patients with multiple sclerosis (Fox et al., 2012; Pertwee, 2002).  Evidence of beneficial use of 
cannabis has now been shown in a number of clinical trials where treatment with cannabinoid 
agonists has been perceived to control symptoms including spasms, pain, spasticity and 
incontinence reported by the patients (Deutsch et al., 2008; Kmietowicz, 2010; Novotna et al., 
2011; Pertwee, 2002; Pertwee, 2007).  
1.8.4 Spasticity, cause and incidence 
Spasticity appear to be among the symptoms resulting from injury to the upper motor neurons 
within the CNS (Adams et al., 2005). The pathophysiology of spasticity remains poorly understood 
but it may reflect a loss of inhibitory circuitry in the spinal cord resulting in excessive levels of 
stimulatory signals. Under normal conditions inhibitory signals are directed via the corticospinal 
tract to the spinal cord but following injury causing damage to the corticospinal tract; this leads to 
excessive contraction of the muscles and in some cases even at rest (Adams et al., 2005; Brown, 
1994; Nielsen et al., 2007). Spasticity is a common feature in MS and affects up to 84.3% of 
patients (Compston et al., 2002b; Oreja-Guevara, 2012). 
1.9. Anti-spastic drugs and mechanisms 
 
Anti-spastic drugs are mainly used for management of spasticity observed in diseases affecting the 
upper motor neurons such as MS most of which exert their effects though centrally mediated 
mechanisms (Meleger, 2006). Baclofen is a GABAB receptor agonist which act both presynaptically 
and postsynaptictically (Meleger, 2006) leading to a decrease in the excitatory neurotransmitter 
release and neurotransmitters involved in transmission of nociceptive impulses such as the 
neuropeptide substance P (Hwang et al., 1989). Baclofen is however associated with side effect 
such as sedation, depression hallucination and nausea (Meleger, 2006). Spasticity is decreased 
upon binding to GABAB receptors on presynaptic terminals of spinal interneurons; this results in 
hyperpolarization of the membrane leading to reduced calcium influx and release of the excitatory 




terminals cause membrane hyperpolarization via a G-protein-coupled receptor causing to 
increases in potassium conductance thereby enhancing inhibition (Milanov, 1992). Dantrolene is a 
muscle relaxant that inhibits the release of calcium from the sarcoplasmic reticulum thereby 
uncoupling motor nerve excitation and muscle contraction.  Dantrolene does not directly affect 
the CNS however it is associated with muscle weakness (Meleger, 2006). Botulinum toxin is a 
protein and neurotoxin produced by Clostridium botulinum, an anaerobic bacillus (Wheeler et al., 
2013).There are seven types of the toxin (A-G) which all block acetylcholine releasebacillus 
(Wheeler et al., 2013).  Botulinum toxin exerts its effects by preventing calcium-dependent release 
of acetylcholine resulting in long duration flaccid paralysis of the muscle into which it is injected 
(Meleger, 2006; Wheeler et al., 2013). Benzodiazepines such as diazepam have an anti-spasticity 
effect by acting on GABAA receptors to hyperpolarize the cellular membrane; this increases 
presynaptic inhibition (Zafonte et al., 2004). Tizanidine is a central acting adrenoceptor agonist 
that mainly affect spinal polysynaptic reflexes and is used for treatment of spasticity in MS 
(Coward, 1994; Kamen et al., 2008). Compounds derived from C. sativa or cannabinoids are used 
for anti-nociception and muscle relaxation in people with MS (Zajicek, 2005; Zajicek et al., 2003). 
Both Dronabinol/Marinol, (THC) and nabilone, a synthetic cannabinoid, have been used for 
treatment of pain and spasticity in MS (Smith, 2007). 
1.10 Cannabinoids in Spasticity 
1.10.1 Symptomatic control 
There are many symptoms of MS that are controlled by different drugs (Table1.1), however these 
are poorly controlled (Compston et al., 2002a). In trials where the effect of smoked cannabis was 
monitored, and there were obvious cannabimimetic effects, it was possible to demonstrate 
benefit in a cross-over study (Corey-Bloom et al., 2012). However, trials aimed at avoiding 










Table 1.2 Symptomatic treatments in MSTable 2 
 
 
Symptomatic treatments in MS(Compston et al., 2002a; Goodman et 
al., 2009) 
Site Symptoms Treatments 




Cerebrum - Depression Antidepressants 
Spinal cord - weakness 
- stiffness 









Other - Pain Carbamazepine 
gabapentin 
- Fatigue Amantadine 
 
Lesion sites, syndromes, and symptomatic treatments in multiple sclerosis. 
 
In experimental autoimmune encephalomyelitis (EAE), an animal model of MS, spasticity develops 
due to repeated neuroimmunological attack of the CNS that leads to loss of axons (Baker et al., 
2000; Baker et al., 2001). In this animal model the stimulation of the cannabinoid receptors with 
agonists has shown to improve limb and tail spasticity (Baker et al., 2000; Baker et al., 2001; Pryce 
et al., 2007). Treatment with the cannabinoid receptor antagonists, SR141716A, however 
worsened the spasticity in the animals (Baker et al., 2000). Although CB2 agonists had also been 
suggested as anti-spastic compounds these are also found to stimulate the CB1 receptor and there 
is no evidence that CB2 mediates any anti-spastic effect (Pryce et al., 2007; Wilkinson et al., 2003). 
CB1 receptors and THC mediate the beneficial control of spasticity and modulate the adverse 
effects of cannabis (Pryce et al., 2007). Numerous clinical trials have been undertaken on spasticity 
in MS (Novotna et al., 2011; Rog, 2010; Wade et al., 2006; Zajicek, 2005; Zajicek et al., 2003; 




(2.5 mg THC: 1.25mg CBD), Marinol (synthetic delta-9-THC in oil 2.5 mg) or placebo on spasticity 
and other MS symptoms was examined.  Overall patients reported that the drugs provided a 
significant improved effect on pain and muscle spasms (Zajicek et al., 2003). The “Multiple 
Sclerosis and Extract of Cannabis” (MUSEC) study conducted between 06/2006 to 09/2008 
confirmed the previous findings reported in the CAMS trial (Zajicek J., 2009). In this study 279 
patient were treated with oral cannabis extract (2.5 mg THC: 1.25 mg CBD) or placebo for up to 12 
weeks. Approximately 30% of the MS patients receiving oral cannabis extract compared to 15% in 
the placebo group reported relief of muscle stiffness and in some patients pain and sleep quality 
also improved (Zajicek J., 2009). In a recent phase III clinical trial MUSEC an extract from C. sativa 
(extraction medium ethanol 96%) in soft gelatine capsules, standardised on CBD (range 0.8-1.8 
mg) and containing 2.5 mg D9- THC was used as the main cannabinoid (Cannador;)to study its 
efficiency for symptomatic relief of muscle stiffness and pain in adult patients with MS (Zajicek et 
al., 2012). Approximately 30% of the patients reported that treatment with oral extract of C. sativa 
relieved muscle stiffness, body pain, spasms and improved sleep quality compared to 15% in the 
placebo group (Zajicek et al., 2012).  
The oromucosal administration allows a rapid absorption similar to smoking cannabis due to direct 
absorption into the systemic circulation avoiding both gastrointestinal absorption and first pass 
metabolism though the liver. Oromucosal administration allows a more accurate self-titration as 
minimal absorption by the oral route helps to minimize the variability of individual responses 
known to occur with other cannabinoids (Rog, 2010). Sublingual administration has shown to be a 
more rapid way of obtaining maximal plasma concentration compared to the oral route (Kappos et 
al., 2008; Rog et al., 2007). Sativex® (GW Pharmaceuticals Ltd., Salisbury, UK) is an oromucosal 
cannabis-based medicine that consists of approximately 1:1 ratio tetrahydrocannabinol (27 
mg/ml) and CBD (25 mg/ml) with less than 10%of other cannabis-based compounds in an alcoholic 
solution (Whittle, 2001).In a recent randomized, double-blind study Sativex®has shown to 
improve spasticity in patients who had previously failed to respond sufficiently to otheranti-
spasticity medications (Novotna et al., 2011). GW has previously achieved positive regulatory 
assessments in the UK, Spain, Germany, Italy, Denmark, Sweden, Austria, Canada, New Zealand 
and the Czech Republic and Sativex® has so far been approved / recommended for approval in 
eighteen countries for the treatment of spasticity (muscle stiffness/spasm) due to MS 
(http://www.gwpharm.com) (Oreja-Guevara, 2012). Recently GW announced that a further ten 
countries had now been recommended for approval under a Mutual Recognition Procedure 




Portugal and Slovakia.  A regulatory filing is also underway in Switzerland. Sativex® has also been 
approved for the treatment of cancer-related pain in Canada (Oreja-Guevara, 2012). Sativex® is 
frequently associated with mild to moderate side effects such as dizziness, drowsiness, fatigue and 
headache however these effects can be reduced by gradually increasing the dose of the drug 
(Sastre-Garriga et al., 2011). 
There is accumulating evidence demonstrating the control of spasticity by the endocannabinoid 
system in the chronic relapsing EAE (CREAE) animal model. Firstly, an increase of endocannabinoid 
levels in areas of nerve damage and in spinal cord lesions in spastic EAE animals has been detected 
compared to EAE animals lacking spastic signs (Baker et al., 2001). Augmented levels of 
endocannabinoids have also been identified in MS tissues suggesting that the endocannabinoid 
system controls irregular neurotransmission. Secondly, spasticity in EAE animals has shown to 
improve with administration of drugs that are considered to increase extracellular concentrations 
of endocannabinoids (Baker et al., 2000; Pertwee et al., 2000).  
1.11 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16R) 
It has been shown that cannabis can control symptoms of MS (Corey-Bloom et al., 2012; 
Kmietowicz, 2010; Zajicek et al., 2012). This supports earlier observations found in animals with 
EAE (Baker et al., 2000; Baker et al., 2012). As THC in cannabis and the CB1 receptor mediate most 
of both the beneficial and adverse effects of cannabis (Baker et al., 2012; Pryce et al., 2007; Varvel 
et al., 2005) an attempt was made to produce a CNS-excluded, CB1 receptor agonist, that can 
control spasticity by controlling peripheral nerve transduction, yet avoid stimulation of CB1 
receptors cognitive centres of the brain (Pryce, 2010). One of these compounds 
(3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide) termed VSN16R 
was a water soluble (over 200mg/ml) molecule. The molecule has been found to be orally active 
with about 30% bioavailability and had a half-life of about 90 min and a Cmax with 15-30min in mice 
(Pryce, 2010). The compound has been found to be highly potent in vitro and inhibits neurogenic 
contractions of the vas deferens at low nanomolar concentrations, and this action was inhibited by 
SR141617A and AM251, two CB1 receptor antagonists (Pryce, 2010). VSN16R has been shown to 
inhibit spasticity in EAE at doses ≥1mg/kg i.v. and ≥5mg/kg p.o. that was maintained following 
repeated administration (Pryce, 2010). This occurred via a CB1-independent mechanism as 
assessed by activity in CB1-/- mice. VSN16R has also failed to show any significant binding to a 
panel of over 70 different neurotransmitter receptors and ion channels, including CB1 and CB2 




of GPR55 (Elbegdorj et al., 2012). However, interesting VSN16R failed to directly agonize or 
antagonize the GPR55 receptor in human GPR55-transfected cell lines. However, the action of 
GPR55 agonist-induced cell signalling was enhanced by VSN16R (Pryce, 2010). This suggested that 
VSN16R could be a novel, selective, allosteric modulator of GPR55 function.  As all reported GPR55 
agonists or antagonists have known additional specificities (Baker et al., 2006a) and that the full 
extent of the endocannabinoid system remains to be elucidated, demonstration of action of 




















1.11 AIMS AND OBJECTIVES 
 
The aims of this project is to investigate the role of GPR55 as a therapeutic target to treat 
spasticity.  
The objectives of this project are; 
1.     Characterize the biology of GPR55. 
2.   Develop monoclonal antibodies against GPR55 as there are currently no commercially 
        specific GPR55 antibodies available.     
3. Identify the distribution profile of GPR55 in rodent tissue, with particular 
       attention to the CNS and peripheral nervous system.            
4.  Identify the function of GPR55 during  EAE in rodents, as it is hypothesized that GPR55 
        may be up-regulated during disease.        
5.     Investigate the effect of GPR55 deletion on VSN16R function.  















Material and Methods 
 
2.1 Mice 
ABH mice were from stock bred at Queen Mary University of London (QMUL), were purchased 
from Harlan UK Ltd, Bicester, Oxon UK or were donated by UCB, Cambridge, UK or from stock held 
by Charles Rivers, Margate, Kent. C57BL/6 mice were purchased from Charles Rivers, UK or were 
from stock bred at QMUL. All animal studies were performed following the Animals (scientific 
procedures) Act 1986. Mice from in-house bred stock were maintained in a 12h light/dark cycle 
with controlled humidity and temperature and housed to standards appropriate to the ARRIVE 
guidelines as described previously (Al-Izki et al. 2012). Animals were fed RM-1E diet and water ad 
libitum. 
2.1.1 GPR55 knockout mice 
Mice, 129xC57BL/6.GPR55tm1Tigm, expressing a GPR55 gene deletion construct were generated by 
by Lexicon Inc. the and founder mice purchased from the Texas Institute of Genomic Medicine 
(TIGM Houston, Texas USA). A targeting vector was constructed to replace part of exon 2 of the 
GPR55 gene (containing the entire coding region) with a selection cassette (Fig. 2.2.1).Homologous 
recombination was carried out in 129SvEvBrd-derived ES cells, followed by injection of targeted ES 
cells into blastocysts. The gene deletion map, primer sequence for detection of wild-type and 
other primers for the knockout targeting molecule and a male 129/C57BL/6.Gpr55 gene knockout 
was supplied. These mice were quarantined and initially backcrossed with C57BL/6 mice and re-
derived by caesarean section to remove pathogens.  A breeding colony was established from a 
single male animal. 
2.2 PCR 
2.2.1 DNA extraction 
Ear biopsies were removed from mice and DNA tissues samples were prepared following digestion 
at 56°C overnight in lysis buffer containing 487.5μl Nucleon™ reagent B (400mM TRIS, 60mM 
EDTA, 15mM NaCl,150mM SDS 1% pH:8.0) and 12.5μl (20mg/ml) proteinase K (Invitrogen, Paisley, 
UK). Sodium perchlorate at a volume of 187.5μl (6M) (Sigma-Aldrich, Poole, Dorset, UK) was then 




of chloroform was added and samples were vortexed for 10 min and centrifuged for 2 min at 478g. 
The aqueous phase was mixed with 1000l (2 volumes) of ethanol to precipitate the DNA. Samples 
were mixed and centrifuged for 5 min at 478g. The supernatant was removed and the pellet was 
dried at 60°C for 10 min. Samples were dissolved in 200μl of distilled H2O (dH2O). A Qiagen DNeasy 
extraction kit from (Qiagen, Crawley, UK) was used for later experiments using the protocol 
provided by the manufacturer. 
 
2.2.2 PCR 1&2 Genotyping 
The following primers and polymerase chain reaction conditions as previously described were 
used (Johns et al., 2007). The GPR55 sequences were following; GPR55 wild-type: DW1: 5′-
TCTTCCCCCTGGAGATCTTT-3′; DW2: 5′-CTGGGAGAAAGGAGACCACA-3′; 30 cycles of 94°C (45 s), 
58°C (45 s), and 72°C (45 s) generated an amplicon of 207 bp and  the GPR55 knockout (Neomycin 
gene) (N-5′, neomycin gene specific 5′ primer: 5′-CCGGCCGCTTGGGTGGAGAGG-3′ and N-3′, 
neomycin gene specific 3′ primer: 5′-TCGGCAGGAGCAAGGTGAGATGACA-3′; 30 cycles of 94°C (30 
s), 68°C (30 s), and 72°C (30 s) generates an amplicon of 299 bp. The PCR components are shown 
in tables 2.2.1 and 2.2.2. Primers were from Sigma-Aldrich (Ltd, Poole, Dorset, UK).The DNA 
samples were screened by PCR using Qiagen PCR core kit reagents (Qiagen, Crawley, UK).Samples 
were run using a Peltier Thermal cycler PTC-225 (MJ Research, Harlow, UK). 
New primers for detection of the different genotypes; wildtype, heterozygous and GPR55 
knockouts were designed and synthesized (Sigma-Aldrich Ltd, Poole, Dorset, UK). The following 
primers were used; Forward 5’-TCTGGATTCATCGACTGTGG-3’, Reverse1 5’-
CTCCACAATCAAGCTGGTCA-3’ WT 207bp, Reverse2 5’-GTCACCCATCCAGGTGATGT-3’ Transgene 
299bp. The cycling conditions for the PCR were following; 35 cycles of  94°C (30 s),94°C for (30 
s),55°C for (30 s),72°C (30 s),72°C (120 s),4°C (), generating an amplicon of 207 bp (GPR55) and 
299 bp (Transgene, Neomycin). The DNA samples were screened by PCR using Qiagen PCR core kit 
reagents (Qiagen, Crawley, UK). The PCR components are shown in table 2.2.3.Samples were run 









Table 2.1 PCR components for GPR55- specific primersTable 3 
 
Initial concentration reaction 
components 
Final concentration reaction 
components 
Volume (µl) 
dH2O dH2O 27 
10 x PCR Rxn buffer 
 (Invitrogen, Paisley, UK) 
(Tris HCl [pH8.3], 50mM KCl) 
10 x PCR buffer 
 (Tris HCl [pH8.3], 50mM KCl) 
5 
50mM MgCl2 (Invitrogen, Paisley, UK) 2.5mM MgCl2 2.5 
2.0mM dNTP (Invitrogen, Paisley, UK) 0.25mM dNTP 5 
20μM Forward DW1 primer 
(Sigma-Aldrich Ltd, Poole, Dorset, 
UK) 
1μM F DW1 primer 2.5 
20μM Reverse DW2  primer 
(Sigma-Aldrich Ltd, Poole, Dorset, 
UK) 
1μM  R DW2 primer 2.5 
1.25U/μl Taq Polymerase 
(Invitrogen, Paisley, UK) 
0.0125U/μl Taq Polymerase 0.5 
DNA sample DNA sample 5 
Total volume  50.00μl/reaction 
 
PCR components for master mix. Initial concentrations, final concentrations and volume of components 












Table 2.2 PCR components for Neomycin primersTable 4 
 
Initial concentration reaction 
components 
Final concentration reaction 
components 
Volume (µl) 
dH2O dH2O 27 
10 x PCR Rxn buffer 
 (Invitrogen, Paisley, UK) 
(Tris HCl [pH8.3], 50mM KCl) 
10 x PCR buffer 
 (Tris HCl [pH8.3], 50mM KCl) 
5 
50mM MgCl2 (Invitrogen, Paisley, UK) 2.5mM MgCl2 2.5 
2.0mM dNTP (Invitrogen, Paisley, UK) 0.25mM dNTP 5 
20μM Forward NEO5’ primer 
(Sigma-Aldrich Ltd, Poole, Dorset, 
UK) 
1μM F NEO 5’primer 2.5 
20μM Reverse NEO3’  primer 
(Sigma-Aldrich Ltd, Poole, Dorset, 
UK) 
1μM  R NEO 3’primer 2.5 
1.25U/μl Taq Polymerase 
(Invitrogen, Paisley, UK) 
0.0125U/μl Taq Polymerase 0.5 
DNA sample DNA sample 5 
Total volume  50.00μl/reaction 
 
PCR components for master mix. Initial concentrations, final concentrations and volume of components 















129/BL6.Gpr55 knockout mice were obtained fromTIGM. The coding sequence of GPR55 is deleted in the 
129/BL6.Gpr55 mice and replaced by LacZ/Neo. The animals were then backcrossed for two generations 
with C57BL/6 mice.  As the knockout animals express LacZ/Neo, detection of this gene can be performed 
using PCR. The mouse GPR55 gene is located in chromosome 1(Ch1:87836112-87857630 bp). The deletion 

















Table 2.3 PCR components for multiplex PCR with primers specific for GPR55 and NeomycinTable 5 
 
Initial concentration reaction 
components 
Final concentration reaction 
components 
Volume (µl) 
dH2O dH2O 24.5 
10 x PCR Rxn buffer 
 (Invitrogen, Paisley, UK) 
(Tris HCl [pH8.3], 50mM KCl) 
10 x PCR buffer 
 (Tris HCl [pH8.3], 50mM KCl) 
5 
50mM MgCl2 (Invitrogen, Paisley, UK) 2.5mM MgCl2 2.5 
2.0mM dNTP (Invitrogen, Paisley, UK) 0.25mM dNTP 5 
20μM Forward GPR55 primer 
(Sigma-Aldrich Ltd, Poole, Dorset, 
UK) 
1μM F GPR55 primer 2.5 
20μM Reverse 1 GPR55 primer 
(Sigma-Aldrich Ltd, Poole, Dorset, 
UK) 
1μM  R1 GPR55 primer 2.5 
20μM Reverse 2 GPR55 primer 
(Sigma-Aldrich Ltd, Poole, Dorset, 
UK) 
1μM R2 GPR55 primer 2.5 
1.25U/μl Taq Polymerase 
(Invitrogen, Paisley, UK) 
0.0125U/μl Taq Polymerase 0.5 
DNA sample DNA sample 5 
Total volume 50.00μl/reaction 
 
PCR components for master mix. Initial concentrations, final concentrations and volume of components 








2.2.3 Gel electrophoresis 
The PCR products were analyzed using gel electrophoresis at (120 volts) for 60-90 min. For each 
sample 18μl DNA was loaded with 3μl bromophenol blue loading buffer (Invitrogen, Paisley, UK). 
PCR products were analyzed by 2% agarose gel, 4g agarose (Fisher BioReagents, Loughborough, 
UK), in 20ml (10x) Tris/Borate/EDTA (TBE) buffer (Sigma, Poole, UK), 10μl ethidium bromide 
(Sigma-Aldrich, Poole, Dorset, UK) and 180ml dH20. A 50bp ladder (Invitrogen, Paisley, UK) was 
used as a reference. Gels were imaged on a luminescent imaging system (UVIdoc). 
2.3 Antibody production 
Fusion peptides corresponding to both the extracellular and intracellular domains of GPR55 were 
obtained from Dr Ken Mackie, University of Indiana, USA. Essentially uncharacterized cell lines 
overexpressing GPR55 in a mouse astrocytoma, murine Delayed Brain Tumor (DBT) E1 cell line, 
and non-transfected controls DBT were obtained from Dr. Nephi Stella (University of Washington, 
Seattle, USA). It has previously been reported that the untransfected DBT cell line does not 
express CB1, CB2 nor GPR55 receptors (Cudaback et al., 2010).  
GPR55 knockout mice (C57BL/6.Gpr-/-) were immunized with GPR55-GST fusion peptides (vector 
pGEX-3X), including an amino terminus and C terminus full length mouse sequences and IC3 the 
third intracellular loop of the mouse protein or with the GPR55 transfected astrocytoma cell line 
E1.  Immunization with cell lines for production of antibodies has previously been described 
(Croxford, 2010). The following sequences were used; NH: MSQPERDNCSFDSVCKLTRT, IC3:  
YRSIHILLRRPDSTEDWVQQRDTKGWVQKRAC and CT-FL: KEFRMRIKAHRPSTIKLVNQDTMVSRG. The 
spleen from immunized mice was fused with a plasmocytoma cell line NS-1 (Healey et al., 1987) 
and hybridomas were screened using Enzyme-linked immunosorbent assay (ELISA) against the 
proteins used for immunization. Flow cytometry, immunostaining and Western blot of membrane 
lysates from GPR55-expressing cell lines was used to test the antibodies. The positive hybridomas 
were then antibody isotyped.   
Dulbecco’s modified eagle medium (DMEM) (Sigma-Aldrich, Poole, Dorset, UK)  was prepared 
before fusion by adding 1% penicillin (Invitrogen, Paisley, UK) and 1% hepes (Sigma-Aldrich, Poole, 
Dorset, UK). The medium was kept at 37°C during the fusion. An aliquot of 10 ml of complete 
medium was transferred into a falcon tube. Immunized mice were then sacrificed and the spleen 
was removed and extracted with a syringe in a Petri dish.  All centrifugation were made on the 
Thermo Fischer heraeus multifuge 3SR centrifuge order no: 75004371. The cell suspension was 




with the NS-1 cells. The supernatant was decanted and 10 ml of medium was added. This was 
repeated 3 times followed by a centrifugation at 478g. An aliquot of cell suspension was taken 
before the last wash in order to count the cells and the two cell types were mixed together and 
centrifuged for 5 min at 478gat a ratio of 5 lymphocytes: 1NS-1 cell. The fusion was started by 
removing the supernatant. 1 ml of Polyethylene glycol (PEG) (Sigma-Aldrich, Poole, Dorset, UK) 
was added to the pellet during 1min 30s and the tube shaken at the same time and then left for 
30s. 1ml of complete medium was then added during 1min 30s followed by adding 20ml of 
medium during 2 min. The cell suspension was then left in a water bath for 5 min. After 
centrifugation for 5 min at 478g, the supernatant was removed and fresh complete medium was 
added. The cells were then left in a 37°C incubator for approximately 3 h. The cells were plated in 
a 96 well plate by adding 100l of cell suspension and 100l of complete medium in each well. The 
hybridomas were then grown in complete medium containing 1xhypoxanthine-aminopterin-
thymidine (HAT) (Sigma-Aldrich, Poole, Dorset, UK). HAT was replaced by hypoxanthine-thymidine 
(HT) after two weeks and added to the cell medium for another two weeks. DMEM (Sigma-Aldrich, 
Poole, Dorset, UK) medium used for preparation of fusion contained Hepes (1%) (Sigma-Aldrich, 
Poole, Dorset, UK), penicillin streptomycin (1%) (Sigma-Aldrich, Poole, Dorset, UK). Complete 
medium used after fusion contained: (5%)  Horse serum (Lonza, Cambridge, UK), (5%) foetal calf 
serum (Invitrogen, Paisley, UK), penicillin streptomycin (1%) (Sigma-Aldrich, Poole, Dorset, UK), 
sodium pyruvate (1%) (Sigma-Aldrich, Poole, Dorset, UK), L-glutamine (1%) (Lonza, Cambridge, 
UK), Insulin (1%) (Sigma-Aldrich, Poole, Dorset, UK), (0.1%)  B-mercaptoethanol (Invitrogen, 
Paisley, UK) and 1x HAT (Sigma-Aldrich, Poole, Dorset, UK). Other components used were PEG 
(Sigma-Aldrich, Poole, Dorset, UK) and 1X HT (Sigma-Aldrich, Poole, Dorset,UK).  
2.4 Enzyme Linked Immunosorbent Assay (ELISA) 
96 well flat bottom culture plates were coated with 10 μg of peptides/fusion proteins and were 
incubated overnight at 4°C. The following day the plate was blocked with 1% bovine serum 
albumin (BSA) prepared in PBS for 1 h at 37°C. The plate was washed 4-5 times with PBS+0.1% 
tween following the addition of primary antibody, 100l serum from immunized animal or 100l 
supernatant from hybridomas, was added. The plate was incubated for a further 1 hour at 37°C. 
Once again 4-5 washes were done with PBS tween before the addition of anti-mouse horseradish 
peroxidase (HP) conjugated secondary antibody (DAKO, Cambridgeshire, UK) prepared at 1:1000 
dilution. After an hour of incubation at 37°C the plate was washed 4-5 times and 100μl of 
substrate3, 3′,5, 5′-Tetramethylbenzidine (TMB) (Sigma-Aldrich, Poole, Dorset, UK), was added to 
each well. After the reaction turned blue it was stopped by addition of 50 μl of hydrochloric acid. 




2.5 Antibody isotyping ELISA 
A 96 well plate was coated with 50l of isotype-specific rat anti-mouse purified monoclonal 
antibodies including IgG1, IgG2a, IgG2b, IgG3, IgM, IgA, Ig and Ig diluted 1:50 in PBS. Plate was 
then incubated at 4°C overnight and washed 4x with 0.05% Tween-20 in PBS. 200μl blocking 
buffer, 10% BSA in PBS, was added to each well and incubated at RT for 30 min. 100μl of each 
supernatant from positive hybridomas was added to plate columns and incubate for 1 hour at RT. 
Plate was then washed 4x with 0.05% Tween-20 in PBS before adding 100 μl of 1/100 HP-labeled 
rat anti-mouse Ig mAb diluted in 10% BSA in PBS to each well and incubated at RT for 1 hour. Plate 
was then washed 6x with 0.05% Tween-20 in PBS and 100 μl of substrate solution was added to 
each well and the plate was read spectrophotometrically at 450 nm. 
2.6 Western blotting  
Western Blotting (WB) was carried out using protein samples from GPR55 transfected and non- 
transfected cells. 10μg of protein samples were loaded onto a 10% Tris HCl gel (Bio-Rad, 
Hertfordshire, UK). The samples were run for approximately 90 min at 120 volts using the Mini-
Protean gel system apparatus from Bio-Rad. The gels were then transferred onto nitrocellulose 
membrane which was blocked overnight with 5% BSA at 4°C. The following day the membrane was 
washed with 1X PBS followed by incubation for 1 h at RT with supernatant from positive 
hybridomas diluted 1:100.  The membrane was washed 4X with PBS after which the secondary 
antibody anti-mouse HP (DAKO, Cambridgeshire, UK) was added for 1 h at RT. Another 4X washes 
with PBS were done again before the addition of enhanced chemiluminescence (ECL) reagent (GE 
Healthcare, Buckinghamshire, UK, 17-0855-02) to the membrane. The membrane was then 
exposed for 1-2 min using a film (Kodak, Amersham Pharmacia Biotech, Bucks, UK, 17-0340-01). 
2.7 Immunofluorescence 
Immunofluorescence was performed on to staining the GPR55 transfected cells with non- 
transfected cells with the supernatant from positive hybridomas. Cells were seeded in a 24 well 
plate and let to grow for 3-4 days. Cells were washed 3 X 5min in PBS 0.1% tween and fixed with 
4% paraformaldehyde (PFA) for 20 min. Cells were washed 3 x 5 min in PBS 0.1% tween. Cells were 
then blocked for 1 hour at room temperature (RT) with 1% BSA in PBS 0.1% tween. 200l 
supernatant (or other ab) were then added per well at incubated for 1 h at RT. Cells were washed 
3 x 5 min in PBS 0.1% tween after incubation and incubated with a 1:100 secondary antibody anti-
mouse IgG (H+L) Fluorescein isothiocyanate (FITC) (other ab) for 2h at RT. Cells were washed 2 X 5 




2.8 cAMP Response Element-binding Protein staining 
Cells were grown onto cover slips in a 24 well plate for 48 h in RPMI media containing 10% FBS. 
Serum free medium was added to each well 24 h prior to experiment. Hepesbuffer (1x) was 
warmed in a 37°C CO2 free chamber. Ligands were diluted in warm hepes and 1ml of ligands was 
added to each well. Cells were fixed with ice cold methanol pre-cold in a -20°C freezer and 
incubated in -20°C freezer for 10 min. Cells were then blocked with 5% milk diluted in hepes buffer 
for 20 min. Wells were then washed with hepes buffer and the cover slips were placed on 
parafilm. The cells were then stained with a primary CREB (cAMP Response Element-binding 
Protein) antibody (UPSTATE Cat no# 05-667 clone E9 Ms pCREB, Anti-phospho-CREB IgG1, 
0.2mg/mg in dH20 and glycerol) (Billerica, MA, USA) (1:1000) for 60 min at RT and kept in the dark 
followed by staining with a secondary ALEXA fluor 488 antibody (Invitrogen, Paisley, UK, Alexa 
fluor 488 donkey anti mouse A21202) (1/500) at RT for 30 min. Cells were washed with hepes 
buffer and analyzed on the LSM 510 confocal laser scanning microscope. 
2.9 Phalloidin staining 
Cells were grown onto cover slips in a 24 well plate for 48 h in RPMI media containing 10% FBS. 
Serum free medium was added to each well 24 h prior to experiment. Hepesbuffer (1x) was 
warmed in a 37°C CO2 free chamber. Ligands were diluted in warm hepes and 1ml of ligands was 
added to each well and incubated for 30 min at 37°C. Cells were fixed with 4% PFA for 10 min. 
Cells were then blocked with 0.01% triton diluted in hepes buffer for 10 min. Wells were then 
washed with hepes buffer and the cover slips were placed on parafilm. The cells were then stained 
with Phallodin (Texas-Red Phalloidin, (Invitrogen, Paisley, UK) (1:500) and incubated for 30 min. 
The cells were washed with hepes buffer and analyzed on the LSM 510 confocal laser scanning 
microscope. 
2.10 Flow cytometry 
Supernatant was taken from cell hybridomas and analyzed by flow cytometry. A total of 1x106 
cells/ml GPR55 transfected cells and non-transfected cells were used.  PBS and supernatant from 
wells without hybridomaswere used as a negative control and 100l of supernatant from wells 
with hybridomas in 5% FBS in phosphate buffered saline (PBS). Cells were incubated with the 
antibodies for 30 min at 4°C and then washed with 5% FBS in PBS. Samples were then incubated 
with Alexa fluor 488 (Invitrogen, Paisley, UK) (1/100) for 30 min at 4°C. Samples were vortexed and 
incubated for a minimum of 10 min at RT and were analysed by flow cytometry (Becton Dickinson, 




2.11 Calcium signalling  
A 2nm stock solution of Fura 2-am solution was initially prepared in DMSO; 499.5l DMSO was 
added to 1mg lyophilized Fura-2-am (ref: F0888, Sigma-Aldrich, Poole, Dorset, UK). A volume of 
3l of 2nm stock was added into a 15 ml falcon tube and followed by 1 ml of hepes buffer. The 
solution was then mixed well with a pipette and vortexed. Cells were grown onto cover slips in a 
24 well plate for 48 h in RPMI media (Sigma-Aldrich, Poole, Dorset, UK)  containing 10% FBS. 
Serum free medium was added to each well 24h prior to experiment start. Wells were washed 
with hepes buffer and 333μl of fura 2-am diluted in hepes was added per well. The cells were 
incubated for 60 min and then washed with hepes buffer and analyzed on the LSM 510 confocal 
laser scanning microscope. 
2.12 Quantitative PCR (qPCR) 
2.12.1 RNA extraction  
Tissues were collected from mice and immediately immersed in liquid nitrogen or RNA later 
solution (Qiagen, Crawley, UK) and then stored at -80°C. RNA extractions were performed with an 
RNeasy mini kit (Qiagen, Crawley, UK). Tissues were initially weighed and approximately 30mg was 
used per sample. Tissues were homogenized in 600 µl lysis buffer either by using a mortar and 
pestle followed bytrituration using a needle or by using a tissuelyser (Qiagen, Crawley, UK). 
The lysates were then centrifuged for 3 min at 8000xg. The supernatants were then transferred by 
pipetting into a new micro centrifuge tube.  One volume of 70% ethanol was added to the cleared 
lysate and mixed immediately by pipetting. Up to 700 μl of the sample was transferred to an 
RNeasy spin column placed in a 2 ml collection tube. If the sample volume exceeded 700 μl, 
aliquots were centrifuged for 15s at 8000xg in the same RNeasy spin column. The flow-though was 
discarded after each centrifugation. An amount of 700 μl of buffer RW1 (wash buffer containing 
ethanol and salts) was added to the RNeasy spin column and samples were centrifuged for 15 s at 
8000xg and the flow-though was discarded.A total of 500 μl Buffer RPE (wash buffer containing 
ethanol and salts) was added to the RNeasy spin column and samples were centrifuged for 15 s at 
8000xg. An additional wash with 500 μl Buffer RPE was added to the RNeasy spin column and 
samples were centrifuged for 2 min at 8000xg. The RNeasy spin column was then placed in a new 
2 ml collection tube to eliminate any possible carryover of Buffer RPE. The RNeasy spin column 
was then placed in a new 1.5 ml collection tube and 30μl of RNase-free water was added directly 
to the spin column membrane to elute the RNA. Samples were then centrifuged for 15 s at 8000xg. 
The RNA concentrations in the samples were then spectrofotometrically measured (Nanodrop ND-




2.12.2 Reference genes: GAPDH and 36B4 
The following primers were used for detection of GAPDH; forward 5'-GCCTTCTCCATGGTGGTGAA -
3', reverse 5'-GCACAGTCAAGGCCGAGAAT -3'. SYBR green was used as a dye for detection of 
GAPDH. The following 36B4 primers and probe; forward 5'-AGATGCAGCAGATCCGCA -3', reverse 
5'-GTTCTTGCCCATCAGCACC -3', 5'-HEX-CGCTCCGAGGGAAGGCCG -TAMRA-3' were tested as 
reference genes in the various mouse tissues. Quantitative PCR was performed in duplicates in 96-
well reaction plates with the Applied Biosystems 7500 Real-Time PCR system (Applied Biosystems, 
Warrington, Cheshire, UK) and the cycling conditions for the qPCR were following; 95°C (10 min), 
40 cycles of 95°C for (45 s), 60°C for (60 s).The PCR components for GAPDH are shown in table 2.5 
and in table 2.6 for 36B4. 
Table 2.4 Reference gene GAPDHTable 6 
Initial concentration reaction 
components 
Final concentration reaction 
components 
Volume (µl) 
dH2O dH2O 5 
2xTaqMan® Gene Expression Master 
Mix(Qiagen, Crawley, UK) 
2 x Gene Expression Master Mix 10 
10μM Forward GAPDH primer 
(Invitrogen, Paisley, UK) 
0.5μM F GAPDH primer 1 
10μM Reverse GAPDH primer 
(Invitrogen, Paisley, UK) 
0.5μM  R GAPDH primer 1 
10μM Taqman probe 
(Invitrogen, Paisley, UK) 
0.5μM Taqman probe 1 
cDNA sample cDNA sample 2 
Total volume 20μl/reaction 
 
PCR components for master mix. Initial concentrations, final concentrations and volume of components required for 






Table 2.5 Reference gene 36B4Table 7 
Initial concentration reaction 
components 
Final concentration reaction 
components 
Volume (µl) 
dH2O dH2O 5 
2xTaqMan® Gene Expression Master 
Mix (Qiagen, Crawley, UK) 
2 x Gene Expression Master Mix 10 
10μM Forward 36B4 primer 
(Invitrogen, Paisley, UK) 
0.5μM F 36B4primer 1 
10μM Reverse 36B4primer 
(Invitrogen, Paisley, UK) 
0.5μM  R 36B4 primer 1 
10μM Taqman probe 
(Invitrogen, Paisley, UK) 
0.5μM Taqman probe 1 
cDNA sample cDNA sample 2 
Total volume 20μl/reaction 
 
PCR components for master mix. Initial concentrations, final concentrations and volume of components required for 












2.12.3 Quantification of GPR55 mouse mRNA levels using qPCR 
The following GPR55  primers and probe;  5'-CTATCTACATGATCAACTTGGCTGTTT-3', 5'-
TGTGGCAGGACCATCTTGAA-3', 5'-FAM-CGATTTACTGCTGGTGCTCTCCCTCCC-TAMRA-3'were used 
for mRNA quantification as previously described (Ryberg et al., 2007). Quantitative PCR was 
performed in duplicates in 96-well reaction plates with the Applied Biosystems 7500 Real-Time 
PCR system (Applied Biosystems, Warrington, Cheshire, UK) and the cycling conditions for the 
qPCR were following; 95°C (10 min), 40 cycles of 95°C for (45 s), 55°C for (45 s), 72°C (45s). The 
PCR components are shown in table 2.5. 
 
Table 2.6 Quantitative PCR components for GPR55Table 8 
Initial concentration reaction 
components 
Final concentration reaction 
components 
Volume (µl) 
dH2O dH2O 6.8 
2xTaqMan® Gene Expression Master 
Mix(Qiagen, Crawley, UK) 
2 x Gene Expression Master Mix 10 
50μM Forward GPR55 primer 
(Invitrogen, Paisley, UK) 
0.25μM F GPR55 primer 0.1 
50μM Reverse GPR55 primer 
(Invitrogen, Paisley, UK) 
0.25μM  R GPR55 primer 0.1 
100μM Taqman probe 
(Invitrogen, Paisley, UK) 
5μM Taqman probe 1 
cDNA sample cDNA sample 2 
Total volume 20μl/reaction 
 
PCR components for master mix. Initial concentrations, final concentrations and volume of components 
required for qPCR master mix to produce a final volume of 20µl per reaction. 
 
2.12.4 Standard curve 
A GPR55 amplicon was designed, ctatct acatgatcaa cttggctgtt ttcgatttac tgctggtgct ctccctccca 
ttcaagatgg tcctgccaca 76bp, and was used for a standard curve in order to determine GPR55 mRNA 




2.13 35S Oligonucleotide in situ hybridization 
Before starting the procedure all equipment was treated with 1 M NaOH then rinsed with dH20 
followed by a rinse with Diethylpyrocarbonate (DEPC) (Sigma-Aldrich, Poole, Dorset, UK) treated 
dH20. All other solutions were also treated with 1ml DEPC per litre of solution. 
The following mouse GPR55 primers were designed and used for labeling: 
Primer 1 mouse gpr55 pos: 424-457“gagggagagcaccagcagtaaatcgaaaacagcc”, primer 2 mouse 
gpr55 pos: 906-939“gcaatggtggagatgcaggctctcttttgtaccc”and primer 3 mouse gpr55 pos: 1750-
1783“cccattggctctgtcatgtctcctatttccacac” 
 
2.13.1 Probe labeling 
The isotype, 35SdATP (1200Ci/mmol, Dupont/NEN#NEG-034) (PerkinElmer LAS, Beaconsfield, 
Bucks, UK), was thawed on ice for 30 min. The following was added to make 50l reactions: 10l 
of 5x tailing buffer (Promega, Southampton, UK), 29l of dH20, 3l of 35S dATP(PerkinElmer LAS, 
Beaconsfield, Bucks, UK) , 4l of oligonucleotide (Sigma-Aldrich, Poole, Dorset, UK) (4l of 
1pmol/l stock) diluted in TE buffer (Tris-EDTA) and 4l terminal deoxynucleotidyl transferase 
(Promega,Southampton,UK).The samples were vortexed and centrifuged briefly followed by an 
incubation at 37°C  for 1-2 h. Separation of the samples was made on Pharmacia Sephadex G50 
DNA grade columns (GE Healthcare,Buckinghamshire, UK, 17-0855-02). The samples were mixed 
and incubated at 37°C for 1-2 h. Excess liquid was then poured off and the columns were rinsed 
once with TE buffer pH 8.0. The bottom cap was then removed and filled with 3 ml of TE buffer 
and left to run though. The probe was added onto the column and 400l TE buffer was added to 
the column.  The eluate was discarded and an additional volume of 400l equilibrium buffer was 
added to the column and collected in a 15ml falcon tube containing 5l dithiotheitol (DTT) (Sigma-
Aldrich, Poole, Dorset, UK). The activity in 2l was then measured with a Beckman coulter liquid 
scintillation counter LS6000SC (Beckman Coulter LTD, High Wycombe, UK) and the probes were 
freeze dried. 
2.13.2 Preparation of tissue sections 
Frozen tissues were cut into 10m sections onto superfrost slides (VWR International Ltd, 
Leicestershire, UK) and air dried for 30 min before storage in -80°C. Tissues were fixed for 5 min in 






Sequential washes were made: 2x5 min in DEPC treated PBS, 1x10 min in triethanolamine (VWR 
International Ltd, Leicestershire)/acetic anhydride (Sigma-Aldrich, Poole, Dorset, UK) in DEPC PBS. 
Triethanolamine (3.75g in 250ml-0.1M/ acetic anhydride (625l in 250ml-0.025M), x5 min in DEPC 
treated PBS, 1x2 min 70% ethanol diluted in DEPC water, 1x2 min 95% ethanol diluted in DEPC 
water, 1x2 min 100% ethanol diluted in DEPC water,1x2 min in chloroform, 1x2 min 100% ethanol 
diluted in DEPC water, 1x2 min 95% ethanol diluted in DEPC water and slides were then air dried 
for 5-10 min. 
2.13.4 Hybridization 
The probe was resuspended in 2 ml of hybridization buffer (2X Denhardts solutionprepared from 
sigma stock 50x (Sigma-Aldrich, Poole, Dorset, UK), 4xStandard saline citrate(SSC), 3M NaCl 0.M 
Tri-sodium citrate pH:7.0, 50% deionised formamide (Sigma-Aldrich, Poole, Dorset, UK), 10% 
dextran sulphate (Amersham Pharmacia Biotech, Bucks, UK, 17-0340-01) and heated for 5 min at 
65°C then put on ice. A volume of 80l was then applied to each slide and covered with a glass 
coverslip. The slides were incubated at 37°C overnight in a humidified chamber. 
2.13.5 Washes 
The following washes were made;  
The coverslips were removed in 2xSSC with beta mercaptoethanol (1ml/250ml 2xSSC buffer), 2x15 
min in 2xSSC/beta mercaptoethanol(Sigma-Aldrich, Poole, Dorset, UK) at 22°C in hood, 2x15 min in 
1xSSC at 50°C in a water bath, 1x15 min in 0.2xSSC at 50°C in a water bath, 2x30 min in 1xSSC at 
22°C,slides were dipped in 0.1 SSC to remove excess SSC,dipped in 70% ethanol for 10-20 seconds, 
dipped in 95% ethanol for 10-20 seconds and finally dipped in 100% ethanol for 10-20 seconds and 
air dried. Once dried, the slides were exposed to x-ray film (BIO-MAX MR-1)(PerkinElmer LAS, 
Beaconsfield, Bucks, UK) for 3-6 days. The development was performed in a darkroom using red 
Kodak no.2 filter (Amersham Pharmacia Biotech, Amersham Bucks, UK, 17-0340-01) with a bulb 
placed one meter from the slides. The slides were developed in Kodak D19 developer (Amersham 
Pharmacia Biotech, Bucks, UK) for 2.5 min and dipped in 0.5 acetic acid stop solution and then 
dipped 2x 5 min in 25-30% sodium thiosulfate solution. The slides were agitated every 30 second 






2.14 Non-RadioactiveIn situ Hybridization (NR-ISH) 
Digoxigenin (DIG)-labeled antisense and sense cRNA probes were synthesized by in vitro 
transcription in the presence of DIG-labeling mix (Roche, Welwyn Garden City, Hertfordshire,UK ) 
following the manufacturer's instruction and using ~1 µg of linearized template and T7 or SP6 RNA 
polymerase (New England Biolabs). The concentration and integrity of each RNA probewas 
analyzed by gel electrophoresis and spectrofotometrically (Nanodrop ND-1000) (Thermo Scientific, 
Ringmer, East Sussex,UK). For each probe, the transcription reaction resulted in ~10 µg of DIG-
labeled RNA, which was diluted with DEPC-treated dH2O to a concentration of 100 ng/µl, 
aliquoted, and stored at -80°C. All probes were usedat a concentration of 800 ng/ml in 
hybridization buffer. Frozen sections were fixed in 4% PFA for 5 min and permeabilized with 
Proteinase K (Sigma-Aldrich, Poole, Dorset, UK), 5 g/ml in 100mM Tris HCl pH 7.5 and 50mM 
EDTA, pH 8.0) for 10 min at 37°C. Post fixation was made in PFA for 5 min. After washes in PBS-
0.1%Tween-20(T-PBS) (Sigma-Aldrich, Poole, Dorset, UK), slides were acetylated in T-PBS 
containing 0.25% acetic anhydride and 0.1% triethanolamine (pH 8.0) for 10 min at room 
temperature (RT). Finally, sections were prehybridized at 57°C in hybridization buffer. After 1 h of 
pre-hybridization the probes were thawed on ice and 8l probe was denaturated in a 95 °C water-
bath for 5 min then resuspended in 1ml of hybridization buffer.  A volume of 400 µl of 
hybridization buffer containing the probes was added to each slide andslides were covered 
byparafilm (VWR International Ltd, Leicestershire). The hybridization reaction was allowed to 
proceed for about 17 h at 57°C. After hybridization, the sections were washed in decreasing 
concentrations of SSC (2X, 1X, 0.2X and 0.05X, where 2X is 0.3M sodium chloride and 0.03M 
sodium citrate, pH 7.0) at 65°C for 15 min each. The slides were then washed in STE buffer (0.5M 
NaCl, 10mM Tris pH 7.5, 5mM EDTA) for 10 min at RT followed by treatment with Rnase A (Sigma-
Aldrich, Poole, Dorset, UK) (25ul of 20mg/ml stock in 50 ml of STE buffer) for 30 min at 37°C. After 
washing the slides twice with Maleic Acid Buffer (MAB) pH:7.5 (0.1M maleic acid, 0.15 NaCl, pH 
7.5) they were incubated overnight at 4°C with anti-digoxigenin (DIG) alkaline phosphatase-Fab 
fragments (Roche,Hertfordshire,UK ) diluted to 1:2000 with 0.5% Blocking Reagent 
(Roche,Hertfordshire,UK ) in MAB/0.1% Tween 20. After two washes with T-PBS the slides were 
equilibrated in alkaline buffer (100mM Tris pH 9.5, 100mM NaCl, 50mM MgCl2, 1% Tween-20) for 
10 min before being incubated at RT with Nitro blue tetrazolium chloride/5-Bromo-4-chloro-3-
indolyl phosphate, toluidine salt(NBT/BCIP)(Roche,Hertfordshire,UK) in alkaline buffer 
supplemented with levimasole (1drop/5ml) (Vector laboratories, Inc, Burlingame, CA 94010-2206). 
Sections were checked every hour until adequate staining was achieved. Sections were finally 




2.15 EAE  
2.15.1 EAE in C57BL/6 mice 
 
The procedure of EAE in C57BL/6 mice was similar except that the spinal cord homogenate is 
replaced with 200µga synthetic peptide amide corresponding to the 35-55amino acid residues of 
mouse myelin oligodendrocyte glycoprotein MOG35-55 made as a peptide amide (Sigma, Poole, 
UK). In subsequent experiments pre-prepared MOG35-55 in Freund's adjuvant was purchased 
from Hooke Laboratories, Lawrence, MA, USA). 
 
2.15.2 EAE in ABH mice 
20ml syringes (Becton Dickinson, Oxford, UK) were to make up the solution (i.e. multiples of 20ml). 
Firstly a stock solution was prepared (stock A), consisting  of 4ml incomplete Freund Adjuvant 
(Difco, Becton Dickinson, Oxford, UK),16mg Mycobacterium tuberculosis H37Ra and 2mg M 
butyicum (Difco, Becton Dickinson, Oxford, UK), in a 5ml Bijou (Sterilin, Caerphilly, UK).  This was 
kept for no longer than 1 month at 4°C. Stock mycobacteria were stored at -70°C. Once a vial was 
opened it was stored in fridge/freezer. If the incidence of EAE dropped to about 50% it was usually 
that the M. tuberculosis had lost its potency and needed replacing.  Complete adjuvant: Freund’s 
adjuvant was prepared by adding 11.5ml adjuvant incomplete Freund’s adjuvant to 1ml stock A 
that was vortex-mixed before use.  
The plunger from a 20ml syringe was removed and the barrel was plugged with a stopper cap 
(Scientific Laboratory Supplies, Nottingham, UK).  5ml sterile PBS was added and 33mg of freeze 
dried spinal cord homogenate (6.6mg/ml). This was mixed and then 5ml of Complete Freund’s 
adjuvant was added (see above). The syringe was sealed with parafilm and vortexed. A retort 
stand, boss and clamp was used to hold the 20ml syringe in place with the water level reaching the 
level of the adjuvant (containing a drop of detergent) in a waterbath sonicator (Bransonic 
Ultrasonicator, Sigma, UK) and sonicated for 10 min to thicken the mixture and dissociate the 
spinal cord homogenate. The adjuvant was vortexed and placed on ice to cool. A 1ml syringe 
(Becton Dickinson, Oxford, UK) was inserted into the 20ml syringe and the adjuvant was pumped 
using the 1ml syringe until it had thickened sufficiently that the solution did not disperse when a 
drop was added to water. The plunger was inserted into the 20ml syringe and the syringe was 
tapped on the bench such that the content moved towards the plunger and then the syringe cap 
was removed. A long (6cm) large bore needle was fixed to the syringe and inserted into 1ml 
syringes with plungers pulled out to the 1ml mark.  The syringe was filled to 1ml and the barrel of 




(Becton Dickinson, Oxford, UK) was fixed to the 1 ml syringe. With the tip of the needle cover on 
the bench, the syringe was pushed very firmly onto the needle. 
 
2.15.3 Injection of animals 
 
Disease was typically induced in 6-8 week male and or female mice. Mice were held at the nape of 
the neck between thumb and forefinger. The tail was held with the right hand with thumb and 
forefinger (tips facing the head) and the mouse was placed on the top of a wire mouse cage.  The 
skin of the dorsal surface of the flank was lifted with thumb and forefinger (left hand) and the 
needle was inserted (facing towards the head) subcutaneously into the mouse.  0.15ml of adjuvant 
was injected into the right flank and another 0.15ml was injected into the left flank. This was day 
0. The procedure was repeated one week later (day 7). Injections were below, more posterior to 
the original injections. EAE ABH disease developed at around day 14-15 (Baker et al., 1990; Amor 
et al., 1994). A relapse could be induced about 7-8 days after a further injection of neuroantigen in 
Freund’s complete or incomplete adjuvant (O’Neill et al. 1991).  ABH mice did not require the 
injection of Bordetella pertussis toxin (Sigma, Poole, UK), however, MOG-induced disease in 
C57BL/6 mice typically required the co-administration of 0.1ml of 200ng B. pertussis toxin in PBS 
on day 0 and day 7.  
2.15.4 Chronic Relapsing experimental autoimmune encephalomyelitis (CREAE)  
Chonic relapsing experimental autoimmune encephalomyelitis (EAE) is an animal disease model of 
MS most commonly used to study autoimmune function. The disease displays relapsing-remitting 
episodes of neurological deficit similar to the most common form of MS (Baker et al., 2000). The 













Figure 2.25Clinical Disease Course of Chronic Relapsing Experimental Allergic Encephalomyelitis 
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Disease was induced in 6-8 week male and or female ABH mice. The animals were injected withspinal cord 
homogenate in Freund’s complete at day 0 and day 7. Animals were weighed and scored daily from day 11 onwards. 
At approximately day 13, mice lost more than 1.5g of weight overnight. Weight loss continued for a few days. On 
about day 16, clinical signs start. This was ascending paralysis that started with the tail. This was scored as 
follows:Normal = 0 Fully flaccid tail = 1. Tail is completely paralysed. Impaired righting reflex. = 2. When turned on 
back, the animal does not rightitself. Hindlimb paresis = 3.Significant loss of motor function of the hindlimbs, 
characterized by hindlimb gait disturbance.Complete hindlimb paralysis = 4. Both hind limbs drag. Moribund/Death = 
5. If forelimbs became paralysed or at a weight loss limit of about 35% from the day 10 the animal was   
 
 
2.15.5 Rotorod Activity Monitoring 
 
Motor control and coordination was assessed on an accelerating (4 – 40 rpm. 12rpm/50s) RotaRod 
treadmill (ENV-575M. Med Associates Inc, St. Albans, VT, USA), during the remission phases of the 
disease, over a maximum 5 minute observation period. The trial was terminated when the mouse 
either fell from the RotaRod spindle or if the mouse failed to tolerate the revolving drum shown by 





Figure 2.3 Protocol of spastic measurement 
Immunize Clinical EAE & Spasticity Develops                      Test
Day 0        Day 7                              6-7 months                                           0-2h
________________________________________________________________________
SCH         SCH Inject Drug
+              +                                                                                          Blindly Monitor Spasticity











2.16 Spastic measurement 
Following EAE induction and the development of chronic relapsing EAE, spasticity typically 
developed after 2-3 relapses, about 80-100 days post-induction(Baker et al., 2000).This was 
assessed during remission from active paralytic episodes by the force required to bend the hind 
limb to full flexion against a strain gauge (Baker et al., 2000). Mice were selected on the basis of 
mice visually showing spasticity. Limbs that were flexed were not measured. Animals were 
randomly assigned to treatment or vehicle and monitoring was performed blinded to treatment or 
nature of the genotype. The limb was extended two-three times and then the limb was gently 
pressed against a strain gauge to full flexion. The measurement of left then right hindlimbs was 
repeated typically 5 times per time point. Analogue signals were amplified and then digitized and 
captured using a DAQcard 1200 PCMICA card (National Instruments Austin, TX, USA) and Acquire 
V1 software (D. Buckwell, Insititute of Neurology, UCL) on the WindowsTM XP platform. Limbs with 
a resistance to flexion force or with a resistance less than 0.15N were excluded from the analysis 
(Figure 2.3). The data were analyzed using Spike 2 software (Cambridge Electronic Design, UK) and 
a mean score for each limb at each time point was calculated and forces were converted to 




which were compared using repeated measures analysis of variance or paired t tests using 
SigmaStat software (Figure 2.4) (Baker et al., 2001). Groups contained a minimum of 5 animals per 
group, where analysis of both limbs would give over 80% power to detect a 25% change at a 
significance level of P=0.05 
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2.17 Flow cytometry analysis-surface and cytokine staining 
Mice were killed by CO2 overdose or by cervical dislocation and leukocytes from blood and spleen 
were collected under sterile conditions. Large spleen fragments were initially removed by passing 
the cell suspension though a nylon mesh on a 50 ml falcon tube and the cells were recovered by 
centrifugation for 5 min at 478g. Erythrocytes from the spleen cell suspension and from the blood 
were then lysed with a hypotonic ammonium chloride red blood cell lysis buffer (eBioscience Ltd, 
Hatfield, UK) for 5 min at room temperature and the reaction was then stopped by adding 20ml of 
1x PBS. The pellet was then resuspended by gentle vortexing. Cells were then counted in a 
Neubauer chamber, based on the trypan blue exclusion, for viability discrimination. Cells were 
then dilutedat 2x106 cells/ml in staining buffer (1xPBS 2% FCS) and a total of 200.000cells were 




various surface antibodies (T-cell CD3, CD4, CD8, B-cell CD19, Dendritic cell CD11c, early T-cell 
CD25, CD44, and Monocyte F4/80 markers) and intracellular cytokines IL-2, IL-4, IL-10, IL-17A and 
IFN- diluted 1:100 per tube and incubated for 30 min in the dark at 4°C or on ice. A transcription 
factor FOX3P was also used to identify regulatory T cells. After incubation 3 ml of staining buffer 
was added to each tube. Tubes were then centrifuged at 478g 5 min at 4oC. After centrifugation 
pellets were resuspended in 300μl of staining buffer. Samples were then read on a LSRII flow 
cytometer (Becton Dickinson, Oxford, UK). 
 
2.17.1 Flow cytometry analysis-CFSE staining 
Leukocytes were obtained as previously mentioned (2.16) and washed in 1x PBS and resuspended 
in a concentration of 2 x106 cells/ml. A final concentration of 5μM CFSE was then added and 
incubated at 37°C for 10 minutes. One volume of ice-cold FCS was then added to quench the 
staining and cells were then washed twice in staining buffer (1xPBS 2% FCS) and then incubated 
for 4 days. Samples were then read on a LSRII flow cytometer (Becton Dickinson, Oxford, UK). 
 
2.17.2 Intracellular cytokine staining-QPCR 
The following primers were used for intracellular cytokine staining (Table 2.7) Quantitative PCR 
was performed in duplicates in 96-well reaction plates with the Applied Biosystems 7500 Real-
Time PCR system (Applied Biosystems, Warrington, Cheshire, UK) and the cycling conditions for 
the qPCR were following; 95°C (15 min), 40 cycles of 94°C for (45 s), 58°C for (45 s), 72°C (40s).The 
PCR components are shown in table 2.8. 
2.18 MOG and Con A proliferation assay   
C56BL/6.GPR55 knockout and heterozygous littermates were immunized with MOG peptide in 
Freund’s adjuvant on day 0 and were injected with 200ng of B. pertussis toxin on day 0 and 1. 
Leukocytes were collected on day 9 and re-stimulated in vitro with MOG peptide at concentrations 
1μg or 10μg for 72h (see methods 2.15.1, 2.15.2). Leukocytes from naïve GPR55 knockout and 
wildtype mice were also collected and stimulated with Con A for 48h. A total of 300,000 cells were 
then resuspended in a final volume of 100 l of RPMI 10% FCS and plated in 96 well-plates.  A total 
of 0.5 units of 3H Thymidine (PerkinElmer LAS, Beaconsfield, Bucks, UK) was added to each well 
and cells were incubated during for 24hr at 37oC in 5%CO2. Cells were then harvested (TOMTEC 
MACH III M CELL HARVESTER 96, Warwick, UK) and analysed on a counter (Wallac 1450, 































Table 2.8 Quantitative PCR components for GPR55T 
able 
Initial concentration reaction 
components 
Final concentration reaction 
components 
Volume (µl) 
dH2O dH2O 7.4 
2x SYBR green Master Mix 
(Invitrogen, Paisley, UK) 
2 x SYBR green Master Mix 10 
10μM Forward cytokine primer 
(Invitrogen, Paisley, UK) 
0.15μM F cytokine primer 0.3 
10μM Reverse cytokine primer 
(Invitrogen, Paisley, UK) 
0.15μM  R cytokine primer 0.3 
cDNA sample                    cDNA sample 2 











GPR55 knockout animals have previously been used in order to establish whether the receptor is 
responsible for the effects of certain atypical cannabinoids (Johns et al., 2007). The existence of a 
novel unidentified atypical cannabinoid receptor in the cardiovascular system was suggested from 
previous studies on the Abn-cbd and its analogue O-1602 (Johns et al., 2007). Earlier studies have 
demonstrated vasodilator effects of the atypical cannabinoids Abn-cbd and O-1602 (Begg et al., 
2005; Jarai et al., 1999; Offertaler et al., 2003) thought to be mediated by a new “cannabinoid-
like” receptor (Jarai et al., 1999). Other reports have proposed that GPR55 interacts with 
endocannabinoids and synthetic cannabinoids that are thought to have an effect at an unknown 
cannabinoid receptor (Baker et al., 2006a). Also, Greasley from an AstraZeneca group reported 
that GPR55 knockout mice were hypertensive in an unpublished talk at the Meeting of the British 
Pharmacological Society in 2006 (Hiley et al., 2007).  
As a result to previous findings, a study was used to determine whether GPR55 is the cannabinoid-
binding receptor mediating vasodilator effects to atypical cannabinoids such as Abn-cbd and O-
1602 (Johns et al., 2007). In that study, GPR55 deficient mice were compared with wildtype 
littermates in order to investigate the potential cardiovascular role of the orphan receptor (Johns 
et al., 2007). Baseline arterial blood pressure and baseline heart rate were found to be similar in 
the GPR55 deficient and wildtype miceand the arterial pressure was rapidly lowered upon 
administration of the Abn-Cbd in both mouse strains (Johns et al., 2007). In addition, O-1602 was 
used to determine whether GPR55 mediated its vasodilatation in mesenteric arteries. The vessels 
from both strains were initially pre-treated with phenylephine, a selective a α1-adrenergic 
receptor agonist that increases blood pressure,and then treated with O-1602; both strains were 
found to have similar vasodilator responses upon treatment with the agonist (Johns et al., 2007). 
Analysis of blood pressure of the mice used in this study failed to demonstrate any influence 
(http://www.informatics.jax.org/external/ko/lexicon/261.html).  
A role for GPR55 in pain regulation was reported by Staton et al in 2008. GPR55 deficient mice, 
previously used by another group, were used to further characterize the mice (Johns et al., 2007; 
Staton et al., 2008). Phenotypic analysis were performed including behavior in cage, posture, body 




wildtype mice (Staton et al., 2008). Rotarod, a motor co-ordination and stamina test, and hot-plate 
tests were also used in order to determine if GPR55 deficient mice displayed any motor or 
nociception deficits (Staton et al., 2008). Blood cell phenotypes were also evaluated in this study 
and no significant differences were found in monocyte, neutrophil, cytotoxic T-cell or T-helper cell 
populations (Staton et al., 2008). The GPR55 knockout mice demonstrated a lack of mechanical 
hyperalgesia following subplantar injection of Freunds’ adjuvant in the left hind paw and upon 
sciatic nerve ligation (Staton et al., 2008). Cytokine analysis demonstrated elevated levels of the 
anti–inflammatory cytokines IL-4, IL-10 and IFN- in the paw samples from GPR55 knockout mice 
compared to wild- type mice (Staton et al., 2008).  
GPR55 has also been suggested to play a role in glucose homeostasis as the activation of the 
receptor in islets of Langerhans by the agonist O-1602 led to increased levels of intracellular 
calcium and insulin secretion in wildtype animals. This effect was reported abolished in the GPR55 
deficient mice (Romero-Zerbo et al., 2011). GPR55 has also shown to play a role in bone 
physiology where the bone formation in GPR55 male knockout mice was abnormal compared to 
wild-type littermates (Whyte et al., 2009). 
No significant differences have been observed in most studies when comparing GPR55 knockout 
males and females however there are a few exceptions. GPR55 knockout females have been 
reported to show significant reduced withdrawal latency in the hot plate test at 50°C when 
compared to male littermates (Staton et al., 2008). Although an abnormal bone formation was 
seen in the male knockout mice, this malformation was absent in the female littermates (Whyte et 
al., 2009). 
In order to characterize and investigate the role of the GPR55 we obtained GPR55 knockout 
animals. A panel of mice, 129xC57BL/6.GPR55tm1Tigm, expressing a GPR55 gene deletion construct 
were generated by Lexicon Inc. /Texas Institute of Genomic Medicine (TIGM) using gene targeting 
or gene trap mutations (Informatics, 2012). The GPR55 knockout animals were further bred onto 
the C57BL/6 background and a colony was established in order to obtain enough animals for our 
experiments. The use of the animals allowed us to examine the function and role of GPR55 by 
comparing GPR55 deficient mice with wild-type littermates. The use of these GPR55 knockout 
mice has been previously reported by (Wu et al., 2010a). We were initially provided with a PCR 
protocol and primer sets from TIGM however these tools gave inconsistent pcr results with faint 
bands showing false negative results hence wrong genotype therefore new primers were 




information regarding the GPR55 knockout mouse was provided by TIGM.  
3.1.2 Methods  





3.2.1 Genetics of GPR55 knockout mice 
Founder uncharacterised mice were purchased from the Texas Institute of Genomic Medicine, as 
they became available. These were randomly generated as part of a commercial exercise to sell 
gene trapped mice by Lexicon Inc. Following a National Institute of Health initative to generate 
gene knockouts of most genes, live mice and embroyonic stem (ES) cells were purchased from 
Lexicon and Deltagen Inc and placed into repositories at markedly reduced costs ($5,000) 
compared to original costs ($24,000). These mice were funded for this project. All information and 
results regarding the GPR55 knockout targeting strategy was provided by TIGM (Figure 3.1, 3.2).. 
Briefly, gene targeting or gene trapping was performed in strain 129SvEvBrd-derived embryonic 
stem (ES) cells. The chimeric mice were crossed with C57BL/6 mice in order to generate 
heterozygous animals.  There were backcrossed onto C57BL/6 mice. The animals carrying the 
GPR55 mutant allele were intercrossed in order to generate wild type, heterozygous, and 
homozygous mutant animals (Informatics, 2012).  
Figure 3.17GPR55 knockout targeting strategy 
 
 
The 5’ primer (5’ – GCCATCCAGTACCCGATCC) and 3’primer (5’ – GTCCAAGATAAAGCGGTTCC) was used for 
detection of the wildtype allele and 5’ primer (5’ – GCAGCGCATCGCCTTCTATC) and 3’primer (5’ – 
TCAAGCTACGTTTTGGGTT) was used for identification of the mutant gene. Predicted size for the wildtype 




3.3.2 Southern blot 
Southern blot was performed in order to identify the GPR55 mutant clone. DNA was initially 
isolated, digested and then transferred to a membrane. The probes were then hybridized to the 
membranes and detected with autoradiography (Croning et al., 2010). 
 





Detection of a GPR55 knockout ES clone was performed by Southern blotting. The 5’ internal probes (5’ – 
GGGCAGCCATGTTAGGAT and 5’ – CTTCTGGCCTGTGGTACATA) and 3’ external probes (5’ – 
CTCTCACTTGCCAGCGACAC and 5’ – CCATGGCAGGTCAGATAAGG) were used for detection of the GPR55 
knockout clone. DNA from animals was digested using restriction enzymes Msc I and Apa LI. The predicted 
size of the wildtype internal band was 16.5kb and external band 13.9. The predicted size of the mutant 
internal band was 20.9kb and external band 15.6kb. The internal probe size corresponded to 387bp and 
the external probe size was 493bp. All data for the southern blot experiment was provided by Texas A&M 





3.3.3 Genotyping using two sets of primers 
PCR protocol provided by TIGM had been previously tested in our lab and did not work therefore 
another PCR protocol and primer set described by Johns et al., 2007 was used. Two separate PCR 
reactions were performed in order to detect the different genotypes and inconsistent results were 
often obtained (Figure 3.3). The GPR55 allele (wild-type) was detected in Figures 3.3A,3.3B and the 
mutant neomycin allele (NEO; GPR55 knockout) was detected in Figures 3.3C and 3.3D. PCR 
reactions often had to be repeated due to inconsistencies and missing bands eg. in Figure 3.3A 
samples 10, 11, 13 and 14 were not detected however when PCR was repeated samples 10, 11, 13 
and 14 were identified in  Figure 3.3B. In Figure 3.3C samples 13, 14, 15, 16 and 17 were not 
detected and in Figure 3.3D sample 9 showed a very weak band.  













Earsnips from animals were taken for genotyping. DNA was prepared and amplified using PCR. The PCR 
products were subjected to 2% agarose gel electrophoresis and bands were detected using ethidium 
bromide. The GPR55 wildtype (WT) allele had a predicted size of 207bp band and the deletion allele had a 
predicted product size of 299bp. Band sizes were determined using a standard 50 base pair (bp) DNA 
ladder.  
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3.3.4 Genotyping using single pcr reaction 
Due to inconsistencies using primers described by Johns et al., 2007 (Figure 3.3) new primers were 
designed (see methods 2.2.2). The newly designed PCR reaction allowed detection of both the 
wild-type GPR55 and the deletion allele, containing the neomycin resistance gene, within the 
cloning cassette that replaced GPR55 in a single PCR reaction. This was optimized to give robust 
detection so that the genotypes could be reliably confirmed in a single PCR reaction. This was used 
to identify the different genotypes: C57BL/6.GPR55+/+, C57BL/6.GPR55+/- and C57BL/6.GPR55-/-.  
Figure 3.4 Genotyping- Detection of GPR55 Alleles using the novel designed polymerase chain 
reaction10  




Earsnips from animals were taken for genotyping. DNA was prepared and amplified using PCR. This was 
subject to 2% agarose gel electrophoresis and bands were detected using ethidium bromide. The GPR55 
wildtype (WT) allele had a predicted size of 209bp. The deletion allele had a predicted product size of 
299bp which corresponds to size between the forward GPR55-related primer and the reverse primer 
detecting the inserted reporter (neomycin) gene. The heterozygous mice showed both bands around 
209bp and 299bp. Band sizes were determined using a standard 50 base pair (bp) DNA ladder.  
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The characterization of our animals was an important step in order to study the biology of GPR55. 
As GPR55 knockout animals had previously been become available as a part of the knockout 
mouse project (KOMP) to knockout all GCPR genes we could purchase the founder mice. The 
obtained animals were primarily backcrossed with C57BL/6 mice. Initially our group was supplied 
with primer sequences by TIGM in order to detect the wild type and mutant alleles and the PCR 
gave inconsistent results. Another PCR protocol was then tested also requiring two separate 
reactions as decribed by Johns et al., 2007. The PCR reaction with these sets of primers also often 
gave inconsistent results. Due to the varying results new primers were designed in order to 
optimize the PCR needed for the genotyping of our animals. The newly designed primer sequences 
and PCR allowed the detection of the different genotypes C57BL/6.GPR55+/+ (GPR55 WT), 
C57BL/6.GPR55+/- (GPR55 heterozygous) and C57BL/6.GPR55-/- (GPR55 knockout) in one single 



















Production of GPR55 reactive antibodies and characterization of 
astrocytoma cell lines  
4.1 Introduction 
 
The aims of this chapter were to generate GPR55 monoclonal antibodies and to characterize 
GPR55 transfected and control astrocytoma cell lines. One of the major issues for detection of the 
GPR55 receptor has so far been the lack or availability of specific antibodies. The development of 
GPR55 (monoclonal antibodies) reactive antibodies was initiated due to the failure to detectGPR55 
in various assays using commercially purchased GPR55 polyclonal antibodies. One of the tested 
antibodies was purchased from Abcam (Cambridge, UK) and another one from GSK was obtained 
from A.Irving. Furthermore, others have found that most commercially available GPR55 polyclonal 
antibodies have failed to show specific GPR55 staining (A.Irving; Personal communication).  
The advantage of polyclonal antibodies is the ability to detect multiple epitopes and that the 
polyclonal reagents are comparatively cheap and simple to produce compared to monoclonal 
antibodies. The use of larger animals also allows large volume of antibody rich serum however the 
disadvantage is that at some point the original batch needs to be replaced and that inevitability 
leads to problem of batch to batch variations. Differences in antibody titres and reactivity are 
common problems and polyclonal reagents in general suffer from a lack of reproducibility. 
Monoclonal antibodies, produced by a continuous antibody secreting B cell hybridoma clone, offer 
a reproducible supply of antibody with same specificity (Nelson et al., 2000). 
 
4.1.1 Material and Methods  
In order to develop GPR55 antibodies GPR55 knockout mice (C57BL/6.Gpr-/-) were immunized with 
GPR55-GST fusion peptides or with the GPR55 transfected astrocytoma cell line E1. The following 
peptide sequences were used; NH: MSQPERDNCSFDSVCKLTRT, IC3:  
YRSIHILLRRPDSTEDWVQQRDTKGWVQKRAC and CT-FL: KEFRMRIKAHRPSTIKLVNQDTMVSRG (see 
methods 2.3). In the absence of knowledge on the precise location of the GPR55 receptor in 
tissues it was important that a cell line was generated or obtained so that reactivity against native 
GPR55 could be assessed. The relatively uncharacterised astrocytoma mouse cell lines DBT 
(control) and E1   (mouse GPR55 transfected)  were obtained from Dr. Nephi Stella. Functional 




Hybridoma antibodies reactivity was tested using ELISA, immunofluorescence, western blotting 












4.2.1 GPR55 antibody production  
Animals were immunized with a pool of GPR55-GST fusion peptides or with the GPR55 transfected 
astrocytoma cell line E1 and screened after 3-5 weeks in general. A total of 9 fusions were made 
and 520 hybridomas were screened out of which 40 were found positive against the immunizing 
peptides or cells by ELISA screening (Figure 4.1). The 40 hybridomas that reacted positive in the 
ELISA were also isotyped in order to indicate whether the may have been clonal however, all of 
the hybridomas except for one displayed reactivity against several isotypes (Figure 4.2). A total of 
6 of these 40 hybridomas only showed reactivity against 1-3 isotypes and were selected to be 
further tested using different techniques (Figures 4.3, 4.5 and 4.10). Figure 4.1 demonstrates the 
antibody titres comparing negative controls with positive hybridomas after one fusion. As the 













 knockout animals were immunized with GPR55-GST fusion peptides or E1 cells in Freunds’ adjuvant 
and killed after 3-5 weeks. The spleen from the immunized animals was then fused with a NS-1 plasmacytoma cell 
line. Wells were screened daily and hybridomas were detected around one to two weeks after the fusion. 
Supernatants from hybridomas were then tested for reactivity against the GPR55-GST fusion peptides or E1 cells using 
ELISA. ELISA plates were coated with GPR55-GST fusion peptides or E1 cell protein followed by tissue culture 
supernatant and peroxidase conjugated anti-mouse immunoglobulin and activity was detected using the ABTS 


























































































4.2.2 Antibody isotyping  
All 40 positive hybridomas were isotyped and due to most hybridomas expressed several isotyes 
only 6 hybridomas expressing less than 3 isotypes were selected for further analysis. This indicated 
that most hybridomas were not monoclonal. The grey highlighted wells correspond to positive 
isotype clones. Hybridoma 4D12 was found to be only one of hybridomas secreting a single isotype 
suggestive of clonality (Figure 4.2). The 6 selected hybridomas were further characterized (Figures 
4.3, 4.5 and 4.10).  
 
Figure 4.2 GPR55 Antibody isotypingFigur 
 
Isotype PBS 2G2 2G1 3A9 3F10 1E8 4D12 Pos ctrl 
IgG1 0.14 0.116 0.09 0.063 0.096 0.636 0.08 1.41 
IgG2a 0.12 0.16 0.13 0.075 0.146 0.117 0.08 1.52 
IgG2b 0.12 1.18 0.35 0.132 0.11 0.62 0.09 1.40 
IgG3 0.27 0.123 1.09 1.526 0.757 1.546 0.86 1.33 
IgM 0.10 1.279 0.12 1.386 1.785 0.06 0.18 1.41 
IgA 0.12 0.113 0.17 0.078 0.096 0.112 0.11 1.51 
Ig 0.10 1.392 0.91 1.375 1.612 1.542 1.57 1.40 
Ig 0.12 0.097 0.14 0.079 0.06 0.563 0.15 1.45 
 
Supernatant from hybridomas that were tested positive against GPR55 peptides were isotyped. The positive wells 
were tested against isotype-specific rat anti-mouse IgG purified monoclonal antibodies. Briefly, the micro titre plates 
were coated with the anti-mouse purified monoclonal antibody isotypes including IgG1, IgG2a, IgG2b, IgG3, IgM and 
IgA followed by tissue culture supernatant and peroxidase conjugated anti-mouse immunoglobulin and activity was 
detected using the ABTS chomogen and H202. The absorbance was measured at 450nm for individual lines. The 
absorbance was measured at 450nm.  
 
Whilst it was evident that some positive reactions to the immunizing peptides or homogenized cell 
proteins were detected using ELISA it was important to try and determine if these antibodies 
would react to native GPR55 and be useful for detection in tissues to determine distribution 
profile of the receptor. As this is an integral membrane G protein couple receptor, we decided to 
utilise a GPR55 expressing cell line. Rather than generating a line, one largely uncharacterised line 
was obtained from Dr Stella. This was functionally assessed using LPI as a GPR55 specific ligand; 






4.2.3 GPR55 activation of cAMP Response Element-binding Protein (CREB)  
Activation of the nuclear transcription factor CREB was analysed using the GPR55 agonist LPI, 
GPR55 modulator VSN16R and TPA proliferation agent was used as a positive control. At a 
concentration of 1m of LPI on its own no activation of CREB was observed. There was also a lack 
of CREB activation when GPR55 transfected cells were treated with 10m of VSN16R on its own. 
However, CREB activation was observed when GPR55-transfected cells were treated with either 
3m of LPI on its own or by combining 1m of LPI with 10m of VSN16R (Figure 4.3).  
There was no activity of these agents on non-transfected cells. Positive control showed nuclear 
localisation of pCREB. 















Cells grown on cover slips were initially fixed in ice cold methanol and incubated with mouse CREB 
primary antibody, Anti-phospho-CREB IgG1, 0.2mg/mg in dH20 and glycerol) at 1:1000, and incubated 
for 60 minutes at RT. A secondary ALEXA fluor 488 antibody (Invitrogen, Alexa fluor 488 donkey anti-
mouse A21202) at a concentration of 1:500 was then added and incubated for 30 minutes at RT. Cells 
were then analyzed using a LSM 510 confocal laser scanning microscope.  
 
 
1µ M LPI 10 µ M VSN16R 
1 µ M LPI +  10 µ M  VSN16R 
+ ve Control 3 µ M TPA 
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mGPR55 +ve DBT cells mGPR55 +ve DBT cells mGPR55 +ve DBT cells 
1 µ M LPI +  10 µ M  VSN16R 
Wildtype DBT cells 





4.2.4 GPR55 mediated cytoskeletal rearrangement using phalloidin staining  
The cytoskeleton is composed of intermediate filaments, actin filaments and microtubules. 
Phalloidin, a mushoom-derived  toxin, is commonly used to label F-actin of the cytoskeleton. 
Phalloidin is labeled with various fluorophores and rhodamines are most commonly used as they 
are more resistant to photobleaching (Chazotte, 2010). Cytoskeletal rearrangement has previously 
been assessed by F-actin phalloidin staining (Balenga et al., 2011a). In HEK transfected GPR55 cell 
lines stimulation by LPI caused RhoA mediated rearrangement of the actin cytoskeleton (Balenga 
et al., 2011a). LPI has shown to promote neurite retraction and redistribution of F-actin in 
differentiated PC12 cells mediated by GPR55, G13 and Rho (Obara et al., 2011). This effect was 
absent in undifferentiated PC12 cells (Obara et al., 2011). Phallodin was used to stain mouse 
GPR55 transfected DBT cell line. Upon stimulation with LPI a rearrangement of the actin 
cytoskeleton was observed. The LPI influence on actin re-arrangement indicates that GPR55 is 
expressed on the cell surface and is functionally active.  










GPR55 transfected DBT cell line was grown on coverslips for 48 h at 37°C overnight. The cells were initially incubated 
in serum free medium for 30 min at 37°C for and then fixed with 4% PFA for 10 min at RT. Cells were then incubated 









1 μ M LPI Control 
mGPR55 DBT cells 
  





4.2.5 GPR55 mediated calcium signalling  
Fura-2-am ester is used to measure cellular calcium by fluorescence. Once added to the cells Fura-
2-am crosses the cell membrane and the acetoxymethyl groups are detached by cellular esterases 
and restore the pentacarboxylate calcium indicator. The calcium induced fluorescence readings 
were measured at 340 nm and 380 nm in order to calculate calcium concentrations based 340/380 
ratios fluorescence. The increase in calcium levels were measures at 61 time points for a period of 
5 min. A signinficant increase of calcium levels were seen in the GPR55 transfected cell line (E1) 
compared to the untransfected cells (DBT) (Figure 4.5). 
 
Figure 4.5 Calcium signaling11 
 
Cells were grown onto cover slips in a 24 well plate. Serum free medium was added to each well 24 hs prior to 
experiment start. Wells were washed with hepes buffer and fura 2-am diluted in hepes was added to each well. The 
cells were incubated for 60 min and then washed with hepes buffer and analyzed on the LSM 510 confocal laser 














Although numerous antibodies have been reported to detect GPR55 levels in cell lines and in 
rodent tissues most of the existing antibodies are probably non-specific and there is a need for 
reliable GPR55 specific antibodies (Henstridge et al., 2011). The antibody used in the following 
experiment was purchased from Genetex (ref: GTX12700). The antibody shows similar staining 
patterns in both the GPR55 transfected and non-transfected cell line (Fig 4.6).  
 


















Cells were grown on coverslips in 24 well plates for 3-4 days. Cells were initially incubated with a primary 
antibody (1:1000) from Genetex (GTX12700). A secondary anti-rabbit IgG FITC antibody was then added. 




E1 mGPR55 DBT cells 1:1000 
E1 mGPR55 DBT cells 1:500 
Wildtype DBT cells 1:1000 
Wildtype DBT cells 1:500 






4.2.7 GPR55 polyclonal antibody  
I received an aliquot ofan GPR55 polyclonal antibody from Dr A. Irving (University of Dundee. This 
was produced by Glaxosmithkline (Stevenage, UK) but unfortunately when their Neuroscience 
research group was being relocated from the UK to China the batch of anti-sera was lost.  The 
polyclonal antibodies were used to stain mouse GPR55 transfected DBT cells and untransfected 
DBT cells. The antibodies were from a limited batch and as mentioned are no longer available 
therefore subsequent experiments could not be performed. The GPR55 transfected cells showed 
specific staining mainly in the cell membranes compared to the untransfected cells. These 
antibodies had previously been tested positive on GPR55-HEK (A.Irving, Dundee, personal 














A GPR55 polyclonal antibody was used to stain mouse GPR55 transfected DBT cell line and untransfected 
DBT cell line. The cells were grown on coverslips for 48 h at 37°C overnight. Cells were then fixed in 4% 
PFA, 200 mM sucrose. Cells were the incubated with primary polyclonal GPR55 antibody for 1h (1:500). A 
secondary antibody was then added and cells were incubated for 30 min (Alexa fluor 488 donkey anti-
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50x 50x 




4.2.8 Staining of cell lines with GPR55 hybridoma produced antibodies 
A number of fusions were made and as mentioned before (4.2.2) six of the isotyped antibodies 
were selected to stain the wild-type DBT and GPR55 E1 DBT transfected cell lines. Staining pattern 
did not differ when comparing the the two cell lines and counting more than 50 cells per sample 























Cells were grown on coverslips in 24 well plates for 3-4 days. Cells were initially incubated with isotyped 
hybridomas. A secondary anti-mouse IgG FITC antibody was then added. The coverslips were mounted on 
slides and analyzed using a fluorescent microscope.  











4.2.9 Western Blotting using GPR55 hybridoma produced antibodies 
Western blotting performed using protein samples prepared by homogenizing GPR55 transfected 
and non-transfected cells (see methods 2.6). An amount of 10μg of protein samples were loaded 
onto the gels and as mentioned before (4.2.2) 6 selected hybridomas were used to stain the gels. 
The hybridoma antibody staining showed multiple bands also at the predicted correct band size 
for GPR55 seen especially in the blot using 4D12 antibody. A stronger band was seen in the GPR55 



















Protein samples were initially prepared by homogenizing GPR55 transfected and non-transfected cells. The gels were 
loaded with 10µg of protein and transferred onto nitrocellulose membranes. The membranes were then incubated 
with supernatants from the positive hybridomas diluted 1/100. The membranes were then incubated with a 
secondary antibody, anti-mouse IgG horseradish peroxidase, and later developed using ECL reagent. All hybridomas 
however demonstrated multiple unspecific bands (white arrows). The results were compared with a prestained 
kaleidoscope standard (Bio-Rad Laboratories Ltd, Hertfordshire, UK). A potential positive band can be detected 
around 37KDa  
4D12 3F10 3A9 
2G1 2G1 1E8 2G2 
WT   GPR55   M WT   GPR55  M WT   GPR55   M 


























4.2.10 Flow cytometry with GPR55 hybridoma produced antibodies 
As mentioned before (4.2.2) the supernatants from the 6 selected hybridomas were used to stain 
GPR55 transfected cells and non-transfected cells in flow cytometry.  All the hybridomas showed 
weak positive reactivity against the GPR55 transfected cells compared to untransfected cells as 
shown in Fig. 4.10. The blue peaks represent the untransfected cells and the pink peaks the GPR55 
transfected cells. PBS was used a control. 
 
Figure 4.10 Flow cytometryFigure 15 
 
 
Supernatant collected from positive hybridomas was analyzed by flow cytometry. A total of 1x10
5
 cells 
per tube were used. PBS and supernatant from wells without hybridomas were used as a negative 
controls and 100l of supernatant from wells with positive hybridomas. Cells were incubated with the 
antibodies for 30 min at 4°C followed by an incubation with Alexa fluor 488 (Invitrogen, Paisley, UK) 
(1/100) for 30 min at 4°C. Samples were then vortexed and incubated for a minimum of 10 min at RT and 
were analyzed by LSRII flow cytometry (Becton Dickinson, Oxford,UK). 
3F10 









Following the production of hydridomas obtained by the fusion of splenocytes from GPR55 
knockout mice immunised with GPR55 fusion peptides and GPR55 transfected cell line with the 
NS-1 plasmacytoma cell line a number of antibody secreting hybridomas were produced that 
recognised the immunizing peptides/cells in the ELISA assay. Although over 520 hybridomas were 
tested and 40 were found to react to the immunizing peptides/cells only 6 of these were selected 
for further analysis. This was due to the fact that most of the antibodies secreted by the 
hybridomas were tested positive to several or all of the different isotypes including IgG1, IgG2a, 
IgG2b, IgG3, IgM and IgA.The development of an IgG monoclonal antibody is desirable as IgG 
antibodies have higher affinity for their target than for instance IgM antibodies. IgG antibodies are 
also more commonly used in various assays, due to their specificity, including ELISA, WB and 
immunohistochemistry and since IgG and not IgM antibodies bind to protein A and G they can also 
be used for assays such as immunoprecipitation (Uma Devi et al., 2001). However, in addition to 
the problem of generating clonal antibodies, it was important to use a mouse GPR55 expressing 
cell line to test the ability of antibodies to react with native protein. One was obtained through a 
collaboration and were first functionally characterised 
 
In order to characterize the obtained astrocytoma cell line, one of the functional assays used was 
based on prior studies in human transfected cell lines (Henstridge et al., 2010). This assay was the 
CREB activation assay. We used a phospho-CREB primary antibody to stain mouse GPR55 
transfected DBT cell line and untransfected DBT cell line after stimulation by either LPI and/or 
VSN16R. Interestingly, LPI on its own at lower concentrations (1µm) did not activate CREB nor did 
VSN16R at a higher concentration (10µm). This indicated that VSN16R is not acting as an agonist. 
However, by treating the GPR55 transfected cell lines with 1µm LPI and 10µm VSN16R activation 
of CREB was observed. This may suggest that VSN16R functions as a GPR55 allosteric modulator 
upon co-stimulation with other ligands/agonists rather than being a direct agonist. Previous 
studies have reported that the GPR55 agonist LPI activates ERK MAP-kinase pathway, Ca2+ and 
CREB in cell lines. VSN16R has previously been demonstrated to relax mesenteric arteries and this 
influence was modified by GPR55 ligands (Baker et al., 2006b; Hoi et al., 2007a; Ryberg et al., 
2007). 
Another method to functionally characterise the cell lines was to detect downstream GPR55-cell 
signalling via RhoA as it influences actin cytoskeleton rearrangement. Phallodin was used to stain 
actin in mouse GPR55 transfected DBT cell line and untransfected DBT cell line. Stimulation caused 




1μM of LPI. Earlier studies have demonstrated GPR55, G13 and Ras homolog gene family, member 
A (Rho A) mediated rearrangement of the actin cytoskeleton in GPR55 transfected cell line upon 
stimulation by LPI (Balenga et al., 2011a; Obara et al., 2011). 
Another assay that is responsive to GPR55 stimulation is calcium flux assays (Hoi et al., 2007, 
Henstridge et al., 2010). In our calcium assay LPI, at higher levels, 10M, induced augmented 
intracellular Ca2+ levels in the GPR55 transfected cells compared to the untransfected cells. At a 
lower concentration of LPI, 1M, no significant difference in levels of calcium was observed when 
comparing the two cell lines. Consistent with previous findings LPI (10M) induced intracellular 
Ca2+ release was increased in GPR55 transfected cells compared to non-transfected cells (Waldeck-
Weiermair et al., 2008); this response was attenuated in cells treated with GPR55 siRNA or 
SR141716A (Bondarenko et al., 2010; Lauckner et al., 2008; Waldeck-Weiermair et al., 2008).  
Although current knowledge involving the downstream signalling pathways of GPR55 are limited 
compared to CB1 and CB2 the activation of GPR55 by agonists has been shown to activate the small 
GTP binding proteins Rho A, Cdc42, and Rac1 (Idris et al., 2010; Ryberg et al., 2007). Activation of 
the receptor has also shown to trigger activation of the ERK/MAPK signalling, provoke release of 
intracellular calcium though activation of phospholipase C and to activate nuclear factor of 
activated T-cells (NFAT) though alterations of intracellular calcium (Balenga et al., 2011a; 
Henstridge et al., 2009; Henstridge et al., 2010; Idris et al., 2010; Kapur et al., 2009; Lauckner et 
al., 2008; Oka et al., 2007; Ross, 2009). Studies suggest that GPR55 is also coupled to G12/13 and 
activation of the receptor causes Ca2+ mobilization (Ho, 2010; Ross, 2009; Waldeck-Weiermair et 
al., 2008). Increases in intracellular Ca2+ levels upon GPR55 activation by the cannabinoid ligands 
THC and JWH015 have been observed in dorsal root ganglion neurons and in GPR55 transfected 
HEK293 cells (Kapur et al., 2009; Lauckner et al., 2008). Other ligands such as LPI and its 2-
arachidonyl analogue act as GPR55 agonists and have the capacity to induce calcium signalling 
upon activation of the receptor (Johns et al., 2007; Kapur et al., 2009; Oka et al., 2007). In human 
endothelial cells the integrins αvβ3 and α5β1 have been reported to be involved in GPR55-
mediated Ca2+ signalling by anandamide and O-1602 (Waldeck-Weiermair et al., 2008).  Although 
THC and anandamide activation of GPR55 demonstrated calcium alterations the endocannabinoid 
2-AG had no effect (Barak et al., 1997; Idris et al., 2010). SR141716A has shown to acts as an 
antagonist by reducing induced calcium rise by THC, JWH015 and methanandamide, a 
metabolically stable analogue of anandamide (Lauckner et al., 2008). The same study 
demonstrated GPR55 mediated intracellular releases of calcium though Gαq, PLC, Gα12, RhoA and 
actin cytoskeleton (Henstridge et al., 2009; Lauckner et al., 2008). Using a reporter gene assay 




another study that found the ligand to act as an antagonist (Kapur et al., 2009; Yin et al., 2009). It 
is possible that some of these discrepancies relate to use of over-expressing cell lines. This may 
exhaust secondary messenger systems such that receptor stimulation may not give a similar 
signaling to that found in normal cells. Although our cell lines have been a useful tool to study the 
functions of the GPR55 receptor the untransfected cell line often had a background or baseline 
immunoreactivity/signaling (Figure 4.5, 4.6, 4.9 and 4.10). 
Purchased antibodies were tested using immunofluorescence and one of the antibodies, from 
Genetex (ref: GTX12700), demonstrated similar staining patterns in both the GPR55 transfected 
and non-transfected cell line. This suggested lack of specificity. Another antibody from 
Glaxosmithkline was also tested and was found to show specific punctuation and staining pattern 
mainly in the outer cell membranes in the GPR55 transfected cells however this batch of antibody 
is no longer available. Antibodies produced by the 6 selected hybridomas were also tested against 
both cell lines using immunocytochemistry and overall similar background staining was detected in 
both cell lines when comparing over at least 50 cells per slide. 
Although there are a number of reported polyclonal antibodies reactive to human GPR55 there is 
no evidence that these cross-react with mouse GPR55 and there are many of the batches of 
antibodies that do not produce consistent activity on human cells either. The Irving lab has tested 
over 11 batches without success (A.Irving, personal communication) and the Baker lab tested 3 
antibodies without success before this project was initiated (D.Baker, personal communication). 
This lack of specificity has been a common finding with cannabinoid directed antibodies notably 
reacting with multiple proteins in CB1 transfected and non-transfected cells on western blotting 
(Grimsey et al., 2008). This may relate to the fact that GPCR are structurally similar receptors and 
are integral membrane proteins that will lack 3 dimensional conformations in solution. Likewise 
cannabinoid receptors are evolutionary conserved (Elphick, 2002). Mouse and human amino acid 
sequence CB1 receptors are 97% identical (Abood et al., 1997) and GPR55 is 75% identical (Ryberg 
et al., 2007). Therefore it is likely that most animals are immunologically tolerant to their own 
protein and suggest that it will be difficult to make antibodies.  
 
The information of GPR55 protein expression and functional significance in various physiological 
systems including the nervous system are at the moment limited. More research on the knockout 
mice and access to more antibodies and ligands will need to be evaluated in order to discover the 
function of the receptor in these systems (Henstridge et al., 2011). A number of studies have 
demonstrated the use of GPR55 antibodies for staining various tissues and cell lines (Fonseca et 




used to tackle the problems with the development of specific GPR55 antibodies. Henstridge et 
alhave demonstrated expression levels of GPR55 in HEK293 cells expressing a 3xhemagglutinin 
(HA) epitope tag at the N-terminus of GPR55 using a monoclonal HA antibody (Henstridge et al., 
2009).  Other studies have also used an HA antibody for detection of GPR55 in human breast 
carcinoma cell line transfected with 3xHA-GPR55 (Ford et al., 2010).  Antibodies against the 
epitope were used in order to detect GPR55 surface levels in the cell line. The GPR55 expression 
levels in the cancer cell line were also knocked down using siRNA against GPR55 (Ford et al., 2010). 
Commercially purchased antibodies from Ab-cam were used to detect GPR55 levels in human 
dermal micro vascular endothelial cells (Zhang et al., 2010).  
The orphan receptor has also been identified in rat uterine tissues thoughout pregnancy using a 
commercial rabbit anti-rat GPR55 antibody. A rabbit IgG antibody was used as a control in the 
experiment (Fonseca et al., 2011). HEK293 cells stably or transiently transfected with N terminus 
tagged GPR55 (FLAG-GPR55) were generated in order to study GASP-1 identified as a key regulator 
of the trafficking of GPR55. GPR55 protein expression was also determined by western blot 
analysis using a specific purchased GPR55 antibody (Kargl et al., 2011). GPR55 expression levels in 
human cholangiocarcinoma cell lines were mainly found in the membrane and cytoplasm in the 
cell lines using a specific primary antibody (Genetex Inc. Irvine, CA) (Huang et al., 2011). Using a 
reported “monoclonal” antibody (Caymen, Cat. no: 10224; Caymen Chemical, Ann Arbor, MI, USA) 
Lin et al., 2011 found that GPR55 was localized mainly in the submucosa and myenteric plexus of 
the gut. The antibody used by Lin et al., 2011 however was a polyclonal antibody and not a 
monoclonal antibody, according to the Caymen chemical website this must be a writing error by 
the authors. The authors demonstrated that GPR55 expression was found to be upregulated in the 
inflammatory intestine of rat suggesting that the activation of GPR55 may play a role in regulating 
intestinal function in pathophysiological conditions (Lin et al., 2011). A rabbit anti-GPR55 antibody 
(Abcam, Cambridge, UK; cat. no. Ab41515) was used to stain mouse pancreatic cells from wildtype 
C57BL/6 and GPR55 knockout mice using immunofluorescence only demonstrated moderate 
staining in the pancreatic cells from the wildtype mice (Romero-Zerbo et al., 2011). U2OS, an 
osteosarcoma cell line, stably transfected HA-GPR55E cells were pre-treated with an anti-HA 
antibody and then stimulated with the agonists virodhamine and AEA causing agonist-induced 
internalization of GPR55 (Sharir et al., 2012). However, in the absence of knockout or knock-down 
experiments any reported activity of antibodies must be cautiously interpreted. This problem was 
evident with CB2 receptor expression of nerve cells (Nunez et al., 2004), which normally lack any 
evidence of receptor ligand binding in CB1 knockout (Zimmer et al., 1999) and lack of mRNA in 




The initial antibodies produced to recognize CB1 receptor in rodent brain and denatured CB1 
proteins on immunoblots were raised against the extracellular amine terminus (Grimsey et al., 
2008; Pettit et al., 1998). Other CB1 antibodies developed against the C-terminus of CB1 have also 
been able to detect CB1 receptors in rodent brain (Hajos et al., 2000). Inconsistencies have also 
been demonstrated as in cases where initial antibody aliquots have previously worked as expected 
subsequent aliquots from the same sources failed to detect CB1 receptors in brain sections 
(Grimsey et al., 2008). Similar localization of CB1 and CB2 immunoreactivity in cerebellar cortex has 
also been identified (Gong et al., 2006; Suarez et al., 2008). CB2 expression levels have also been 
detected in the rat cerebellum (Ashton et al., 2006). The presence of CB1 and CB2 receptors has 
also been detected in the hippocampus of neonatal rats (Suarez et al., 2009). Although CB2 
expression has also been identified in the hippocampus of adults rats the distribution profile show 
a discrepancy, it is hypothesized that CB2 expression changes during development until its final 
adult distribution (Gong et al., 2006; Suarez et al., 2009). CB2 distribution in the peripheral and 
central nervous systems have been reported using different techniques and different groups have 
reported variable expression patterns of the receptor (Atwood et al., 2010). The distribution 
profile of CB1 receptor in wildtype compared to knockout animals is very different however CB2 
antibodies show a fainter but similar pattern in the CB2 knockout animals compared to wildtype 
animals (Ashton, 2011). It has also been reported that attempts to identify CB2 levels have also 
been a hurdle as there are currently no available highly specific CB2 antibodies available (Onaivi et 
al., 2012).   
Western blot was used to investigate the specificity of the obtained hybridomas and all antibodies 
demonstrated unspecific binding relating to the target antigen and reacted with several proteins in 
both the GPR55 transfected and in the untransfected cell lines. However, in one of the antibody 
secreting hybridomas 4D12 a stronger band at the predicted size of GPR55 was detected in the 
GPR55 transfected cell line and a weak band in the untransfecetd cell line. Previous studies have 
also been performed where western blot analysis of liver and spleen homogenates from wildtype 
C57BL/6 mice showed 3 bands one at the expected size of 37 kDa and two other unspecific bands. 
The findings were explained by the authors as possible post-translational modifications of the 
receptor (Romero-Zerbo et al., 2011). Although further optimization of the 4D12 hybridoma might 
have reduced the background staining, these experiments would be time consuming and almost 
one year of this study was focused on producing antibodies therefore alternative techniques such 





FACS analysis was also used to determine the specificity of the hybridomas. Although minor 
differences were observed when comparing binding of the hybridomas to the wildtype DBT cells 
compared to the GPR55 transfected cells these low reactivities were comparable to isotype 



























An aim of this chapter was to identify GPR55 levels in mouse tissues and in the astrocytoma cell 
line. Due to the lack of production of specific antibodies as mentioned in chapter 4 alternative 
techniques were applied to study mRNA levels of GPR55.  
 
5.1.1 GPR55 mRNA levels  
 
Mouse GPR55 mRNA (Table 5.1) levels have been detected in the adrenals, frontal cortex, ileum, 
jejunum, striatum and lower levels in the hypothalamus, brainstem, spleen, hippocampus and 
cerebellum (Ryberg et al., 2007; Wu et al., 2013). Background levels of GPR55 mRNA were 
detected in mouse adipose tissue (Ryberg et al., 2007). GPR55 mRNA has also been found to be 
exp ressed in a primary mouse microglia and in the BV-2 mouse microglial cell line (McHugh et al., 
2010; Pietr et al., 2009). In mice lacking the adipocyte hormone leptin, which causes increased 
food intake, and rats fed on high fat diet, significantly reduced GPR55 mRNA and protein levels 
were observed in the white adipose tissue when compared to lean littermates(Colombo et al., 
2002; Moreno-Navarrete et al., 2012). 
 
Table 5.1 Mouse GPR55 mRNA levelsTable 
 
GPR55 mRNA levels mouse tissues ( Ryberg et al., 2007; Henstridge et al., 2011; Wu et 
al., 2013) 
 
High expression levels Low expression levels 
Adrenals  Hypothalamus  
Frontal cortex Brainstem  
Ileum  Spleen  
Jejunum  Hippocampus  
Striatum  Cerebellum  
 
Previous studies have reported GPR55 mRNA in rat hippocampus, thalamic nuclei and in the 
midbrain (Sawzdargo et al., 1999). GPR55 and also CB1, CB2, TRPV1 mRNA levels have also been 
detected in human proximal tubular (HK2) cells and in rat kidney (Jenkin et al., 2010). GPR55 and 




mRNA and protein expression levels in the HK2 cells have also been detected by Lim et al., 
2010.GPR55 mRNA and protein levels have been detected in PC12 cells however no CB1 or CB2 
mRNA expression was observed in the cell line (Obara et al., 2011). 
Human GPR55 expression levels have been detected in different parts of the brain, in lymphoid 
and in gastrointestinal organs (Table 5.2) (Brown et al., 2003; Henstridge et al., 2011; Oka et al., 
2009; Sawzdargo et al., 1999). GPR55 have also been detected in the testis, myometrium and in 
cells including Peripheral Blood Mononuclear Cells (PBMC), lymphocytes and osteoclasts (Table 
5.1)(Brown et al., 2003; Henstridge et al., 2011; Moreno-Navarrete et al., 2012; Oka et al., 2009; 
Whyte et al., 2009). It was also reported that GPR55 is highly expressed in normal human breast 
adipose tissue and is present in visceral fat (Brown et al., 2003). Levels of GPR55 mRNA have also 
been confirmed in human visceral (VAT) and subcutaneous adipose (SAT) tissues by another group 
(Moreno-Navarrete et al., 2012). The same study also reported similar GPR55 mRNA levels in the 
liver when comparing obese or diabetic patients with healthy patients (Moreno-Navarrete et al., 
2012). GPR55 and CD14, a monocyte marker, were found to be expressed in adipocytes and in the 
stromal vascular fraction of fat tissues (Moreno-Navarrete et al., 2012). GPR55 mRNA levels have 
also been detected in the spleen and thymus these findings lead the authors to explore the 
expression in lymphoblastoid cell lines (Oka et al., 2007; Oka et al., 2009). GPR55 expression was 
detected in IM-9 cells however no levels were identified in the Jurkat, Raji and Daudi cell lines (Oka 
et al., 2009). GPR55 expression  has been verified in a number of human cancer cell lines including 
ovary, prostate, pancreas, bile ducts, blood, brain, breast, cervix, skin and liver (Andradas et al., 
2011; Ford et al., 2010; Henstridge et al., 2011; Huang et al., 2011; Pineiro et al., 2011). GPR55 





In this chapter qPCR and in situ hybridization was used for detection of mRNA levels. To determine 
the tissue distribution, a GPR55 Taqman probe was used to examine the production of GPR55 
mRNA in mouse tissues (see methods 2.12.3). The expression levels in the tissues were quantified 
using a GPR55 standard curve (see methods 2.12.4). In the first instance an analysis of tissue 
distribution was assessed compared with GPR55 deficient mice. Radioactive (see methods 2.13) 
and non-radioactive (see methods 2.14) in situ hybridization was also used to localize GPR55 





Table 5.2 Human GPR55 mRNA levels Table 9 
 
GPR55 mRNA levels in human tissues and cells 
 
High expression levels Low expression levels 
 
Brain:(Henstridge et al., 2011) 
 
Regions in Brain: 
Putamen(Henstridge et al., 2011) 
Striatum(Henstridge et al., 2011) 
Nucleus Accumbens(Henstridge et al., 2011) 
Caudate Nucelus (Henstridge et al., 2011) 
 
Brain: (Oka et al., 2009) 
 
Regions in Brain: 
Caudate nucleus(Sawzdargo et al., 1999) 
Putamen(Sawzdargo et al., 1999) 
Hypothalamus(Henstridge et al., 2011) 
Pituitary(Henstridge et al., 2011) 
Lymphoid organs: 
Spleen(Henstridge et al., 2011; Oka et al., 2009) 
Thymus (Oka et al., 2009) 
Lymphoid organs: 
Adenoid (Brown et al., 2003) 
Gastrointestinal organs: 
Ileum (Brown et al., 2003) 
Small intestine (Oka et al., 2009) 
Intestine(Henstridge et al., 2011) 
 
Gastrointestinal organs: 
Ileum (Brown et al., 2003) 
Colon(Oka et al., 2009) 
Stomach(Henstridge et al., 2011) 
Testis(Brown et al., 2003; Oka et al., 2009) Liver (Moreno-Navarrete et al., 2012) 
Breast adipose(Brown et al., 2003) Visceral fat (Brown et al., 2003; Moreno-
Navarrete et al., 2012) 




(Moreno-Navarrete et al., 2012) 
Myometrium (Brown et al., 2003) Subcutaneous adipose (Moreno-Navarrete et al., 
2012) 
Cells: 
Osteoclasts (Whyte et al., 2009) 
Lymphocytes(Henstridge et al., 2011) 
PBMC (Henstridge et al., 2011) 
Trachea (Oka et al., 2009) 
Cervix (Oka et al., 2009) 
Lung (Henstridge et al., 2011; Oka et al., 2009) 
Cells: 
Monocytes (Whyte et al., 2009) 
Neutrophils(Henstridge et al., 2011) 
Macrophages (Henstridge et al., 2011) 
Platelets(Henstridge et al., 2011) 







   - Stromal vascular  





Table 5.3 Human GPR55 mRNA levels 
 
 
GPR55 mRNA levels human cell lines (Henstridge et al., 2011) 
 
High expression levels Low expression levels 
NT-2 PRE Neuronal precursor derived tumor CCF-STTG1 Astrocytoma 
SAOS2 Sarcoma osteogenic HS-2683 Neuronal glioma 
UT7-EPO Erythopoietin dependent leukemia 
HOS Osteosarcoma 






















5.2.1 Reference genes 
 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was initially tested as a reference gene; 
however, results showed variation in expression levels in different mouse tissues and was 
therefore not used.  A second reference gene, acidic ribosomal phosphoprotein P0 (36B4), was 
also used for the GPR55 assay and this reference also demonstrated variations in expression levels 
in our study. However, the use of 36B4 as a reference gene for quantification of GPR55 mRNA 







































Various tissues were collected tissues from GPR55 knockout and wild-type mice were taken for analysis of the 
reference genes GAPDH and 36B4. The reference gene expression levels were tested in the brain, spleen, testis and 
pancreas from 3 C57BL/6 mice. RNA extractions and cDNA synthesis were done on all tissues and cells and mRNA 
analysis was performed using qPCR. The Ct (threshold cycle) value represents the intersection between an 
amplification curve and a threshold line. The results represent the mean of GAPDH or 36B4 mRNA levels ± SEM. n= 3 







5.2.2 Standard curve for GPR55 template 
As the reference genes varied in the different tissues it was decided to use a standard curve for 
quantification of the GPR55 mRNA levels. As mentioned previously (see methods 2.12.4) an 
amplicon of GPR55 was designed to make a standard curve. The efficiency (E) of PCR (slope) 
should be around 100% and corresponds to double the amount (E=2) for each cycle. Although an 
efficiency of 100% (100%) is ideal, a good reaction should have values between 90% and 110% 
corresponding to values between -3.58 and -3.10 (Larionov et al., 2005). It was found that the 
efficiency was approximately -3.4. 
 
Figure 5.1 GPR55 standard curve: Amplification of a GPR55 amplicon 
Figure 16 
  
A 76bp GPR55 amplicon “ctatct acatgatcaa cttggctgtt ttcgatttac tgctggtgct ctccctccca ttcaagatgg tcctgccaca" was 















, 2 x 10
14
, were selected to make the standard curve.  The samples were 
amplified using qPCR. The various standard curve concentrations covered the different range of GPR55 mRNA levels 




5.2.3 GPR55 Standard curve 
 
The standard curve was run in duplicates in 96-well reaction plates and also run on an agarose gel 
in order to confirm the band size of the samples.  The size of the samples corresponded to the 
predicted size of the designed amplicon at 76bp.  
 
 















A 76bp GPR55 amplicon “ctatct acatgatcaa cttggctgtt ttcgatttac tgctggtgct ctccctccca ttcaagatgg 
tcctgccaca" was designed in order to make a standard curve. A series of dilutions were made and 12 























, 2 x 10
14
, were run on the gel.  The samples were amplified using qPCR. The various 
standard curve concentrations covered the different range of GPR55 mRNA levels from the various mouse 
tissues.The samples were amplified using qPCR. The reactions were then subject to 2% agarose gel 
electrophoresis and bands were detected using ethidium bromide. The GPR55 standard had a predicted 
size of 76bp. Band sizes were determined using a standard 50 base pair (bp) DNA ladder 
 
 
M M 1 2 3 4 6 5 8 7 9 10 11 12 
 200bp  
 150bp  






5.2.4 GPR55 mRNA expression levels of in mouse tissues. 
In order to determine the tissue distribution of GPR55, mRNA levels were prepared from a variety 
of different tissues. GPR55 mRNA levels were found expressed at higher levels in the brain, fat, 
liver, lung, small intestine, spleen, testis, thymus, tongue and in the GPR55 transfected cell line. 
Lower levels of GPR55 were detected in the heart, kidney, pancreas, salivary glands, and spinal 
cord and in the wild type cell line. The levels of GPR55 in KO tissues were comparable with control 
samples and did not produce appreciable levels of GPR55. The results suggested that DBT have 
low basal levels of GPR55.  
 




Various tissues were collected tissues from GPR55 KO and wild-type mice were taken for analysis of GPR55 mRNA 
levels. The mRNA levels of GPR55 in the GPR55 transfected cell line E1 DBT and WT DBT cells were compared to the 
levels in the tissues. RNA extractions and cDNA synthesis were performed on all tissues and cells and mRNA analysis 
was performed using qPCR. The mRNA expression levels of GPR55 receptor in mouse WT tissues was quantified using 
a GPR55 standard curve (Figure 5.1). The results represents the mean  SEM fold increase compared with the levels 




5.2.5 Radioactive In situ hybridization 
 
In situ hybridization using 35S radioactive labeled probes was performed in order to localize specific 
mRNA sequences in tissue sections. This demonstrated marked expression in GPR55 transfected 
cells compared to non-transfected cells. However, this experiment showed no  
detectable expression of GPR55 in brain tissues. High levels of GPR55 were detected in the GPR55 
transfected astrocytoma cell line.  
 
Figure 5.4 In situ hybridization was used for detection of GPR55 mRNA levels in GPR55 transfected  
 
cell line (E1 DBT), non-transfected (DBT) and mouse brain WT and KO tissuesFigure 23 
 
GPR55 transfected                Wild-type                      GPR55 KO                    Non-transfected 





 cells per well were made from a Gpr55 transfected astrocytoma cell line, the non-transfected 
astrocytoma cell line and 10m cryostat sections from the brain of a wild-type and GPR55 KO mouse were made. 
Analysis of mRNA expression levels of GPR55 in the wild-type and GPR55 KO tissues was performed using in situ 
hybridization using a 
35
S radioactive labeled GPR55 probe.  Slides were coatedin developing emulsion to detect 












5.2.6 Non-Radioactive In situ Hybridization (NR-ISH)-Digoxigenin (DIG)-labeled GPR55 RNA probe 
Due to the high background often observed in the in situ hybridization using radioactive labeled 
probes these were replaced by non-radioactive labeled probes to localize specific mRNA 
sequences in tissue sections. This was first investigated in the testis as qPCR analyses indicated 
that this tissue had a higher level of expression than in the brain as previously shown (Figure 5.3). 
Staining with the anti-sense (AS) GPR55 probe was mainly observed in the outer layer of the 
tubular wall in the wildtype testis (Figure 5.5) (arrows). A strong staining was observed in the 
GPR55 transfected E1 DBTcell line compared to the non-transfected WT DBT cell line (Figure 5.6). I 
did not get this approach to give a specific signal in the brain. 

















Cryostat sections (10m) from (A) a GPR55 KO mouse and (B) a wild-type mouse were prepared and fixed in 4% PFA. 
GPR55 mRNA was detected using in situ hybridization analysis using a non-radioactive AS DIG labeled, GPR55-specific 
probe. Digoxin was dected using specific antibody staining. This was incubated on the sections for 72h. Staining was 




GPR55 KO testis AS  
  
GPR55 KO testis AS  
  
GPR55 WT testis AS  
  
GPR55 WT testis AS  
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A total of 2.5x10
6
 cells per well were used from the Gpr55 transfected E1 DBT cell line and the non-transfected WT 
DBT cell line. Cytospins were made and GPR55 mRNA was detected using in situ hybridization analysis using a non-





WT DBT cells GPR55 AS  
  
WT DBT cells GPR55 AS  
  
E1 DBT cells GPR55 AS  
  
E1 DBT cells GPR55 AS  
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In the current study the tissue distribution of GPR55 was analyzed. A standard curve was used to 
quantify the levels of a GPR55 amplicon diluted at various concentrations. The CT values from the 
standard curve with known concentrations were used to correlate the different copy numbers. 
The efficiency of the PCR was 97% and was within the range of accepted values for a reaction at -
3.3959 (5.2.2). Although other ways of quantifying mRNA levels using reference genes such 
GAPDH and 36B4, would be an alternative to the standard curve, in our case the levels of the 
reference genes highly varied in the different tissues (Table 5.1)  
High GPR55 levels were expressed in the E1 GPR55 DBT transfected cell line compared to the non- 
transfected DBT cell line. In the mouse tissues the highest levels of GPR55 were detected mainly in 
the spleen, testis and adipose tissues. Lower levels were seen in the heart, kidney, salivary gland 
and spinal cord.   
Ryberg et al., 2007 reported background levels of GPR55 mRNA in mouse adipose tissue. In this 
study high levels of GPR55 was found in mouse adipose tissue consistent with initial reports in a 
patent (Brown et al., 2001). Substantial levels of GPR55 expression have also been reported in 
normal human breast adipose tissue and in visceral fat (Brown et al., 2003). The authors in the 
same study however did not detect GPR55 levels in subcutaneous adipose tissues (Brown et al., 
2003). The various observations may be due to the use of different mouse strains or technical 
difficulties. Also, as the orphan receptor is expressed at seeming very low levels throughout most 
tissues compared to other targets such as CB1 it could be due to insufficient technical sensitivity 
(Ryberg et al., 2007).  
Although human GPR55 expression levels have been detected in the caudate nucleus and 
putamen, no GPR55 expression levels were however detected in other parts of the brain including 
the hippocampus, thalamus, pons, cerebellum, frontal cortex of the brain or in the liver 
(Sawzdargo et al., 1999). Expression of GPR55 and CD14 mRNA has also been observed in 
adipocytes and in the stromal vascular fraction of fat tissues; this might suggest that the receptor 
is present on monocytes, macrophages and lymphocytes (Moreno-Navarrete et al., 2012).  
In situ hybridization using radioactively labeled probes was performed to localize specific GPR55 
mRNA sequences in tissue sections. So far, positive controls have been found to work, however 
problems with supply of batches of radioactivity have hampered attempts to detect GPR55.  Due 
to the high background sometimes found in in situ hybridization using radioactive labeled probes 
the technique was replaced by in situ hybridization using non-radioactive labeled probes. Although 




however not sensitive enough to detect mRNA levels in any other tissue tested including spleen 
and brain. This demonstrates the insensitivity of the technique compared to qPCR (Figure5.3). 
Likewise it also indicates that GPR55 is expressed at very low levels in tissues. Levels of GPR55 
mRNA in the transfected cell lines were detected using both radioactive and non-radioactive in 
situ hybridization. However, some background punctate artifact staining was observed in the 
untransfected cell line but only in a few patches. This artifact staining was not observed in the 
untransfected cell line when using non-radioactive in situ hybridization. 
A 10 fold difference in mRNA levels was observed when comparing GPR55 transfected cell lines 
with brain tissue and a 100 fold difference between the untransfected and transfected 
astrocytoma cell lines. The GPR55 mRNA levels in the testis were 5 fold less than in the transfected 
cell line or 5 times more than in the brain. Detection of mRNA levels in the brain using PCR and not 
when using in situ hybridization could be due to that the signal in the brain is distributed in many 























The aim of this chapter was to investigate the function of the GPR55 receptor during EAE. We 
generated and genotyped GPR55 knockout mice on the C57BL/6 (chapter 1) background that were 
initially used for our EAE experiments. However, the EAE experiments on this strain showed 
inconsistencies in disease course. These animals were then backcrossed for over 11 generations 
onto the ABH backgroundto generate fully congenic mice and this allowed us to investigate the 
function of GPR55 during EAE on the more stable background.  
 
EAE is mainly used as an animal model of autoimmune, inflammatory diseases of the CNS and is 
the most common experimental model used to study MS(Constantinescu et al., 2011; Farooqi et 
al., 2010; Gold et al., 2006; Steinman et al., 2005). EAE can be induced in susceptible animal strains 
by active immunization with CNS-derived antigen such as spinal cord homogenate, myelin basic 
protein, proteolipid protein, MOG, myelin associated glycoprotein, infection with neurotropic 
viruses or with adoptive transfer of encephalitogenic myelin-reactive T cell lines (Denic et al., 
2011).Transgenic mouse EAE models which have a preponderance of myelin-specific T cell 
receptors have also been reported (Bettelli et al., 2006; Ellmerich et al., 2005; Friese et al., 2006). 
EAE is most commonly induced in mouse strains however the disease has been replicated in a 
wide range of species including chickens (Ranzenhofer et al., 1958), dogs (Thomas et al., 1950), 
goats(Lumsden, 1949), guinea pigs (Freund et al., 1947), hamsters (Tal et al., 1958) marmosets 
(Genain et al., 1995), rabbits (Morrison, 1947), rats (Lipton et al., 1952) and sheep (Innes, 1951).  
 
EAE varies between animal species and strains from a chronic form of paresis in the C57BL/6 mice 
to a relapse-remitting disease that develops to secondary progression in ABH mice (Al-Izki et al., 
2012; Baker et al., 2000). Whereas EAE in C57BL/6 mice is induced by immunization of MOG 35-55 
peptide it is induced by immunization of spinal cord homogenate in complete Freunds’ adjuvant in 
ABH animals. However, immunization of ABH mice with MOG 35-55 peptide results in an 
immediate progressive chronic disease similar to that occurring in MOG35-55 peptide induced 





EAE is characterized by a number of immunopathological and neuropathological mechanisms that 
lead to similar key pathological features of MS including inflammation, demyelination, axonal loss 
and gliosis (Constantinescu et al., 2011). A perivascular infiltration of CD4+ T cells and macrophages 
has been observed mainly in the spinal cord during clinical episodes of neuroinflammation in ABH 
mice (Baker et al., 1990; Butter et al., 1991). This accumulation of immune cells correlates with 
severity of disease (Al-Izki et al., 2012; Allen et al., 1993; Baker et al., 2000; Butter et al., 1991). 
Demyelination is mainly observed during the relapse stage of the disease and rarely in the acute 
phase (Amor et al., 2005; Baker et al., 1990).  An increased level of axonal degeneration in the 
spinal cord during EAE in ABH mice leads to the development of signs of neurological impairment 
such as decreased locomotor performance and clinical signs such as spasticity and tremor (Baker 
et al., 2000).  
 
Many of the current developed drugs used for treatment of multiple sclerosis have been assessed 
and validated on the basis of EAE studies (Constantinescu et al., 2011; Farooqi et al., 2010; Gran, 
2007). While immunization with a known CNS antigen or antigens is used to develop EAE, the 
causative factor of MS remains unknown and there is no unique identified antigen in the human 
disease (Constantinescu et al., 2011; Gran, 2007). The influence of GPR55 was unknown at the 
initiation of this project. EAE is known to be a largely CD4+ T cell induced disease (Mokhtarian et 
al., 1984; O'Neill et al., 1993). We aimed to detect phenotype and functional changes in immune 
cells in vitro and determine whether there was any influence of the genetic deletion on in vivo 




In this chapter EAE induced by either MOG35-55 peptide in C57BL/5 mice (see methods 2.15.1) or 
by spinal cord homogenate in mice on the ABH background (see methods 2.15.2). 
Immunophenotypical analyses were performed using flow cytometry and were used to 
characterize and compare the different strains, on the C57BL/6 background, in naïve state and 
after stimulation by MOG35-55 peptide (see methods 2.16). CFSE or radioactive proliferation 
assays using MOG35-55 peptide or Con A (see methods 2.16.1) were also performed. Cytokine 
profiling was analyzed using flow cytometry (see methods 2.16). Rotarod was used to measure 








6.2.1 Immunophenotypes (Naïve T- and B-cells in spleen) 
The immunophenotypes (T- and B-cells) of GPR55 KO mouse lymphocytes in spleen were 
compared with wild-type littermates in order to investigate potential differences. Analysis was 

















Naïve GPR55 knockout (C57BL/6.GPR55
-/-
) and wildtype (C57BL/6 
+/+
) littermates were used for immunophenotyping. 
Leukocytes from spleen were collected and the cells were stained with various surface antibodies (T-cells CD4, CD8 









































































6.2.2 Immunophenotypes (Naïve T- and B-cells in blood) 
The immunophenotypes (T- and B-cells) of GPR55 KO mouse lymphocytes in blood were compared 
with wild-type littermates in order to investigate potential differences. Analysis was peformed by 
flow cytometry. Results displayed no significant difference between the two strains. 
 


















Naïve GPR55 knockout (C57BL/6.GPR55
-/-
) and wildtype (C57BL/6 
+/+
) littermates were used for immunophenotyping. 
Leukocytes from blood were collected and the cells were stained with various surface antibodies (T-cells CD4, CD8 and 




































































6.2.3 Immunophenotypes (Naïve monocytes and dendritic cells) 
The immunophenotypes (Monocytes and dendritic cells) of GPR55 KO mouse leukocytes in spleen 
and blood were compared with wild-type littermates in order to investigate potential differences. 
Analysis was peformed by flow cytometry. Results displayed no significant difference between the 






















Naïve GPR55 knockout (C57BL/6.GPR55
-/-
) and wildtype (C57BL/6 
+/+
) littermates were used for immunophenotyping. 
Leukocytes from blood were collected and the cells were stained with various surface antibodies (Monocyte-F4/80 












































































































Figure 6.3 Spleen and blood monocytes and dendritic cells from C57BL/6.GPR55 -/- and C57BL/6 +/+  
 





6.2.4 Immunophenotypes (Naïve T- cells in thymus and lymph nodes) 
Further analysis was performed to investigate T- cell immunophenotypes in the thymus (Figure 
6.4A) and in the lymph nodes (LN) (Figure 6.4B) comparing GPR55 KO (C57BL/6) with wild-type 
animals. Early T-cell development markers CD25 and CD44 in the thymus were also investigated. 
No significant difference between the two strains was observed. 

















Naïve GPR55 knockout (C57BL/6.GPR55
-/-
) and wildtype (C57BL/6 
+/+
) littermates were used for immunophenotyping. 
Cells from the thymus (Figure A) and lymph nodes (Figure B) were collected and stained with surface antibodies 






























































































































6.2.5 Stimulation of lymphocytes 
Leukocytes (spleen) from GPR55 KO mice and wild-type littermates were isolated and stimulated 
with either the mitogen Concanavalin A (Con A) or MOG 35-55 peptide. Whilst cells responded to 
Con A there was essentially no specific proliferation in either wild-type or knockout animals in the 
cells stimulated with MOG 35-55 peptide. 
























C56BL/6.Gpr55 knockout and heterozygous littermates were immunized with MOG peptide in Freund’s adjuvant on 
day 0 and were injected with 200ng of B. pertussis toxin on day 0 and 1. Splenocytes were collected on day 9 and re-
stimulated in vitro with MOG peptide at concentrations 1μg or 10μg for 72h (Figure A). Splenocytes from Naïve GPR55 
knockout and wildtype mice also collected and stimulated with Con A for 48h.A total of 300.000 cells were 
resuspended in a final volume of 100 l of RPMI 10% FCS and plated in 96 well-plates.  After 24-48h a total of 0.5 units 
of 
3
H Thymidine (PerkinElmer LAS, Beaconsfield, Bucks, UK) was added to each well and cells were incubated during 
for 24hrs at 37
o
C in 5%CO2. Cells were then harvested (TOMTEC MACH III M CELL HARVESTER 96, Warwick, UK) and 























































Con A  MOG 35-55  




6.2.6 Function of GPR55 in Neuroinflammation-C57BL/6 mice 
 
GPR55 knockout mice were generated by either backcross of C57BL/6.Gpr55-/- with heterozygotes 
littermates or following a cross of heterozygote (C57BL/6.Gpr55-/+ x C57BL/6.Gpr55-/+) mice. These 
were injected with MOG35-55 peptide in Freund’s adjuvant. Results indicated that GPR55 
knockout mice failed to generate an autoimmune response suggesting that GPR55 controls 
immune function (Figure 6.6, Table 6.1). The low susceptibility was also observed in additional 
experiments (n=4). There was a consistent lack of susceptibility in knockout animals but in some 
experiments the control groups failed to develop disease. The incidence and severity of disease 
















C56BL/6.Gpr55 knockout and heterozygous female littermates were immunized with MOG peptide in Freund’s 
adjuvant on day 0 and 7 and were injected with 200ng of B.pertusssis toxin on day 0 and 1. Animals were scored 0 = 
normal 1= limptail, 2= impaired righting reflex, 3= paresis and 4= complete hindlimb paralysis. The results represent 
the mean daily clinical score of animal ± SEM. n= 8-10 animals per group. Experiments were performed in 






Figure 6.6 Experimental autoimmune encephalomyelitisFigure 24 
Time Post-inoculation (days)
























Table 6.1 Function of GPR55 in Neuroinflammation-C57BL/6 miceTable 11 
_______________________________________________________________________________               
Mice      No. EAE Mean EAE     Group Score ±SEM        EAE Score ±SEM      Day of Onset±SD 
                                                                         All animals   Animals with Disease 
 _______________________________________________________________________________ 
GPR55-/-: Females 2/8                         1.0 ± 0.7                4.0 ± 0.0           15 ± 1.9 
GPR55-/-: Males  4/6                 2.5 ± 0.8                3.8 ± 0.8           18 ± 1.9 
GPR55-/+: Females 7/7                 2.8 ± 0.4                2.8 ± 0.4           16 ± 1.6 
GPR55-/+: Males  4/6                 2.5 ± 0.8                           3.6 ± 0.1              16 ± 1.2 
GPR55+/+: Females 4/5                 3.0 ± 0.8                 4.0 ± 0.0           16 ± 0.5  
GPR55+/+: Males 5/6                 3.4 ± 0.7                      4.0 ± 0.0                    15 ± 0.8 
_____________________________________________________________________________ 
EAE was induced in GPR55 knockout (C57BL/6.GPR55
-/-
), heterozygote (C57BL/6.GPR55-/+) and wildtype 
(C57BL/6.GPR55
+/+
) mice. These were immunized with MOG 35-55 peptide in Freund’s adjuvant on day 0 and 7 and 
were injected with 200ng of B.pertusssis toxin on day 0 and 1. Animals were scored 0 = normal 1= limptail, 2= 
impaired righting reflex, 3= paresis and 4= complete hindlimb paralysis. The results represent The mean maximum 
score for all animals within the group or the (EAE score) animals that got EAE n= 5-8 animals per groups. Experiments 




























6.2.7 Immunophenotypes (MOG 35-55 peptide stimulated T- and B-cells in spleen) 
Immunophenotyping of naïve animals was previously done (Figure 6.1) and due to the observed 
reduced disease in the GPR55 (C57BL/6) knockout mice we decided to investigate the 
immunophenotypes post MOG stimulation. The immunophenotypes (T- and B-cells) of MOG 35-55 
peptide stimulated GPR55 KO mouse lymphocytes in spleen were compared with wild-type 
littermates in order to investigate potential differences. Analysis was performed by flow 
cytometry. Results displayed no significant difference between the two strains. 
 
Figure 6.7 Immunophenotyping of spleen cells from in vivo and/or in vitro MOG stimulated  
























In vivo (A) and in vitro re-stimulated (10μg/ml) (B) MOG stimulated GPR55 knockout (C57BL/6.GPR55
-/-
) and wild-type 
(C57BL/6 
+/+
) littermates were used for immunophenotyping. Leukocytes from spleen were collected and the cells 
were stained with various surface antibodies (T-cells CD4, CD8 and B-cells CD19) diluted 1:100. Samples were then 






































































































































6.2.8 IL-4 cytokine responses 
The IL-4 cytokine response in T- and B-cells from MOG 35-55 peptide stimulated GPR55 KO mouse 
lymphocytes in spleen were compared with wild-type littermates in order to investigate potential 
differences. Analysis was performed by flow cytometry. Results displayed no significant difference 
between the two strains. 
 
 
Figure 6.8 IL-4 cytokine responses in T- and B-cells from MOG stimulated C57BL/6.GPR55-/- and 
 































In vivo (A) and in vitro (10μg/ml) (B) MOG stimulated GPR55 knockout (C57BL/6.GPR55
-/-
) and wild-type (C57BL/6 
+/+
) 
littermates were used for cytokine profiling. Lymphocytes from spleen were collected and the cells were stained with 
various surface antibodies/ T-cells markers CD4, CD8, CD19 and cytokine marker IL-4 diluted 1:100. Samples were 



























































































































































6.2.9 IL-17A cytokine responses 
The IL-17A cytokine response in T- and B-cells from MOG 35-55 peptide stimulated GPR55 KO 
mouse lymphocytes in spleen were compared with wild-type littermates in order to investigate 
potential differences. Analysis was performed by flow cytometry. Results displayed no significant 
difference between the two strains. 
 
Figure 6.9 IL-17A cytokine responses in T- and B-cells from MOG stimulated C57BL/6.GPR55-/- and 
 


































In vivo (A) and in vitro (10μg/ml) (B) MOG stimulated GPR55 knockout (C57BL/6.GPR55
-/-
) and wild-type (C57BL/6 
+/+
) 
littermates were used for cytokine profiling. Leukocytes from spleen were collected and the cells were stained with 
various surface antibodies/ T-cells markers CD4, CD8, CD19 and cytokine marker and IL-17A diluted 1:100. Samples 


































































































































































6.2.10 IFN-  cytokine responses 
The IFN- cytokine response in T- and B-cells from MOG 35-55 peptide stimulated GPR55 KO 
mouse lymphocytes in spleen were compared with wild-type littermates in order to investigate 
potential differences. Analysis was performed by flow cytometry. Results displayed no significant 
difference between the two strains. 
 
Figure 6.10 IFN-  cytokine responses in T- and B-cells from MOG stimulated C57BL/6.GPR55-/- and 
 


































In vivo (A) and in vitro (10μg/ml) (B) MOG stimulated GPR55 knockout (C57BL/6.GPR55
-/-
) and wildtype (C57BL/6 
+/+
) 
littermates were used for cytokine profiling. Leukocytes from spleen were collected and the cells were stained with 
various surface antibodies / T-cells markers CD4, CD8, CD19 and cytokine marker IFN-) diluted 1:100. Samples were 



















































































































































6.2.11 IL-10 cytokine responses 
The IL-10 cytokine response in T- and B-cells from MOG 35-55 peptide stimulated GPR55 KO 
mouse lymphocytes in spleen were compared with wild-type littermates in order to investigate 
potential differences. Analysis was performed by flow cytometry. Results displayed no significant 
difference between the two strains. 
 
Figure 6.11 IL-10 cytokine responses in T- and B-cells from MOG stimulated C57BL/6.GPR55-/- and 
 

































In vivo (A) and in vitro (10μg/ml) (B) MOG stimulated GPR55 knockout (C57BL/6.GPR55
-/-
) and wildtype (C57BL/6 
+/+
) 
littermates were used for cytokine profiling. Leukocytes from spleen were collected and the cells were stained with 
various surface antibodies/ T-cells markers CD4, CD8, CD19 and cytokine marker IL-10 diluted 1:100. Samples were 
































































































































































6.2.12 Fox3P responses 
The Fox3P responses in T- and B-cells from MOG 35-55 peptide stimulated GPR55 KO mouse 
lymphocytes in spleen were compared with wild-type littermates in order to investigate potential 
differences. The CD4 +FoxP3+CD25 markers were used to analyze regulatory T cells. Analysis was 
performed by flow cytometry. Results displayed no statistical significant difference between the 
two strains. 
 
Figure 6.12 Fox 3P responses in T- and B-cells from MOG stimulated C57BL/6.GPR55-/- and 
 

































In vivo and in vitro (10μg/ml) MOG stimulated GPR55 knockout (C57BL/6.GPR55
-/-
) and wild-type (C57BL/6 
+/+
) 
littermates were used for (A) CD4-CD25 and (B) CD4-Fox3P staining. Leukocytes from spleen were collected and the 
cells were stained with various surface antibodies CD4, CD25, and Fox3P diluted 1:100. Samples were then read on a 































































































































































6.2.13 CFSE proliferation assay 
Lymphocytes (spleen) from GPR55 KO mice and wild-type littermates were isolated and stimulated 
with MOG 35-55 peptide in vivo and re-stimulated in vitro. Proliferation was seen in both in vivo 
and in in vitro re-stimulated cells however no significant difference was seen between both 
groups. Also, proliferation did not differ when comparing lymphocytes from WT with knockout 
animals.  
 
























C56BL/6.Gpr55 knockout and heterozygous littermates were immunized with MOG peptide 35-55 in Freund’s 
adjuvant on day 0 and were injected with 200ng of B. pertussis toxin on day 0 and 1. Lymphocytes were collected on 
day 9 and left either unstimulated or were re-stimulated in vitro with MOG peptide at a concentrations of 10μg/mg 
for 72h. Lymphocytes were stained with CFSE (5μm) and incubated at 37°C for 4 days. Samples were then read on a 









6.2.14 Function of GPR55 during experimental autoimmune encephalomyelitis in ABH mice  
 
ABH.GPR55-/-congenic mice were generated following a cross of GPR55 knockout mice on the 
C57BL/6 background (C57BL6.GPR55-/-) with ABH wild-type mice for more than 11 generations. 
These were injected with spinal cord homogenate in Freund’s adjuvant. The severity of the disease 
was marginally reduced in the GPR55 knockout mice on the ABH background during the acute 
phase particulary when comparing the female groups (Figure 6.14A: females; Figure 6.14B: males 




























Males and female ABH.GPR55
-/- 
knockout and wild-type littermates were immunized with spinal cord 
homogenate in Freund’s adjuvant on day 0 and 7. Animals were scored 0 = normal 1= limptail, 2= impaired 
righting reflex, 3= paresis and 4= complete hind limb paralysis. The results represent the mean daily 
clinical score of animal ± SEM. n= 8-10 animals per groups.  
 
Figure 6.14 Experimental autoimmune encephalomyelitis in ABH mice 
Time Post-Inoculation (Days)

























































6.2.15 Function of GPR55 during relapse remitting EAE in ABH animals 
 
The initial acute phase of disease is largely inflammatory, without much demyelination or axonal 
damage. However, relapsing disease is associated with greater neurological damage, which allows 
neuroprotective effects to be monitored (Al-Izki et al. 2012). EAE induced in ABH mice were 
monitored for more than 50 days. As noted results showed a marginally reduced disease during 
first attack (Figure 6.14, 6.15) however, this difference was not seen during the first relapse.  
 
Time Post-Innoculation (Days)


























Male and female ABH.GPR55
-/- 
knockout (n=34) and wild-type littermates (n=28) were immunized with spinal cord 
homogenate in Freund’s adjuvant on day 0 and 7 and day 28 (inverse triangles). Animals were scored 0 = normal 1= 
limptail, 2= impaired righting reflex, 3= paresis and 4= complete hindlimb paralysis and 5= moribund/death. The 










   




Table 6.2 Function of GPR55 in Neuroinflammation in ABH miceTable 12 
 
____________________________________________________________________________                
Mice                      EAE/Total No     EAE Group acute    EAE 1st relapse      Day of Onset 
                                             Score ±SEM            Score ±SEM   ±SD  
____________________________________________________________________________ 
Initial Acute Phase 
GPR55-/-: Females        21/21                    3.1 ± 0.2*              3.1 ± 0.2*               16.6 ± 2.4 
GPR55-/-: Males           12/13          3.2 ± 0.3              3.5 ± 0.1                 17.1 ± 0.2 
GPR55+/+: Females      12/12                    3.8 ± 0.1               3.8 ± 0.0                  15.2 ± 1.2 
GPR55+/+: Males         16/16                     3.6 ± 0.1                    3.6 ± 0.1                 16.6 ± 2.2 
Induced Relapse 
GPR55-/-: Females        21/21                    3.8 ± 0.1              3.8 ± 0.1                  34.8 ± 1.0 
GPR55-/-: Males           13/13                     3.7 ± 0.2                    3.7 ± 0.2                 34.7 ± 1.4 
GPR55+/+: Females      12/12                    3.9 ± 0.1               3.9 ± 0.1                  35.4 ± 1.3 
GPR55+/+: Males         16/16          3.9 ± 0.1              3.9 ± 0.1                 34.9 ± 1.4 
____________________________________________________________________________ 
EAE was induced in ABH.GPR55
-/- 
knockout mice and wildtype littermates. These were immunized with 
spinal cord homogenate in Freund’s adjuvant on day 0 and 7 and a relapse was induced by a further 
injection on day 28. Animals were scored 0 = normal 1= limptail, 2= impaired righting reflex, 3= paresis 
and 4= complete hindlimb paralysis, 5= moribund/death. The results represent disease incidence, the 
mean maximal clinical scores animals ± SEM of all animals in the group, the mean maximal score ± SEM of 












6.2.16 Weight losses and function of GPR55 during relapse remitting EAE in ABH animals 
 
Although the severity of the acute disease was marginal it was not statistically significantly 
reduced in the GPR55 knockout mice on the ABH background (Figure 6.14; Table 6.2), this 
observation was however not reflected by significant weight differences (Figure 6.16). This showed 
a clear sexual dimorphism with males heavier than females however there was no influence of the 
genotype. 
  
Figure 6.16 EAE- weight losses in ABH miceFigure 26 
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GPR55 KO Females  





EAE was induced in ABH.GPR55
-/- 
knockout mice and wild-type littermates. These were immunized with 
spinal cord homogenate in Freund’s adjuvant on day 0 and 7. Animals were weighed from day 10. The 










6.2.17 Measurement of motor performance in relapsing EAE in ABH mice 
 
The Accelerating Rotarod treadmill was used to access the motor control and coordination in both 
strains. Assessment was done during the remission phases of the disease, over a maximum 5 
minute observation period. The first assessment was done on day 27 after animals had recovered 
from the initial attack. Following the development of acute disease a relapse was induced to 
determine whether significant disability indicative of nerve loss (Al-Izki et al., 2012) would be 
observed. Second assessment was done on day 56 post first relapse.  It was found that there was 
no statistical significant difference in the incidence of relapse or maximum severity of relapse 
(Figure 6.15). When comparing female GPR55 knockout females with wild-type littermates there 
was no difference observed. However, when comparing GPR55 knockout males with wild-type 
males it was found that the wild-type males had statistically significant (P<0.05) reduced motor 
coordination  after acute attack. Wild-type males also showed a trend toward significant motor 
































































Day 27 ost relapse










































EAE was induced with spinal cord homogenate in Freund's adjuvant in ABH mice on day 0 and 7. Animals were 
allowed to undergo an acute phase inflammatory attack and relapse was induced by re-immunization with spinal cord 
homogenate in Freund’s adjuvant at day 28. Motor co-ordination was assessed by an accelerating Rotarod 
performance measurement post-acute phase in remission at day 27 and post-1
st
 relapse in remission phase at day 56.  





6.3 Discussion  
The results of this study suggest that there may be some immune deficit, particulary in female 
C57BL/6 mice in relation to the development of EAE. However, analysis of the thymus, lymph 
nodes and T and B cell numbers and function did not reveal the nature of the defect. In these 
experiments there was essentially no antigen-specific T cell proliferation detected when cell were 
stimulated with MOG 35-55 peptide in vitro. It has previously been reported that peptides that 
induce pathogenic response often give a non-existent T cell proliferative responses (Amor et al., 
1993; Heijmans et al., 2005). However, MOG peptide induced responses have been reported in 
many studies (Graham et al., 2010; Heijmans et al., 2005; Issazadeh et al., 2000). The lack of 
responses therefore probably relates to the inconsistent level of sensitization as shown by the 
inconsistent induction of EAE. The immunophenotype in C57BL/6.GPR55-/- may also have 
contributed to the difficulties in generating monoclonal antibodies (chapter 4). 
C57BL/6.GPR55-/- knockout and C57BL/6+/+ wild-type mice were initially immunophenotyped and 
there was no obvious difference in the immunophenotype in naïve animals and there was no 
significant difference in theT cell proliferative response to MOG or Con A mitogenic stimulation. 
C57BL/6.GPR55-/- knockout and C57BL/6+/+ wild-type mice were also immunophenotyped post 
MOG in vivo stimulation and in vitro re-stimulation and no significant differences were observed 
when comparing the two strains. 
C57BL/6+/+ wildtype and C57BL/6.GPR55-/- knockout mice were injected with MOG35-55 peptide in 
Freund’s adjuvant in order to induce EAE. The disease was markedly reduced the GPR55 knockout 
mice on the C57BL/6 mice suggesting that GPR55 controls immune function. This would suggest 
that GPR55 antagonism would be anti-inflammatory, however it has been reported that the non–
selective GPR55 agonist O-1602 modulates the inflammatory response in a number of conditions 
(Li et al., 2013; Lin et al., 2011; Schicho et al., 2012). However, O-1602 may act on GPR18 which is 
expressed by immune cells (McHugh 2012) as the ligand has also been reported to be a GPR18 
agonist (Caldwell et al., 2013). Although the low susceptibility was consistently observed in two 
additional experiments one of the difficulties with EAE in C57BL/6 mice is that the disease in 
controls is variable and the severity of disease may be high or low dependent on the experiment 
(Axtell et al. 2011(Coquet et al., 2013).    As such in two experiments the wildtype controls likewise 
failed, as found in the GPR55 knockout animals, to get disease and thus failed quality control that 
justifies analysing data from these failures. When the sexes were compared it seemed that 
females were marginally less susceptible than males. This would suggest some sex hormone 




To elliminate the influnece of low grade disease induction associated with MOG-induced disease in 
C57BL/6 mice GPR55 knockout mice were generated on the ABH background as this strain gives 
consistent disease incidence and severity (Baker et al. 1990, Al-Izki et al. 2012). Knockout mice 
were generated following a cross of GPR55 knockout mice on the C57BL/6 background 
(C57BL6.GPR55-/-) x (ABH+/+) with ABH wildtype mice. EAE was induced in the animals by injections 
with spinal cord homogenate in Freund’s adjuvant. Although a marginally lower susceptibility 
remained in the GPR55 knockout (ABH.GPR55-/-) mice compared to wild-type littermates this 
difference was not as obvious as on the C57BL/6 background. The lower susceptibility was mainly 
observed in the first attack and the incidence and severity of disease increased and no significant 
differences between the two strains were observed in the first relapse (Figure 6.14). This observed 
disease susceptibility differences may be due to differences in strain backgrounds therefore the 
lower susceptibility might be due to minor influences of GPR55 receptor. This study demonstrates 
that the influence of GPR55 is largely dependent on the genetic background of the mouse and 
when on a fully EAE susceptible background GPR55 exhibits minor influence. Similar effects have 
been noted with CB2 receptor where Cnr2-deficiency leads to enhanced susceptibility in C57BL/6 
background mice (Maresz et al., 2007; Palazuelos et al., 2008). However, on the ABH background 
the influence of CB2 deficiency is lost and CB2 agonists exhibit no influence on EAE susceptibility 
(Croxford et al., 2008) (G.Pryce unpublished observations). This is lack of immune phenotype is 
also apparent in differences between ABH.CB1 and C57BL/6.CB1 deficient mice (Pryce et al. 2003, 
Rossi et al. 2011) and ABH.Trpv1 and C57BL/6.Trpv1 knockout mice (Pryce 2010,Musumeci et al 
2010) As most EAE studies uses gene knockout animals on the C57BL/6 background it is of concern 
that many studies may not translate even to other mouse strains. The chances of this then 
translating to humans is unlikely. This may be a further reason for the failure to translate 
treatments of rodent EAE to human benefit (Vesterinen et al., 2010). Therefore many treatments 
are essentially tried in one individual inbred mouse strain, which may not be the typical response 
of the outbred population. The difference found in the C57BL/6 may be as much to do with the 
inconsistent disease susceptibility and the influence of the transgene therefore it is important that 
disease the susceptible in the control group is stable. As such it is often the case that when a 
transgene enhances EAE susceptibility the control group shows weak EAE (Bettelli et al., 2003; 
Elhofy et al., 2005) and when the transgene inhibits EAE the susceptibility of the control group is 
strong (Das et al., 2000; Sinha et al., 2011). The level of susceptibility in spinal cord-induced EAE 
has remained consistent over many years (Baker et al., 1990; Al-izki et al., 2012). 
 
Both strains also had comparable weight losses. A Rotarod treadmill was used to access the motor 




both female groups (ABH+/+, ABH.GPR55-/-). ABH wild-type males were found to be the most 
neurologically impaired in comparison to the different groups. Although a statistical difference 
was observed after the initial attack there was no statistical difference after the first relapse even 
though the ABH wild-type male performance was reduced overall compared to all the other 
groups on both days. Likewise it has been found that males are more likely to develop progressive 
neurodegeneration after onset (Runmarker et al., 1993). Recently it has been reported that GPR55 
knockout mice exhibit significant motor coordination deficits compared to wild-type littermates 
(Wu et al., 2013). This view is not supported by our studies where no differences in Rotarod 
performance were observed when comparing GPR55 knockout females with wild-type females. In 






















The cannabinoid system has been demonstrated to exhibit tonic control of spasticity using EAE 
models of MS (Baker et al., 2001). The phytocannabinoid THC and CB1 receptor have been 
reported to act as important mediators for the control of spasticity by cannabis (Pryce et al., 2007; 
Wilkinson et al., 2003). The use of THC is associated with unwanted, psychotrophic effects of 
cannabis due to CB1 receptor stimulation in certain cognitive-control centres in the brain (Howlett 
et al., 2002; Varvel et al., 2005). Cannabis therefore has a small therapeutic window in spasticity 
because THC and CB1 receptors mediate both the therapeutic and adverse effects of cannabis 
(Pryce et al., 2007; Varvel et al., 2005).  Although disease symptoms of MS are generated by 
lesions within the CNS aberrant neurotransmission must traverse the peripheral nervous system 
and neuromuscular junction to cause spasticity (Baker et al., 2012). Likewise sensory and 
positional signals must be transmitted back to the CNS through synapses expressing CB1 receptors 
(Baker et al., 2012). Spasticity results from lack of inhibition of excessive neurotransmission in the 
CNS, resulting in excessive contraction of muscles.  It was hypothesised it may be possible to 
maintain therapeutic activity, whilst limiting psychoactive potential (Baker et al., 2012; Pryce, 
2010). It was believed altered neurotransmission could be controlled between muscles and the 
spinal cords by targeting CB1 in peripheral sensory and motor pathways (Baker et al., 2012). In 
attempt to generate CNS-excluded CB1 receptor agonists, VSN16 series compounds were made 
(Hoi et al., 2006), based around some cyclic anandamide compounds (Berglund et al., 1998; Tong 
et al., 1998). These were found to be anti-spastic but had a mechanism of action that was 
independent of CB1 receptor (Hoi et al., 2006; Pryce, 2010). The presence of novel cannabinoid 
receptor(s) in the vasculature has been suggested by many studies (White et al., 1997). In a recent 
study, anandamide showed to cause vasorelaxation that is sensitive to rimonabant and is 
insensitive to PTX, suggesting a non-CB1 receptor-mediated vasorelaxation (White et al., 1997). 
VSN16R has also shown to relax rat mesenteric arteries in an endothelium-dependent manner, via 
a PTX-insensitive mechanisms (Hoi et al., 2006). Importantly the vasorelaxation induced by 
VSN16R was reduced by rimonabant, AM251 and O-1918 which were reported to influence GPR55 
function (Baker et al., 2006b; Hoi et al., 2007a; Ryberg et al., 2007). In addition, the mechanism of 
action was found to be CB1 receptor-independent and VSN16R failed to bind or agonise to the CB1 




These molecules may also influence the abnormal cannabidiol receptor, thought to be GPR18, 
however activation of this receptor is reported to be PTX-sensitive (Kohno et al., 2006). GPR55 has 
been was reported to be expressed in dorsal root ganglion (Lauckner et al., 2008) and has a 
reported  influence on neurotransmission (Lauckner et al., 2008; Staton et al., 2008; Sylantyev et 
al., 2013). It has been suggested that VSN16R may act via GPR55 (Hoi et al., 2007b; Pryce et al., 
2007). Whilst VSN16R had a pharmacological influence on GPR55 function, it was important to 
determine to what extent GPR55 was involved in the control of spasticity. Having established a 
method to generate EAE-susceptible mice that could develop EAE, it was hypothesised that GPR55 



















7.2.1 VSN16- a water soluble compound without cannabimimetic effects in the CNS 
VSN16R (Figure 7.1, Table 7.1) is a water soluble (>30mg/ml) compound that can cause 
sympathetic muscular relaxation in the vas deferens (Table 7.1) at a dose of 1mg/kg i.v. (Pryce, 
2010). This failed to induce any obvious cannabimimetic effects including the visible sedative 
effects, or motor outcomes such as hypomotility or resultant hypothermic responses, in contrast 
to that observed following administration of CNS-penetrant cannabinoid receptor agonists or high 
doses of the GABAB-agonist (Pryce, 2010). 5mg/kg i.v. VSN16R induced comparable level of control 
of spasticity as found following administration of baclofen or the botanical drug substances found 
in Sativex (Figure 7.2), but did not induce sedative effects as found with administration of baclofen 
and Sativex® as reported previously (Hilliard et al., 2012). Previous studies demonstrated that 
VSN16 is orally bioavailable (about 30%) with a Cmax within 15 minutes of administration (Pryce, 
2010). Doses of 40mg/kg p.o. for 24 days were well tolerated (Pryce, 2010). Following 
administration of 100mg/kg, 500mg/kg and 1000mg/kg p.o. there were no obvious abnormal 
behavioral responses of animals. Mice appeared alert and mobile during an observation period for 
up to 2h following drug administration. There was no evidence of immobility when assessed 
visually and the temperature of mice receiving 1g/kg was 37.5°C ± 0.4 (n =3) 90 minutes after drug 
administration. This was within the normal range and was consistent with lack of a hypomotile 
phenotype.  There was no evidence of toxicity of VSN16R as shown by no weight loss following 5 
daily treatments (Table 7.2). There was however a significant (P<0.05) weight gain (growth) of 
mice treated with both 100mg/kg and 500mg/kg p.o. by the fifth day of treatment (Day 4) 
compared to baseline (Day 0), which only appeared to occur in 1/3 mice treated with 1000mg/kg 
p.o. However there was no significant difference in the weight of mice treated with either 1g/kg or 
0.1g/kg VSN16R at the start (29.0 ± 2.0g vs. 27.7 ± 0.6g. p=0.33) or end (30.2 ± 1.1g vs. 31.1 ± 0.5g. 
p=0.26) of treatment (Pryce, 2010). 
 
VSN16R was found to be orally active and whilst 0.5mg/kg p.o. administered in water failed to 
inhibit spasticity in EAE. It was however found that 5mg/kg p.o. and 40mg/kg p.o. inhibited 
spasticity (Pryce, 2010). In an attempt to generate more additional therapeutically active 
compounds, following analysis of the original series of compounds (Hoi et al., 2007b; Pryce, 2010), 
more compounds were synthesised by Prof D.L. Selwood (Figure 7.1). These included VSN17 




VSN17S and VSN40R all had potent activity in the low nM range in relaxation of mouse vas 
deferens with VSN16R being the most potent (EC50 = around 10nM (Table 7.1). VSN16R is about 
85% CNS excluded (Pryce, 2010) and it was therefore of interest that VSN40R was as potent in the 
vas deferens assay (Table7.1), but had a CLogP , which is logarithm of its partition coefficient 
between n-octanol and water as a marker of lipophilicity, of 3.5 that would suggest the potential 
for entry into the CNS. However, upon in vitro estimation of pharmacokinetic potential, it was 
found that VSN40R was rapidly metabolised by liver cells, which indicated it would have limited 
merit in investigating this compound in vivo (Table 7.1). It was therefore not studied further. 
However, it was found that VSN16R, VSN16S and VSN17R and VSN17S were sufficiently 
metabolically stable in vitro (Table 7.1). As there were insufficient animals to perform extensive 
dose-response studies, an oral dose of 10mg/kg was arbitrary selected for initial studies using oral 
delivery of agents. This was based on doses that were active with VSN16R and their in vitro 






Figure 7.1 Chemical structure of VSN series compounds 
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Table 7.1 Physiochemical properties of compounds 
_______________________________________________________________________ 
Compound     CLogP   Vas Deferens (LogEC50)         Cyp Inhibition        Hepatocyte Stability 
_______________________________________________________________________ 
VSN16R 0.9  -7.98 (10.5nm)            >10            >200min 
VSN16S  0.9  -7.44 (36.3nm)      >>3            >200min 
VSN17R 1.2  -6.95 (112nm)      >>3            >200min 
VSN17S  1.2  -6.95 (112nm)      >>3            >200min 
VSN40R 3.5  -7.22 (60.3nm)     >>3               2 min 
VSN44R 1.2  -8.85 (1.4nm)          N.D.      N.D. 
______________________________________________________________________ 
Compounds were synthesized by Prof. David Selwood, London who estimated the CLogP ,a measurement 
of a compound's hydrophilicity, based on the structure of the molecule. The cytochrome P450 activity and 
hepatocyte stability was assessed on a variety of Cyp enzymes in rat hepatocytes, both performed by 




7.2.2 VSN16R anti-spastic effects 
Following the development of spasticity animals were treated with VSN16R, Sativex, Baclofen and 
vehicle.  Animals were treated with 5mg/kg of each compound.  The effects of VSN16R was 
compared to baclofen and showed similar effects when comparing the two anti-spastic agents. 
However, a double dose of Sativex was required in order to obtain similar effects as with baclofen 
or VSN16R.   
Figure 7.2 VSN16R is as at least as effective as current anti-spastic agents 
Time Post-Administration (min)



























































ABH mice were immunized with spinal cord antigens in Freund’s adjuvant to induce relapsing EAE. 
Following the development of spasticity, animals received a single intravenous administration of 0.1ml of 
vehicle (ethanol:cremaphor:PBS) or 5mg/kg of either (+)baclofen, 5mg/kg VSN16R or the botanical drug 
substances within Sativex® containing 5mg/kg tetrahydrocannabinol and 5mg/kg cannabidiol or twice the 
amount (Sativex® x 2) with 10mg/kg tetrahydrocannabinol and 10mg/kg cannabidiol. These experiments 
were run in separate groups of animals and caution should be made when comparing effects between 
groups. * P<0.05, **P<0.01, ***P<0.001 compared to baseline in pair wise analysis. The studies involving 






 Table 7.2 VSN16R Does not induce weight loss following repeated administration 
 
 
   Drug  Treatment 
                          Weight (g) 
Baseline   Day 1     Day 2    Day 3    Day 4 















Mean ± SD 29.0 ± 2.0 29.5 ± 1.2 29.4 ± 1.4 29.6 ± 1.4 30.2 ± 1.1 















Mean ± SD 27.7 ± 0.3 28.3 ± 1.2 29.0 ± 0.8 28.6 ± 0.4 30.7 ± 0.9 















Mean ± SD 27.7 ± 0.6 29.5 ± 1.5 30.1 ± 1.5 30.4 ± 1.2 31.1 ± 0.5 
 
Animals were weighed and then administered daily with 100mg/kg, 500mg/kg or 1000mg/kg p.o. VSN16R 














7.2.3 VSN17 enantiomers anti-spastic effects  
It was found that the VSN17 enantiomers had potent activity in the low nM range in relaxation of 
mouse vas deferens (Table 7.1).  VSN17 enantiomers exhibited significant (P<0.001) anti-spastic 
activity in EAE (Figure 7.3).   
Figure 7.3 VSN17R and VSN17S are novel anti-spastic agents 
 
                      

















ABH mice were immunized with spinal cord antigens in Freunds adjuvant to induce relapsing EAE. 
Following the development of spasticity (3-4months after disease induction), animals were administered 
orally with 10mg/kg (A) VSN17R (n=13 limbs) or (B) VSN17S (n=16limbs) in water. The level of limb 
spasticity was assessed by the resistance to hind limb flexion force when the limb was placed against a 
strain gauge. Results represent the ± SEM resistance to hind limb flexion of individual limbs n=16 hind 
limbs/group). ***P<0.001 compared to baseline.  This was performed in collaboration with G. Pryce. 
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7.2.4 Comparison of VSN16 and VSN17 enantiomers anti-spastic effects  
It was found that VSN16R, VSN16S, VSN17R and VSN17S all had potent activity in the low nM 
range in relaxation of mouse vas deferens with VSN16R being the most potent (EC50 = around 
10nM (Table 7.1). All VSN16 and VSN17 enantiomers exhibited significant (P<0.001) anti-spastic 
activity.  In this series of experiments VSN16R seemed to perform better than VSN16S and VSN17 
compounds (Figure 7.4). 
Figure 7.4 VSN16 and VSN17 compounds are novel anti-spastic agents 
Time post-administration (min)





























































ABH mice were immunized with spinal cord antigens in Freunds adjuvant to induce relapsing EAE. 
Following the development of spasticity (3-4months after disease induction), compounds were 
administered at 10mg/kg. These were administered orally in water. Animals were administered with 
VSN16R (n= 16 limbs), VSN16S (n=15 hind limbs), VSN17R (n=13 limbs) or (B) VSN17S (n=16limbs) in 
water. The level of limb spasticity was assessed by the resistance to hind limb flexion force when the limb 
was placed against a strain gauge.  The data was normalised to baseline readings and results represent 
the mean ± SEM percentage change from baseline. ***P<0.001 compared to baseline.  This was 




7.2.5 VSN16R anti-spastic effects in GPR55 knockout mice 
It has been previously shown that VSN16R is active in CB1 receptor knockout mice (Pryce, 2010). 
VSN16R was administered intravenously to spasticity GPR55-deficeint mice and surprisingly the 
compound was still active (Figure 7.5A) and demonstrated comparable levels of activity to that 
found following administration of VSN16R to wild-type mice (Figure 7.5B). 
Figure 7.5 VSN16R inhibits spasticity in GPR55 knockout mice 
Time Post-administration (mins)
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ABH.Gpr55+/+ VSN16R 10mg/kg iv








ABH mice were immunized with spinal cord antigens in Freund’s adjuvant to induce relapsing EAE. 
Following the development of spasticity (3-4months after disease induction), animals were administered 
intravenously with with 10mg/kg VSN16R. The level of limb spasticity was assessed by the resistance to 
hind limb flexion force when the limb was placed against a strain gauge. Spastic ABH animals received 
VSN16R in water or vehicle (into either wildtype ABH or ABH.GPR55 knockouts) and (A) resistance to 
flexion against a strain gauge was assessed. All animals were genotyped prior to use in the assay and were 
confirmed to be either wildtype homozygous or fully GPR55 deficient. (B) Results of resitance of the lmb 
to flexiontwere converted to a percentage change from baseline. The results represent the mean ± SEM. 





7.2.6 VSN44 anti-contractile effects  
An additional compound was also synthesised. This was termed VSN44R (Figure 7.1). This was 
based on analysis of mass spectroscopy of plasma samples obtained during pharmacokinetic 
analysis performed at a contract research organization, and VSN44 was predicted to be acid 
metabolite of VSN16R. This was highly active in the vas deferens assay with EC50 of 1.4 nM 
compared with 3.9nM for R-(+) WIN55,212-2 (Table 7.1, Figure 7.6). VSN44 was highly active 
causing an anti-contractile effect in the vas deferens assay with EC50 of 1.4 nM compared with 
3.9nM for R-(+) the cannabinoid agonist WIN55, 212-2 (Table 7.1, Figure 7.6). 
Figure 7.6 VSN44R induces relaxation of the mouse vas deferens 
 
The vas deferens from C57BL/6 mice were isolated and contractions were monitored following 
incubation with various concentrations of VSN44R or WIN55212-2. The results represent the 






7.2.6 VSN44 and VSN16R anti-spastic effects  
As formal pharmacokinetics have yet to be performed, VSN44 was administered intravenously in 
spastic EAE animals in the first instance to avoid any issue with poor oral bioavailability. It was 
found that VSN44 significantly (P<0.001) inhibited spasticity (Figure 7.7A) and induced an 
inhibition of spasticity to a comparable level to that obtained with VSN16R (Figure 7.7B). 














ABH mice were immunized with spinal cord antigens in Freund’s adjuvant to induce relapsing EAE. 
Following the development of spasticity, animals were received a single intravenous administration of (A, 
B) VSN44R (n=18 limbs) or (B) VSN16 in saline (n= x . (A) The results represent the mean ± SEM forces to 
bend hind limbs to full flexion against a strain gauge or (B) the percentage change from baseline. * P<0.05, 










































































































7.2.7 VSN16R and VSN44 anti-spastic effects in GPR55 knockout mice 
VSN16R and VSN44 was administered intravenously to spasticity GPR55-deficeint mice and the 
compounds were still active (Figure 7.8). This suggests that while VSN16R may be a pro-drug, the 
mechanism of action is clearly not via GPR55 and another target candidate is now sought.  
Figure 7.8 VSN44R inhibits spasticity in GPR55 knockout mice 
Time post-administration (Min)





























































































Wildtype ABH (closed circles) and GPR55 Knockout (open circles) mice were immunized with spinal cord 
antigens in Freund’s adjuvant to induce relapsing EAE. Following the development of spasticity, animals 
were received a single intravenous administration of 10mg/kg i.v. of VSN44R in saline (n=18 limbs) or (B) 
VSN16R in saline (n= 12hindlimbs . (A) The results represent the mean ± SEM forces to bend hindlimbs to 
full flexion against a strain gauge (n=12 limbs) or (B) the percentage change from baseline in wildtype 
(n=18) or GPR55 knockout (n=12). * P<0.05, ** P<0.01, ***P<0.001 compared to baseline. These studies 








The study further demonstrates the activity in controlling spasticity by VSN16R. Although the 
initial chemical series failed to identify many active compounds besides VSN15 and VSN16 that 
exhibited activity (Hoi et al., 2007b) additional chemical entities were synthesised that had efficacy 
in a similar manner to VSN16R. VSN16R was slightly more active than VSN16S as found previously 
in in vivo rodent (mouse and rat) studies (Pryce, 2010) in vitro in rat (Hoi et al., 2007b). However, 
VSN16S had 100% bioavailability compared to about 30% for VSN16R (D.Selwood Unpublished), 
though this could perhaps influence toxicology profiles. VSN16R is clearly very well tolerated. 
There were no behavioural effects when administered up to 120mg/kg p.o.in rats (Pryce, 2010) 
and it was demonstrated here that there is no overt toxicity when administered at 40mg/kg p.o. 
for nearly one month. Furthermore, there were no apparent effects when administered up to 
1000mg/kg/day, which is the regulatory maximum for toxicology purposes for such small 
molecules. As the compound is active as an anti-spastic drug at 5mg/kg (Pryce, 2010) or less then 
there is a minimum 200 fold therapeutic window. Additional studies in Sprague Dawley rats have 
confirmed a No Observable Effect Level (NOEL) of 1g/kg p.o.in 28 day toxicology studies (Charles 
Rivers, Edinburgh UK. D.Selwood/D.Baker unpublished) 
VSN16R could potentially act on GPR55 within neural circuits. This is because it has been shown 
that GPR55 is expressed in nervous tissue including dorsal root ganglion (Lauckner et al., 2008; 
Sylantyev et al., 2013; Wu et al., 2013) and can influence nerve transmission (Kargl et al., 2011; 
Sylantyev et al., 2013; Waldeck-Weiermair et al., 2008; Wu et al., 2013). Allosteric modulators of 
the cannabinoid receptors have been reported previously (Price., 2005). VSN16R may act at an 
allosteric site of GPR55 to augment the action of GPR55 agonism such as that occurring following 
co-incubation with LPI, as shown here in mouse cells. This has previously been seen with CB1 
receptor-agonists in human cells (Pryce, 2010). However, this activity was only found at high 
concentrations above 1µM compared to the low nanomolar range for biological activity found in 
rat vasculature (Hoi et al., 2007b; Pryce, 2010). This may reflect a problem with the cell lines used 
in in vitro binding assays compared to normal cells. It is clear that where GPR55 is expressed in 
tissues it is expressed at low levels. In contrast, in transfected GPR55 over-expressing cells, there 
are high levels of surface GPR55, therefore second messenger systems may become more quickly 
exhausted and thus limit the biological activity of GPR55 binding molecules (Ross, 2009). 
Alternatively, VSN16R may need to be metabolically altered to form an active compound. This 
could have helped to explain why VSN16R fails to bind to receptors in in vitro tests, including CB1, 




anti-spastic effects in both GPR55 knockout mice and wild-type littermates. Perhaps future studies 
could confirm whether the metabolite can directly bind to receptors in in vitro assays. 
As found previous in rat mesentery artery relaxation studies (Hoi et al., 2007b), VSN16R was 
slightly more active than VSN16S in the relaxation of the vas deferens. This appeared to be the 
case for the anti-spastic effect of VSN16S found here and shown previously following intravenous 
administration (Pryce, 2010). However, caution needs to be made when making such a conclusion. 
This is because the compounds were tested in different cohorts of animals.  Animals with 
spasticity show significant variability in the degree of limb stiffness (Baker et al., 2000) and the 
level of relaxation that can be achieved therefore may be variable between limbs. Therefore, 
further analysis of drug efficacies in the same animals will be needed to directly compare the level 
of efficacy of one drug vs. another. However, the level of inhibition of spasticity with VSN 
compounds was similar to that achievable with cannabinoids (Baker et al., 2000) and baclofen and 
Sativex botanical drug substances (Hilliard et al., 2012). The advantage of VSN16 compounds were 
that they were very well tolerated and caused no obvious sedative effects in mice as seen here or 
in an Irwin behavioral test, which is a panel of behavioural studies for CNS side-effects  in rats up 
to 150mg/kg p.o. (Pryce, 2010). Levels of THC above 2.5mg/kg i.p. induced cannabimimetic effects 
in mice (Croxford et al. 2008) and VSN16R was at least as active as Sativex botanical drug 
substances at 5mg/kg THC doses that also causes cannabimimetic effects (Hilliard et al., 2012).  
Although studies in vas deferens may suggest that VSN16 is an allosteric modulator of the GPR55 
receptor it is possible that the effects of the compound acts on a possible co-receptor. The 
molecular target has proved elusive and in comparison to positive controls. It has been shown that 
there is a lack of direct agonism of VSN16R at concentrations >10µM on a large number of 
receptors (Pryce, 2010). These include  A1, A2A, A3, α1 (non-selective), α2 (non-selective),β1, AT1, 
BZD, β2, CCKA, Cnr1, Cnr2, D1, D2S, ETA, GABA (non-selective), Glycine, GAL2,  CXCR2,  CCR1,  H1, 
H2, MC4, ML1, M1, M2, M3, NK2, NK3, Y1, Y2,NT1,δ2, κ, μ, ORL1, 5-HT1A, 5-HT1B, 5-HT2A, 5-HT3, 5-HT5A, 
5-HT6, 5-HT7, somatostatin (non-selective), TRPV1, VIP1, V1a, Ca
2+ channel (L verapamil site), K+V 
channel, SK+Ca channel,  Na+ channel (site 2), Cl- channel, FAAH, NE transporter, DA transporter, 
Nav 1.5 Na+ channel, hERG Kv11.1 K+ channel, GPR6, GPR12, GPR35, GPR55, GPR119 (Pryce, 2010). 
There has been a weak activity at lysophosphatidic acid receptors such as LPA1 EC50= 1.1µM,    
LPA2 =3.4µM, LPA3=0.96µM, LPA4 (GPR23) =3.4µM based on calcium responses in B10, LPA-
receptor transfected cells (D. Selwood, London, J. Chang, La Jolla USA), which are higher than the 









GPR55 was essentially an uncharacterized orphan receptor at the beginning of this project. There 
were only a few papers that described the identification of the receptor and mRNA expression 
levels in a few tissues. The existence of a new cannabinoid-like receptor in the cardiovascular 
system was proposed on the basis of previously reported findings on the Abn-cbd (Johns et al., 
2007) as the atypical cannabinoid had demonstrated vasodilator effects in earlier studies (Jarai et 
al., 1999). Further studies determined that the observed vasodilatory effect of abnormal 
cannabindiol was not mediated by GPR55 (Johns et al., 2007). Likewise a pronociceptive influence 
of GPR55 has been inconsistent (Breen et al., 2012; Schuelert et al., 2011; Staton et al., 2008; Wu 
et al., 2013). GPR55 was identified as a cannabinoid receptor in 2006 as it was suggested to 
interact with cannabinoids (Baker et al., 2006). Since then a series of data has been published 
describing the functions of the receptor using a number of non-selective, putative GPR55 agonists 
and antagonists in various expression assays however the pharmacology remains diverse and 
inconsistent (Pertwee, 2005; Ross, 2009). Although 0-1602 and O-1918 have shown to exert 
effects that are GPR55 dependent, these molecules also mediate notably vascular affects that are 
independent of GPR55 (Johns et al., 2007). LPI is the only ligand that has been consistently 
reported as an endogenous ligand that possesses agonistic effects on GPR55 in a number of 
expression systems (Anavi-Goffer et al., 2012; Henstridge et al., 2009; Kotsikorou et al., 2011; 
Lauckner et al., 2008; Oka et al., 2007). 
One of the main hurdles in the characterization of the GPR55 receptor was a lack of validated 
commercially available reagents to probe GPR55 function. During this project a number of 
polyclonal antibodies have become available and we and other groups (unpublished) have tested 
several of them however these have been shown to contain significant GPR55 non-specific 
activities. This means that staining profiles may be unreliable in identifying true tissue distribution; 
this observation has been previously reported with other cannabinoid receptors (Graham et al., 
2010; Grimsey et al., 2008). There are a number of studies that have demonstrated the use of 
GPR55 antibodies for staining various tissues and cell lines (Fonseca et al., 2011; Henstridge et al., 
2011; Romero-Zerbo et al., 2011). Blockade of antigen binding is a control that is used to validate 
antibodies. However, whilst this might confirm that binding is via the antigen-binding site of the 
antibody, it would not prove that the antibody could not detect more than one protein, which may 




controls that are often lacking in many cannabinoid receptor staining studies. In this study 
different approaches using either recombinant protein/peptide fragments of mouse GPR55 or 
GPR55 transfected cell lines were used to generate hybridomas from GPR55 knockout mice. 
However, none of them were found to bind specifically, without reactivity to other targets, to the 
native GPR55 protein. As earlier mentioned one of the hybridoma (4D12) antibodies showed a 
band at around 37kDa corresponding to the size of the GPR55 protein therefore there might have 
been some reactivity to the native protein. However, due to reactivity of the hybridoma antibodies 
(4D12) to other targets as well we did not observe any specific GPR55 staining when comparing 
staining of GPR55 transfected and untransfected cells. The inability to develop antibodies may 
have been a problem with the immunizing peptides and not adopting a conformation that exists in 
the native protein, which is a transmembrane G protein coupled receptor. Alternatively this may 
have reflected some form of immune defect that appears to be present in some GPR55 knockout 
mice. 
 
At the beginning of this study the biological role of GPR55 was mainly unreported with a few 
exceptions. Earlier studies revealed that GPR55 signaling pathways differ from CB1 and CB2 
receptors. In one of the studies an increase of calcium was found in the stimulated GPR55 
transfected cells involving Gq, G12, RhoA, actin, phospholipase C, and calcium release from inositol 
1,4,5-trisphosphate receptors-gated stores (Lauckner et al., 2008). GPR55 has also been suggested 
to play an important role in mechanical hyperalgesia as GPR55 knockout mice lacked an increased 
sensitivity to pain (Staton et al., 2008). The GPR55 knockout mice also had increased levels of the 
anti–inflammatory cytokines IL-4 and IL-10 which have previously been described to exert anti-
nociceptive effects (Staton et al., 2008; Vale et al., 2003).  
 
More recent studies have identified various other functions of GPR55. GPR55 has been shown to 
be expressed in various gastrointestinal tissues (Li et al., 2013; Lin et al., 2011; Ross, 2009; Ryberg 
et al., 2007; Schicho et al., 2012). The precise function of this receptor in these tissues is not clear 
(Duncan et al., 2005), although it appears that GPR55 agonism can alter gut motility (Li et al., 
2013; Ross, 2009). GPR55 is detected in enteric neurons of the rat ileum and GPR55 expression 
was increased in these cells upon the development of LPS-induced inflammation (Lin et al. 2011). 
This suggests that GPR55 may be involved in the response of the gut to intestinal inflammation 
(Lin et al., 2011). Although CB1 receptor activation has been shown to reduce gastrointestinal 
motility and affect lower esophageal sphincter relaxations (Izzo et al., 2010; Martin et al., 2004), 
recently, O-1602 was shown to inhibit neurogenic contractions in the gut, an effect mediated by 




previously been shown to reduce spontaneous contractions in the rat ileum and LPS induced 
contractions in the colon (Lin et al., 2011; Ross et al., 2012). O-1602 as well as CBD has been 
shown to have anti-inflammatory properties in acute pancreatitis possibly mediated by GPR55 (Li 
et al., 2013; Schicho et al., 2012). Activation of CB2 receptors has been shown to reduce 
inflammation (Maresz et al., 2007; Palazuelos et al., 2008). 
One example of a cannabinoid ligand that has shown to inhibit EAE is the phytocannabinoid CBD 
(Kozela et al., 2011). Although CBD has been reported to be a GPR55 antagonist, the mechanisms 
of action of this ligand are unclear (Whyte et al., 2009; Li et al., 2013). CBD has been previously 
been suggested to be a transient receptor potential vanilloid two receptor agonist and a CB1 
receptor antagonist (Li et al., 2013; Pertwee, 2008; Qin et al., 2008). While it has been reported 
that CBD can inhibit EAE in C57BL/6 mice (Kozela et al., 2011), this compound exhibited no 
inhibitory effect in EAE in Biozzi ABH mice (Maresz et al., 2007).  
As GPR55 knockout EAE animals in this current study developed less severe disease, GPR55 
antagonism could potentially be an approach to inhibit EAE as the receptor might be predicted to 
influence T cell-driven neuroinflammation. It is interesting that the reduced susceptibility of EAE 
shown here in this study was observed in both C57BL/6 and ABH GPR55 knockout mice. The 
mechanism of action of this has not been clear and although the inhibitory effect in EAE suggests 
that it may inhibit T cell function, this could not be verified. Therefore, there may be an effect on 
antigen presenting cell function. Further studies will be required to find changes in immune 
function that can account for this small effect. 
Other explanations in susceptibility to EAE have also previously been reported (Bolton et al., 
2013). There may be some gender influence in susceptibility to EAE suggesting that there may be a 
hormonal effect. Differences in sex hormone levels could account for different susceptibilities to 
disease. Although females develop more MS than males (Compston et al., 2002) studies in EAE 
show that this can be a complex relationship with females sometimes more susceptible to males 
and vice versa (Okuda et al., 2002; Smith-Bouvier et al., 2008; Spach et al., 2009). Vitamin D levels 
may be a risk factor in multiple sclerosis and many susceptibility genes, notably the major 
histocompatibility complex, might have vitamin D response elements in their promoters (Disanto 
et al., 2012). It has been found that the sex and age specific effects of calcifediol, a vitamin D 
prehormone, differ between C57BL/6 and ABH mice (Bolton et al., 2013). In our study it was found 
that mainly GPR55 knockout female mice were less susceptible to EAE on the C57BL/6 background 




Endocannabinoids have been suggested to mediate some of their additional effects through 
GPR55 (Ryberg et al., 2007). Virodamine has previously shown to act as a partial agonist at CB1 and 
full agonist at CB2 (Porter et al., 2002) and has been shown to act as a partial GPR55 agonist at low 
concentrations and a partial antagonist at higher concentrations (Sharir et al., 2012). These 
findings suggest a role for virodamine in modulating cannabinoid receptor function (Porter et al., 
2002). 
Increased levels of LPI have also been observed during a number of pathological conditions (Ford 
et al., 2010; Moreno-Navarrete et al., 2012). For instance, levels of endocannbinoids and the 
GPR55 agonist LPI have been shown to be increased during inflammation (Walter and Stella 2004; 
Ford et al. 2010) and it has been suggested that GPR55 activity may play a pivotal role in balancing 
the involvement of the endocannabinoids during inflammation (Sharir et al., 2012). Increased LPI 
levels have also recently been observed in obese patients and the same study also demonstrated 
higher GPR55 expression levels in adipose tissue in diabetic obese patients than in the control 
group (Moreno-Navarrete et al., 2012). Another GPR55 agonist O-1602 has been reported to 
promote enhancement of glucose-stimulated insulin secretion in isolated rat pancreatic islets via a 
GPR55 mediated mechanism (Romero-Zerbo et al., 2011). 
 
GPR55 has also been shown to form heteromers with CB1 receptors in HEK293 cell line expressing 
both receptors (Kargl et al., 2012). Whilst GPR55-mediated signalling was shown to be inhibited in 
the presence of CB1  receptor,  in contrast,CB1 signalling properties were found to be increased in 
the presence of GPR55 (Kargl et al., 2012). The three-dimensional structure of GPR55 was recently 
examined and the involvement of hydrogen bonding and hydrophobic interactions for ligand 
binding has been described. In that study the amino acid residue Lys80 was identified as the main 
residue for receptor recognition (Elbegdorj et al., 2012). In human endothelial cells CB1 and GPR55 
receptors have been shown to mediate signalling induced by anandamide activation. Furthermore, 
the activation status of integrins determines whether CB1 receptor or GPR55 signalling cascades 
are stimulated (Waldeck-Weiermair et al., 2008). The endogenous ligand LPI has previously been 
reported to activate the ERK MAP-kinase pathway, Ca2+ signalling and the downstream target 
CREB (Balenga et al., 2011a; Henstridge et al., 2011; Henstridge et al., 2010; Oka et al., 2007). In 
our study LPI was found to induce intracellular Ca2+ release in the GPR55 transfected cells 
compared to non-transfected cells. The augmentation of calcium levels in the GPR55 transfected 






Most recently a signalling role for GPR55 in synaptic circuits of the brain was reported (Sylantyev 
et al., 2013). By combining pre-synaptic and post-synaptic imaging GPR55 function at the single 
synapse level has been confirmed using GPR55 knockout animals as a control. The authors also 
described the receptor to activate both inositol triphosphate (IP3) and non-IP3 stores although 
previous studies have only shown activation of IP3-dependent Ca2+stores (Sylantyev et al., 2013). 
Therefore, this suggests that GPR55 may influence neurotransmission both in the CNS (Sylantyev 
et al., 2013) and peripheral nervous system as shown by the relaxation of the vas deferens (Pryce, 
2010). Molecules that stimulate GPR55 may have the potential role to modulate 
neurotransmission. 
 
GPR55 is a “lipid-receptor” that is mainly stimulated by LPI and atypical cannabinoids (Kapur et al., 
2009; Oka et al., 2007). The receptor may be functionally related to the cannabinoid receptors as it 
appears to be bound and modulated by some endocannabinoids (Baker et al., 2006; Sharir et al., 
2012). VSN16R is a water soluble drug that has shown to inhibit experimental spasticity and 
modulate GPR55. VSN16R has been demonstrated to inhibit neurogenic contraction in the vas 
deferens of the testis and is relatively CNS excluded. The spasticity was significantly inhibited in 
EAE animals treated with VSN16R at a concentration of 1-40mg/kg (Pryce, 2010), however 
treatment with the compound did not influence susceptibility to EAE. VSN16R has been shown to 
act as an allosteric modulator and not as a direct agonist or antagonist. Although the initial 
experiment with VSN16R in the vas deferens assay indicated that the anti-contractile effect was 
mediated by the GPR55 receptor, results from this study demonstrated an anti-spastic effect in 
GPR55-deficient mice treated with VSN16R. These results conclude that the anti-spastic effect of 
VSN16R in EAE is not mediated by the GPR55 receptor. 
As VSN16R was potentially mediating its effects via GPR55 as suggested by the vas deferens assay 
(Pryce, 2010), further work was conducted in cell cultures. GPR55 transfected and untransfected 
astrocytoma cell lines treated with VSN16R on its own did not induce activation of CREB. It has 
previously shown that the compound does not induce calcium responses in GPR55 transfected 
HEK cells (Pryce, 2010). However, the combination of 1µm LPI and 10µm VSN16R did however 
induce CREB activation. This suggests that VSN16R functions as a GPR55 modulator rather than 
being a direct agonist. The GPR55 transfected and untransfected astrocytoma cell lines were 
stimulated with LPI and the cytoskeletal rearrangement was assessed using Phallodin staining.  
Results showed GPR55 mediated cytoskeletal morphology rearrangement in the GPR55 
transfected cell line upon stimulation with 1μM of LPI; consistent with previously reported findings 




astrocytoma cells confirms previous observations in assays where human GPR55 HEK cells have 
been stimulated by LPI (Pryce, 2010). However, the concentrations required to modulate GPR55 
function were substantially higher in these cell based assays than in the low nanomolar activity 
tissue based cell assays such as mesenteric artery bed and vas deferens (Hoi et al., 2007; Pryce, 
2010). This suggests that maybe VSN16R requires metabolism for activity, it has weak affinity for 
another receptor that interacts with GPR55 or that transfected cell lines that have supranormal 
and supraphysiological levels of GPR55 may not have sufficient intracellular signalling molecules to 
accommodate the high level of expression of GPR55. The difference in GPR55 expression levels 
might also explain the variations in pharmacological responses when comparing cell based assays 
with tissue based assays. Although VSN16R augmented the responses induced by AM251 in 
GPR55-transfected cells, the action of VSN16R was antagonized by AM251 and O-1918 in tissue-
based assays (Hoi et al., 2007; Pryce, 2010). However, whilst there may be some activity via GPR55 
in some in vitro assays, the activity of VSN16R in spastic GPR55-deficient animals clearly shows 
that that VSN16R has an activity that is not GPR55-dependent. As mentioned earlier, screening 
against a large panel of receptors has been performed (see discussion chapter 7 ). However, there 
was some weak agonist activity on LPA1 (EC50 1.1μM), LPA2 (EC50= 3.4μM), LPA3 (EC50 = 0.9μM), 
LPA4 (EC50= 3.4μM) receptors (D. Selwood, Multispan Inc, J. Chung, Scripps Institute USA. 
Unpublished). Whether these lipid receptors contribute to the biological activity of VSN16R 
requires further study. 
 
The cannabinoid system has previously shown to regulate various immune functions including 
suppression of immune cell activation and cytokine production; it has also shown to alter cell 
proliferation and enhance apoptosis (Klein et al., 2003). CB1 receptor expression by neurons, but 
not T cells, has been demonstrated to be necessary for cannabinoid-mediated EAE suppression 
(Croxford et al., 2008; Maresz et al., 2007). However, encephalitogenic T cells have been shown to 
be essential for the control of EAE associated inflammation (Maresz et al., 2007). CB2-deficient T-
cells in the CNS during EAE has shown to exhibit a higher rate of proliferation and increased 
production of inflammatory cytokines; these findings were associated with a more severe clinical 
disease (Maresz et al., 2007). It has been found that the disease was more severe in the CB2 
knockout mice, this prompted the idea that the encephalitogenic CD4 T-cell effector functions are 
regulated via the CB2 receptor (Maresz et al., 2007; Palazuelos et al., 2008). T-cells from the CB2-
deficient mice were reactivated in vitro and the cytokine production of IFN- and IL-2 was 
examined. Upon adding a CB2 receptor agonist a reduction in proliferation and production of both 




effector functions were mediated by CB2 (Maresz et al., 2007). However, whilst we have been able 
to confirm augmentation of MOG35-55  induced EAE disease in two CB2 knockout strains on the 
C57BL/6 background (C57BL/6.Cnr2TgZim1 and C57BL.Cnr2TgDelt1) when the CB2 deficiency is on the 
ABH mouse background, which is highly susceptible to spinal cord-induced EAE, there is no 
phenotype (G.Pryce Unpublished). This may explain the consistent finding that CB2 receptor 
agonists or antagonists exhibit no influence on the development or severity of EAE (Croxford et al., 
2008). These observations that the immunophenotypes seem to become minimal when the  gene 
deficiency is introduced into a highly susceptible background might also suggest that GPR55 
ligands might not have much influence on the development of EAE. 
The immunophenotypes of our GPR55 knockout mice on the C57BL/6 background was compared 
with wild-type littermates prior to the EAE experiments to investigate potential differences. 
Overall, no significant variation between the two strains was observed. In vitro stimulation with 
Con A or MOG peptide was used to induce proliferation in our GPR55 knockout mice and wild-type 
mice and no significant differences was observed when comparing the two animal groups. 
MOG35-55 peptide in Freund's adjuvant was used to induce EAE in GPR55 knockout and wild-type 
mice on the C57BL/6 background where GPR55 knockout mice were found to develop a much 
milder disease than wild-type littermates. GPR55 knockout mice were also generated on the ABH 
background and although a lower disease susceptibility remained in the GPR55 knockout mice on 
the ABH background this difference was not as obvious as on the C57BL/6 background. The lower 
susceptibility was only observed in the first attack. The two strains had comparable weight losses. 
Motor control and coordination was assessed using a Rotarod and no apparent difference was 
observed when comparing both female groups however, ABH wild-type males were found to be 
the most neurologically impaired when comparing the two male groups.   
EAE induced in gene knockout mice on the C57BL/6 mouse background, which is a relatively 
resistant strain (Levine et al., 1973; Tuohy et al., 1988), gives a markedly augmented phenotype in 
CB2 deficient mice (Maresz et al., 2007) and a reduced phenotype in GPR55 deficient mice that is 
either marginal or absent in EAE induced in knockout mice in the ABH background, which is highly 
susceptible to EAE induction (Baker et al., 1990). These observations suggest that many 
phenotypes observed in EAE in C57BL/6 background knockout mice may not be reproducible if the 
gene deficiency is on a different genetic background. Spinal cord-induced EAE in ABH mice has 
been remarkably consistent over a number of years and these experiments provides a level of 
quality of control of expected susceptibility (Al-Izki et al., 2012; Baker et al., 1990). MOG-induced 
disease in C57BL/6 mice is remarkably inconsistent, in our and others hands. As such there is more 




C57BL/6.Gpr55-/- deficient mice typically developed less severe disease, positive controls 
sometimes failed to become sensitized. In the case of the C57BL/6.Cnr2 knockout mice 
experiments the controls gave poor disease, whereas CB2 knockout mice exhibited good disease 
(see supplementary Figure 9, G.Pryce Unpublished). Therefore the phenotype is in part dictated by 
the disease severity in controls. This inconsistency of disease in C57BL/6 mice has been shown 
repeatedly within the EAE literature and the type of phenotype appears often as a product of the 
susceptibility in wild-type animals in individual experiments (Axtell et al., 2010; Coquet et al., 
2013). This may in part account for the poor translatability of studies from rodents to humans 
(Baker et al., 2012; Vesterinen et al., 2010). 
 
Future studies 
Future studies would be required to investigate the possible mechanisms behind the milder EAE 
disease in the GPR55 knockout animals possibly mediated by protective anti-inflammatory 
properties as previously been suggested (Staton et al., 2008). It would also been interesting to 
further investigate cells belonging to the immune system such the functional role of antigen 
presenting cells including the role of macrophages and dendritic cells in other systems using eg. 
cell migration assays. Furthermore neutrophil function should be explored. Polymorphonuclear 
neutrophils express GPR55 which may influence the GPR55-mediated activity (Balenga et al., 
2011b; Schicho et al., 2012) and may have a phenotype associated with altered neutrophil 
migration (Johns et al., 2007; Schicho et al., 2012). It is also interesting that neutrophils have 
limited role in multiple sclerosis and are a minor component of EAE lesions in ABH mice (Baker et 
al., 1990), although they are maybe more abundant in EAE in C57BL/6 mice (Wu et al., 2010). 
Interestingly, GPR55 deletion exhibits a greater activity in EAE susceptibility in C57BL/6 rather than 
ABH mice. Furthermore, different forms of inflammation should be examined to determine 
whether there is a consistent immune inhibition in GPR55 knockout mice.  
There is a need for development of specific antibodies in order to detect GPR55 and further 
optimize other techniques such as in situ hybridization for detection in tissues. Antibody 
production may be achieved following immunization with native protein in its natural 
conformation in the membrane eg. with GPR55 transfected cells. Other receptors such as GPR18 
have been suggested to mediate some of the atypical cannabinoid effects in various systems that 
are not mediated by GPR55. GPR18 assays have become commercially available and therefore 
future studies will soon examine the action of VSN16R and its metabolites on GPR18. However, 




whereas the activity of VSN16R has been found to be insensitive to PTX (Hoi et al., 2007). Further 
GPR55-dependent activities should be assessed such that lack of activity of VSN16R in GPR55 can 
be confirmed or refuted. In addition it will be important to address the function and receptor 
binding activity of any metabolites of VSN16 compounds. In this study we also tested VSN44, a 
VSN16R metabolite, and it was found to have anti-spastic effects in both GPR55 knockout EAE 
mice on the ABH background and in wild-type littermates. However, the function of VSN44 would 
still need to be tested in other functional assays and it must be determined whether its activity is 
similar if only more potent to VSN16R as its metabolite. 
There is also a need to identify the target for VSN16R so that the anti-spastic mechanisms 
mediated by the chemical agent can be further investigated and identified. This unidentified 
receptor may be a target for future development of anti-spastic drugs. VSN16R has proved 
exceptionally safe in rodents with no detectable toxic effect up to 1g/kg p.o./day. Rodent and dog 
28 day in vivo toxicology have been completed (D.Selwood, D.Baker, Unpublished) and future 
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Supplementary Figure 1 : TG0039 Project Materials- GPR55 mouse deletion sequence 
 















Genomic Locus: (The deleted sequence represents nt 19548-20658 in the sequence below. The 





































































































































































































































































































































































































































































































































































































































Supplementary Figure 2A: FACS raw data –immunophenotyping of naïve animals 
 
 





















Supplementary Figure 3B: FACS raw data –immunophenotyping of naïve animals 
 



































Supplementary Figure 5D: FACS raw data –immunophenotyping of naïve animals 
 



































Supplementary Figure 7F: FACS raw data –immunophenotyping of naïve animals 
 
 






















Supplementary Figure 3: FACS raw data – IFN and IL-10 cytokine responses in T- and B-cells 
 








Supplementary Figure 4: FACS raw data – IFN and IL-10 cytokine responses in T- and B-cells 
 











Supplementary Figure 5:  FACS raw data – IL-4 and IL-17A cytokine responses in T- and B-cells 
 








Supplementary Figure 6:  FACS raw data – IL-4 and IL-17A cytokine responses in T- and B-cells 
 

















Supplementary Figure 8:  FACS raw data – Fox 3P responses in T- and B-cells from MOG  
 
stimulated C57BL/6.GPR55-/- and C57BL/6 +/+ mice 
 
A. In vivo MOG stimulation 
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